<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD000514.pub2" GROUP_ID="STROKE" ID="347999080314140691" MERGED_FROM="" MODIFIED="2013-04-02 10:32:41 +0100" MODIFIED_BY="Hazel Fraser" REVIEW_NO="00040002" REVMAN_SUB_VERSION="5.2.3 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="6.0">
<COVER_SHEET MODIFIED="2013-04-02 10:32:41 +0100" MODIFIED_BY="Hazel Fraser">
<TITLE>Thrombolysis (different doses, routes of administration and agents) for acute ischaemic stroke</TITLE>
<CONTACT MODIFIED="2013-04-02 10:32:41 +0100" MODIFIED_BY="Hazel Fraser"><PERSON ID="8267" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Joanna</FIRST_NAME><MIDDLE_INITIALS>M</MIDDLE_INITIALS><LAST_NAME>Wardlaw</LAST_NAME><POSITION>Professor of Neuroradiology and Honourary Consultant Neuroradiologist</POSITION><EMAIL_1>joanna.wardlaw@ed.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Division of Clinical Neurosciences</DEPARTMENT><ORGANISATION>University of Edinburgh</ORGANISATION><ADDRESS_1>Western General Hospital</ADDRESS_1><ADDRESS_2>Crewe Rd</ADDRESS_2><CITY>Edinburgh</CITY><ZIP>EH4 2XU</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 131 537 3110</PHONE_1><FAX_1>+44 131 332 5150</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2013-04-02 10:32:41 +0100" MODIFIED_BY="Hazel Fraser"><PERSON ID="8267" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Joanna</FIRST_NAME><MIDDLE_INITIALS>M</MIDDLE_INITIALS><LAST_NAME>Wardlaw</LAST_NAME><POSITION>Professor of Neuroradiology and Honourary Consultant Neuroradiologist</POSITION><EMAIL_1>joanna.wardlaw@ed.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Division of Clinical Neurosciences</DEPARTMENT><ORGANISATION>University of Edinburgh</ORGANISATION><ADDRESS_1>Western General Hospital</ADDRESS_1><ADDRESS_2>Crewe Rd</ADDRESS_2><CITY>Edinburgh</CITY><ZIP>EH4 2XU</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 131 537 3110</PHONE_1><FAX_1>+44 131 332 5150</FAX_1></ADDRESS></PERSON><PERSON ID="21309383374451187527100929141516" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Panos</FIRST_NAME><LAST_NAME>Koumellis</LAST_NAME><POSITION>Consultant Neuroradiologist</POSITION><EMAIL_1>pkoumellis@yahoo.com</EMAIL_1><ADDRESS><DEPARTMENT>Department of Neuroradiology</DEPARTMENT><ORGANISATION>Hurstwood Park Neurosciences Centre</ORGANISATION><ADDRESS_1>Lewes Road</ADDRESS_1><CITY>Haywards Heath</CITY><ZIP>RH16 4EX</ZIP><REGION>West Sussex</REGION><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></PERSON><PERSON ID="16502" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Ming</FIRST_NAME><LAST_NAME>Liu</LAST_NAME><POSITION>Professor of Neurology</POSITION><EMAIL_1>wyplmh@hotmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Department of Neurology</DEPARTMENT><ORGANISATION>West China Hospital, Sichuan University</ORGANISATION><ADDRESS_1>No. 37, Guo Xue Xiang</ADDRESS_1><CITY>Chengdu</CITY><ZIP>610041</ZIP><REGION>Sichuan</REGION><COUNTRY CODE="CN">China</COUNTRY><PHONE_1>+86 28 8542 3551</PHONE_1><FAX_1>+86 28 8542 3551</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2013-03-28 12:26:57 +0000" MODIFIED_BY="jmw ">
<UP_TO_DATE>
<DATE DAY="19" MONTH="3" YEAR="2013"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="31" MONTH="5" YEAR="2012"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="28" MONTH="3" YEAR="2015"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="1997"/>
<REVIEW_PUBLISHED ISSUE="4" YEAR="1998"/>
<LAST_CITATION_ISSUE ISSUE="4" YEAR="1998"/>
</DATES>
<WHATS_NEW MODIFIED="2013-04-02 10:26:04 +0100" MODIFIED_BY="jmw ">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2013-04-02 10:25:15 +0100" MODIFIED_BY="Hazel Fraser">
<DATE DAY="19" MONTH="3" YEAR="2013"/>
<DESCRIPTION>
<P>There has been no change to the conclusions of the review</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2013-04-02 10:25:28 +0100" MODIFIED_BY="jmw ">
<DATE DAY="19" MONTH="3" YEAR="2013"/>
<DESCRIPTION>
<P>The review has been updated with the inclusion of 10 trials. It now has 20 included trials involving 2165 participants. The text has been revised throughout</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2013-01-21 14:07:48 +0000" MODIFIED_BY="Hazel Fraser">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2013-01-21 14:07:48 +0000" MODIFIED_BY="Hazel Fraser">
<DATE DAY="14" MONTH="10" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-10-14 11:50:33 +0100" MODIFIED_BY="Hazel Fraser">
<DATE DAY="22" MONTH="10" YEAR="2003"/>
<DESCRIPTION>
<P>For this first update of the review, two trials have been added.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2011-11-21 20:36:51 +0000" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES MODIFIED="2011-11-21 20:36:51 +0000" MODIFIED_BY="[Empty name]">
<SOURCE>
<NAME>University of Edinburgh, Scotland</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE MODIFIED="2011-11-21 20:36:51 +0000" MODIFIED_BY="[Empty name]">
<NAME>University of Edinburgh</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION>
<P>This work was undertaken as part of the MSc in Neuroimaging for Research (a final year project) University of Edinburgh, 2010-2011</P>
</DESCRIPTION>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>Medical Research Council</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>University of Heidelberg - Faculty of Medicine Mannheim</NAME>
<COUNTRY CODE="DE">Germany</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2013-03-28 12:31:51 +0000" MODIFIED_BY="jmw ">
<SUMMARY MODIFIED="2013-03-28 12:21:48 +0000" MODIFIED_BY="Hazel Fraser">
<TITLE MODIFIED="2013-01-21 14:39:17 +0000" MODIFIED_BY="Hazel Fraser">Clot-dissolving drugs (different doses, routes of administration and agents) for breaking down a blood clot blocking a blood vessel in the brain</TITLE>
<SUMMARY_BODY MODIFIED="2013-03-28 12:21:48 +0000" MODIFIED_BY="Hazel Fraser">
<P>Many strokes are due to a sudden blockage of an artery in the brain. Treatments to dissolve the clot (also called thrombolytic treatment) can improve the chance of making a good recovery from a stroke. This review aimed to find out if there were important differences between different clot-dissolving drugs. It also aimed to find out if there were differences in effect when giving the same drug in different doses or by different routes (into an artery or a vein). The review, which included 20 studies involving 2527 participants, showed that there was some evidence that lower doses of thrombolytic agents led to serious bleeding in the brain less often. However, it was not clear if the benefit from lower doses was as big as with higher doses. There was no evidence to show that one thrombolytic agent was clearly better than another, or that intra-arterial treatment was better than intravenous treatment. Therefore, more larger randomised controlled trials are required to answer questions about which drug, or dose or route of administration is best for thrombolysis. At present, rt-PA as currently licensed in many countries, should be regarded as best practice.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2013-03-28 12:31:51 +0000" MODIFIED_BY="jmw ">
<ABS_BACKGROUND MODIFIED="2013-02-01 10:33:56 +0000" MODIFIED_BY="[Empty name]">
<P>Stroke is a leading cause of death and disability world wide. Thrombolysis with recombinant tissue plasminogen activator (rt-PA) is licensed for treatment of acute ischaemic stroke in the early hours after symptom onset. It has been shown in randomised controlled trials (RCTs) and the 2009 Cochrane review of thrombolysis for acute ischaemic stroke to reduce dependency but at the increased risk of intracranial haemorrhage. Methods to reduce the risk of haemorrhage while retaining or enhancing the benefit could increase the use of thrombolytic treatment. While most available information comes from RCTs of intravenous rt-PA at 0.9 mg/kg, it is possible that other doses, drugs and other routes of administration might increase benefit and reduce the hazard.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2013-01-21 14:28:51 +0000" MODIFIED_BY="[Empty name]">
<P>To assess the risks and benefits of different thrombolytic agents, doses and routes of administration for the treatment of acute ischaemic stroke.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2013-02-01 10:33:58 +0000" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Stroke Group Trials Register (May 2012), MEDLINE (1966 to May 2012) and EMBASE (1980 to May 2012). We handsearched journals and conference proceedings, searched ongoing trials registers and contacted pharmaceutical companies and researchers.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2011-11-21 22:43:19 +0000" MODIFIED_BY="[Empty name]">
<P>Unconfounded randomised and quasi-randomised trials of different doses of a thrombolytic agent, or different agents, or the same agent given by different routes, in people with confirmed acute ischaemic stroke.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2013-01-21 14:30:58 +0000" MODIFIED_BY="[Empty name]">
<P>Two review authors independently assessed trial eligibility and quality, and extracted the data using a structured proforma. We cross-checked and resolved discrepancies by discussion to reach consensus. We obtained translations and additional information from study authors where required.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2013-03-28 12:31:51 +0000" MODIFIED_BY="jmw ">
<P>We included 20 trials involving 2527 patients. Concealment of allocation was poorly described. Different doses (of tissue plasminogen activator, urokinase, desmoteplase or tenecteplase) were compared in 13 trials (N = 1433 patients). Different agents (tissue plasminogen activator versus urokinase, tissue-cultured urokinase versus conventional urokinase, tenecteplase versus tissue plasminogen activator) were compared in five trials (N = 875 patients). Five trials (N = 485) compared different routes of administration. As some trials compared different agents and different doses, some patients contributed to two analyses. There was an approximately three-fold increase in fatal intracranial haemorrhages in patients allocated to higher than to lower doses of the same thrombolytic drug (odds ratio (OR) 2.71, 95% confidence interval (CI) 1.22 to 6.04). There was no difference in the number of patients who were dead or dependent at the end of follow-up between those allocated higher or lower doses of thrombolytic drug (OR 0.86, 95% CI 0.62 to 1.19). Higher versus lower doses of desmoteplase were associated with more deaths at the end of follow-up (OR 3.21, 95% CI 1.23 to 8.39). There was no evidence of any benefit for intra-arterial over intravenous treatment.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2013-03-28 12:21:43 +0000" MODIFIED_BY="[Empty name]">
<P>These limited data suggest that higher doses of thrombolytic agents may lead to higher rates of bleeding. However, the evidence is inadequate to conclude whether lower doses of thrombolytic agents are more effective than higher doses, or whether one agent is better than another, or which route of administration is the best, for acute ischaemic stroke. At present, intravenous rt-PA at 0.9mg/kg as licensed in many countries appears to represent best practice and other drugs, doses or routes of administration should only be used in randomised controlled trials.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2013-03-28 12:25:36 +0000" MODIFIED_BY="jmw ">
<BACKGROUND MODIFIED="2013-03-28 12:11:56 +0000" MODIFIED_BY="jmw ">
<CONDITION MODIFIED="2013-02-01 10:34:03 +0000" MODIFIED_BY="[Empty name]">
<P>Stroke is a leading cause of death and disability world wide. Most strokes are ischaemic and due to a thrombotic or embolic occlusion of an intracranial artery. Rapid administration of intravenous thrombolytic therapy with the drug recombinant tissue plasminogen activator (rt-PA, generic name alteplase) is the principal treatment in the early hours after the onset of symptoms and has been shown in randomised controlled trials (RCTs) to improve outcomes (<LINK REF="REF-Wardlaw-2012" TYPE="REFERENCE">Wardlaw 2012</LINK>; additional information in <LINK REF="REF-Hacke-2004" TYPE="REFERENCE">Hacke 2004</LINK> and <LINK REF="REF-Lees-2010" TYPE="REFERENCE">Lees 2010</LINK>). Although rt-PA is the only thrombolytic drug licensed for the treatment of acute ischaemic stroke, other thrombolytic drugs have also shown promise (<LINK REF="REF-Wardlaw-2009" TYPE="REFERENCE">Wardlaw 2009</LINK>; <LINK REF="REF-Wardlaw-2010" TYPE="REFERENCE">Wardlaw 2010</LINK>). The earlier the thrombolytic agent is administered the more patients remain alive and independent (<LINK REF="REF-Lees-2010" TYPE="REFERENCE">Lees 2010</LINK>; <LINK REF="REF-Wardlaw-2012" TYPE="REFERENCE">Wardlaw 2012</LINK>). However, the major risk of the treatment is intracranial haemorrhage, which is the single most frequent cause of death following thrombolysis regardless of which drug is used (<LINK REF="REF-Wardlaw-2009" TYPE="REFERENCE">Wardlaw 2009</LINK>; <LINK REF="REF-Wardlaw-2010" TYPE="REFERENCE">Wardlaw 2010</LINK>; <LINK REF="REF-Wardlaw-2012" TYPE="REFERENCE">Wardlaw 2012</LINK>). Systemic bleeding is a less common but potentially serious complication.</P>
</CONDITION>
<INTERVENTION MODIFIED="2013-02-01 10:34:13 +0000" MODIFIED_BY="[Empty name]">
<P>Most of the randomised controlled trials (RCTs) of thrombolytic drugs to date have tested intravenous rt-PA but other routes of administration, drugs or doses of drug might reduce hazard or be more beneficial. Intra-arterial thrombolysis offers some theoretical advantages such as regionally localised therapy, reduced overall dose and hence systemic effects of thrombolytic therapy. However, this comes at the cost of a more invasive technique, delay in treatment initiation and the requirement for a specialised radiological unit. Despite this, in recent years there has been increasing interest in intra-arterial therapy and also in mechanical devices to extract the intraluminal clot with or without the use of pharmacological thrombolysis (<LINK REF="REF-Lee-2010" TYPE="REFERENCE">Lee 2010</LINK>; <LINK REF="REF-Lindsberg-2006" TYPE="REFERENCE">Lindsberg 2006</LINK>; <LINK REF="REF-Lisboa-2002" TYPE="REFERENCE">Lisboa 2002</LINK>; <LINK REF="REF-RECANALISE-2009" TYPE="REFERENCE">RECANALISE 2009</LINK>). However, there are as yet no completed randomised trials testing mechanical devices, although some are expected to start soon.</P>
<P>Apart from rt-PA, other thrombolytic drugs have also been tested in stroke. Two RCTs testing streptokinase were terminated early due to a high rate of symptomatic haemorrhage and a third was stopped due to the adverse climate generated by termination of the other two, although the third trial had not demonstrated any excess hazard (<LINK REF="REF-Wardlaw-2009" TYPE="REFERENCE">Wardlaw 2009</LINK>; <LINK REF="REF-Wardlaw-2010" TYPE="REFERENCE">Wardlaw 2010</LINK>). Urokinase has been used in the treatment of stroke, although less often recently. Newer thrombolytic agents, such as tenecteplase and desmoteplase, are variants of the native plasminogen activators and are currently being evaluated as alternative fibrinolytic agents.</P>
</INTERVENTION>
<THEORY MODIFIED="2013-01-21 15:10:54 +0000" MODIFIED_BY="[Empty name]">
<P>Alternative routes of administration, drugs or doses might reduce hazard whilst preserving benefit. Amongst trials mostly comparing intravenous thrombolysis with control (summarised in <LINK REF="REF-Wardlaw-2009" TYPE="REFERENCE">Wardlaw 2009</LINK>; <LINK REF="REF-Wardlaw-2010" TYPE="REFERENCE">Wardlaw 2010</LINK>), there was marked heterogeneity in case fatality rates. It was possible to explore reasons for the heterogeneity only in a very limited way but several points emerged. For example, the case fatality at the end of follow-up in the thrombolysis-treated patients was lower in the trials that tested lower doses of thrombolytic drug than in the trials that tested doses similar to those used to treat acute myocardial infarction (MI), although the difference was not statistically significant and there was no obvious trend in case fatality between the trials using the lowest and highest doses. There are of course many other reasons for the between-trial heterogeneity.</P>
</THEORY>
<IMPORTANCE MODIFIED="2013-03-28 12:11:56 +0000" MODIFIED_BY="[Empty name]">
<P>The available data on the use of thrombolytic drugs to treat acute ischaemic stroke have posed questions for further research. Do lower doses of thrombolytic drugs reduce the hazard without compromising the benefit? Which thrombolytic drug has the least hazard and most benefit or are they all the same? Which is the best route of administration: intravenous, intra-arterial or other?</P>
<P>Recently, with the development of several newer thrombolytic drugs, there have been more trials testing different doses and comparing different drugs with the licensed drug rt-PA. We updated this systematic review to identify what information there is concerning choice of thrombolytic drug, dose and route of administration for treating acute ischaemic stroke. We sought to identify which, if any, regimen might have the most benefit and least hazard in acute ischaemic stroke, and highlight where more trials are needed.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2013-01-23 11:51:09 +0000" MODIFIED_BY="Hazel Fraser">
<P>The aims of this review were as follows.</P>
<OL>
<LI>To compare a higher dose with a lower dose of thrombolytic therapy to determine whether there are important differences in:</LI>
<OL>
<LI>the proportion with poor long-term outcome (efficacy);</LI>
<LI>the number of early deaths (safety);</LI>
<LI>the number of deaths by the end of the scheduled follow-up period (safety); and</LI>
<LI>symptomatic (including fatal) intracranial haemorrhage (safety).</LI>
</OL>
<LI>To compare one thrombolytic agent with an equivalent dose of another agent to see whether there are important differences in:</LI>
<OL>
<LI>the proportion with poor long-term outcome (efficacy);</LI>
<LI>the number of early deaths (safety);</LI>
<LI>the number of deaths by the end of the scheduled follow-up period (safety); and</LI>
<LI>symptomatic (including fatal) intracranial haemorrhage (safety).</LI>
</OL>
<LI>To compare intravenous with intra-arterial thrombolysis (with the same agent) to see whether there are important differences in:</LI>
<OL>
<LI>the proportion with poor long-term outcome (efficacy);</LI>
<LI>the number of early deaths (safety);</LI>
<LI>the number of deaths by the end of the scheduled follow-up period (safety); and</LI>
<LI>symptomatic (including fatal) intracranial haemorrhage (safety).</LI>
</OL>
</OL>
<P>The primary outcome in this review was poor functional outcome at the end of follow-up. We considered early and total deaths at the end of follow-up, symptomatic and fatal intracranial haemorrhages and major extracranial haemorrhages to be secondary outcomes.</P>
</OBJECTIVES>
<METHODS MODIFIED="2013-03-28 12:12:50 +0000" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2013-02-01 10:34:26 +0000" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2013-02-01 10:34:15 +0000" MODIFIED_BY="[Empty name]">
<P>All unconfounded truly randomised or quasi-randomised trials in patients with acute ischaemic stroke within 14 days of stroke onset in which:</P>
<OL>
<LI>a lower dose of the thrombolytic agent was compared with a higher dose of the same agent; or</LI>
<LI>one thrombolytic agent was compared with another agent; or</LI>
<LI>two different routes of administration of the same agent were compared.</LI>
</OL>
<P>We included trials that had a placebo group as well as two groups receiving different doses of the same thrombolytic agent, but the placebo patients do not appear in this review. Trials comparing thrombolysis with placebo are presented in the Cochrane review of 'Thrombolysis for acute ischaemic stroke' (<LINK REF="REF-Wardlaw-2009" TYPE="REFERENCE">Wardlaw 2009</LINK>; <LINK REF="REF-Wardlaw-2010" TYPE="REFERENCE">Wardlaw 2010</LINK>).</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2013-02-01 10:34:19 +0000" MODIFIED_BY="Hazel Fraser">
<P>Trials which included patients of any age or sex within 14 days of onset of acute ischaemic stroke (pre-randomisation computerised tomography (CT) or magnetic resonance imaging (MRI) having excluded cerebral haemorrhage as the cause of symptoms) were eligible. Although it is likely that thrombolysis is most effective if given within the first few hours of stroke, we have included trials treating patients at comparatively late stages in this version of the review because, in general, the trials that treated patients late were testing very low doses - i.e. a different approach to the use of thrombolysis and there was no good logical reason for excluding these trials at this stage. In future, should more data become available, it will be possible to conduct sensitivity analyses of early high-dose versus later lower-dose treatment.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2013-02-01 10:34:22 +0000" MODIFIED_BY="[Empty name]">
<P>We included trials that tested, in a randomised design, any type of thrombolytic drug - urokinase (UK), pro-urokinase (PRO-UK), streptokinase (SK), recombinant and tissue plasminogen activator (rt-PA and t-PA respectively), tenecteplase (TNK), desmoteplase, retevase or lumbrokinase (LK) - either in different doses (e.g. lower dose of half to two-thirds of that of a higher dose) or by different administrative methods (of the same drug) or comparing different drugs to treat acute ischaemic stroke. The drugs could be given intravenously, intra-arterially or orally (where appropriate). We excluded confounded trials (e.g. lower dose of thrombolytic drugs plus another agent versus higher dose of thrombolytic drug).</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2013-02-01 10:34:26 +0000" MODIFIED_BY="[Empty name]">
<P>We considered five main outcomes.</P>
<CRIT_OUTCOMES_PRIMARY MODIFIED="2013-01-23 11:51:21 +0000" MODIFIED_BY="[Empty name]">
<P>Poor functional outcome at the end of follow-up (where follow-up was performed at one month or longer after the stroke). This was defined as death or dependency on others in activities of daily living, at the end of the trial follow-up period where this was one month or later after the stroke (although we accept that dependency measured earlier than three months may not allow sufficient time for maximum recovery to have occurred).</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2013-02-01 10:34:26 +0000" MODIFIED_BY="[Empty name]">
<OL>
<LI>Death from any cause and vascular/unknown death (a) within the first two weeks of treatment, and (b) during the whole trial follow-up period (we included trials with final follow-up at one month or longer).</LI>
<LI>Intracranial haemorrhage: symptomatic (i.e. associated with a deterioration in the patient's neurological state) and fatal (i.e. leading directly to the death of the patient). Intracranial haemorrhage includes haemorrhagic transformation of the infarct, haemorrhage elsewhere in the brain, and haemorrhage into the spaces surrounding the brain.</LI>
<LI>Major extracranial haemorrhage (i.e. fatal or requiring a transfusion or an operation).</LI>
<LI>Other major extracranial events (e.g. deep vein thrombosis (DVT), ischaemic leg and haematoma at the puncture site following angiography).</LI>
</OL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2013-03-28 12:12:50 +0000" MODIFIED_BY="[Empty name]">
<P>See the 'Specialized register' section in the <A HREF="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/STROKE/frame.html">Cochrane Stroke Group</A> module. We searched for relevant trials in all languages and arranged translation of trial reports published in languages other than English.</P>
<ELECTRONIC_SEARCHES MODIFIED="2013-03-28 12:12:37 +0000" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Stroke Group Trials Register, which was last searched by the Managing Editor in May 2012. We also searched MEDLINE (1966 to May 2012) (<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>) and EMBASE (1980 to May 2012) (<LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>). We included trials known to be completed and published by Febuary 2013.</P>
<P>We sought Information from the Stroke Trials Registry (<A HREF="http://www.strokecenter.org/trials">www.strokecenter.org/trials</A>), ClinicalTrials.gov (<A HREF="http://www.clinicaltrials.gov/">www.clinicaltrials.gov/</A>), EU Clinical Trials Register (<A HREF="http://www.clinicaltrialsregister.eu">www.clinicaltrialsregister.eu</A>), Current Controlled Trials (<A HREF="http://www.controlled-trials.com">www.controlled-trials.com</A>) and the WHO International Clinical trials Registry Platform (<A HREF="http://apps.who.int/trialsearch/">http://apps.who.int/trialsearch/</A>). We used Google to search for individual trial names and then searched any online resources of the relevant trials (e.g. trials websites).</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2013-03-28 12:12:50 +0000" MODIFIED_BY="[Empty name]">
<P>We handsearched the following journals from 1979 to April 1994 for the first review: <I>Japanese Journal of Stroke</I>; <I>Clinical Evaluation</I>; <I>Japanese Journal of Pharmacology &amp; Therapeutics</I>; <I>Rinsho Ketsueki</I>. We obtained translations of the non-English language publications from people in whose native language the paper was published. For the latest update of the review, and in order to validate the results of the MEDLINE and EMBASE searches, we handsearched three journals (<I>American Journal of Neuroradiology</I>, <I>New England Journal of Medicine</I> and <I>Stroke</I>) from January 2006 to December 2010.</P>
<P>In 1997 we contacted all pharmaceutical companies listed in the British National Formulary (BNF) and the Monthly Index of Medical Specialties (MIMS) for more information about trials, both those known to exist from the above efforts, and any trials which were unknown to the review authors. Only one company, Genentech, an American company, did not respond. For the previous update we contacted Gruenenthal for trial details. We did not contact any other companies for this update.</P>
<P>We searched the abstracts presented at international conferences for acute stroke (the European Stroke Conferences 1991 to 2012, the biennial International Symposia on Thrombolysis in Acute Ischaemic Stroke 1992 to 2011, the biennial World Stroke Conferences 2000 to 2012, and the American Heart Association International Stroke Conferences 1990 to 2013). We also searched abstracts of other neurological and cerebrovascular symposia as published in journals and through colleagues who attended.</P>
<P>We contacted the principal investigators of trials in Europe, the USA, Japan and China when we required additional information.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2013-02-01 10:34:41 +0000" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2013-01-24 12:39:00 +0000" MODIFIED_BY="[Empty name]">
<P>For the update of this review two authors (PK, JMW) independently screened titles and abstracts, excluded obviously irrelevant articles and selected trials for inclusion in the review. We resolved any disagreements by discussion. We obtained the full text of the remaining articles and the same two authors independently selected studies meeting the inclusion criteria. We resolved any further disagreements by discussion if necessary. One author (PK) extracted data on the methodological quality and outcome assessments. The other author (JMW) cross-checked all the extracted data and we resolved differences by discussion if necessary.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2013-02-01 10:34:36 +0000" MODIFIED_BY="[Empty name]">
<P>Review authors extracted data by using a standard proforma (ML and JMW for trials included in the previous version of the review; PK and JMW for trials identified since the last version of this review). The review authors resolved disagreements by discussion or by correspondence with the trial authors. For the most recent update, PK entered data into Review Manager (<LINK REF="REF-RevMan-2011" TYPE="REFERENCE">RevMan 2011</LINK>) and JMW checked the data.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2013-02-01 10:34:40 +0000" MODIFIED_BY="[Empty name]">
<P>We collected information about the method of randomisation, allocation concealment, blinding (both of treatment administration and of outcome assessment), whether an intention-to-treat analysis was done or could possibly be done and the number of patients who were lost to follow-up, to assess the methodological quality and risk of bias in the included studies (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2013-02-01 10:34:41 +0000" MODIFIED_BY="[Empty name]">
<P>For outcome assessment we extracted the number of patients originally allocated to each treatment group irrespective of compliance to allow an intention-to-treat analysis (trials that included a placebo group are included in the present review, but the placebo patients are included in the Cochrane review of 'Thrombolysis for acute ischaemic stroke' (<LINK REF="REF-Wardlaw-2009" TYPE="REFERENCE">Wardlaw 2009</LINK>; <LINK REF="REF-Wardlaw-2010" TYPE="REFERENCE">Wardlaw 2010</LINK>), and trials of rt-PA are published in the 2012 systematic review (<LINK REF="REF-Wardlaw-2012" TYPE="REFERENCE">Wardlaw 2012</LINK>), not in this review).</P>
<P>We then collected the number of patients who:</P>
<OL>
<LI>died in the early stage (within the first two weeks of the stroke) and by the end of the trial follow-up;</LI>
<LI>were disabled (dependent on others in activities of daily living) by the end of the trial follow-up period. We defined dependency as a score of three to five on the modified Rankin Scale (mRS) (or equivalent);</LI>
<LI>developed symptomatic or fatal intracranial haemorrhage (confirmed by CT or MR or post mortem) in the acute stage. We defined symptomatic intracranial haemorrhage as intracranial haemorrhage, confirmed by a CT, MR scan, lumbar puncture or autopsy, accompanied by deterioration in the neurological condition of the patient. Fatal intracranial haemorrhage is death attributed to intracranial haemorrhage confirmed by CT or MR brain imaging or post mortem examination. There is a problem with the estimation of the true number of symptomatic or fatal intracranial haemorrhages because some patients died without a CT or MR scan or post mortem. Patients who died in the acute stage of neurological causes may have had an intracranial haemorrhage, so we collected the number of patients who had symptomatic intracranial haemorrhage or who died in the acute stage to avoid underestimation of major intracerebral haemorrhage;</LI>
<LI>had major extracranial haemorrhage, defined as haemorrhage outside the cranial cavity that resulted in clinical deterioration of the patient, prolonged immobility or stay in hospital, or required transfusion or surgical evacuation;</LI>
<LI>had complications that might be a consequence of the administration route, e.g. groin haematoma or limb ischaemia following angiography.</LI>
</OL>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2013-01-21 15:52:13 +0000" MODIFIED_BY="[Empty name]">
<P>We used mRS scores where available. Where not available we converted other relevant stroke scales to the mRS. Where it was not possible to convert, or where functional outcome was not assessed, we omitted the trial from analysis of functional outcome. The only other outcome where there was potential for variable measures was symptomatic intracranial haemorrhage. Here we used the trial-specific definition and did not attempt to convert these to some other standard as there is no consensus on how symptomatic intracranial haemorrhage should be standardised, nor did the trials provide information to allow any conversion.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2013-01-21 15:53:02 +0000" MODIFIED_BY="[Empty name]">
<P>We sought missing data from trial investigators and any other associated contacts. If it was not possible to obtain data omitted from the trial publication, we omitted the trial from that analysis. These are highlighted in the results section. We have used all available data.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2013-01-23 12:03:25 +0000" MODIFIED_BY="[Empty name]">
<P>We assessed heterogeneity using the I² statistic. We also reported the Chi²<SUP> </SUP>test in the tables and figures (<LINK REF="REF-APT-1994" TYPE="REFERENCE">APT 1994</LINK>).</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2013-01-21 15:54:25 +0000" MODIFIED_BY="[Empty name]">
<P>We assessed reporting biases using funnel plots.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2013-01-21 15:54:56 +0000" MODIFIED_BY="[Empty name]">
<P>We calculated the Peto odds ratios for each outcome.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2013-01-21 15:55:11 +0000" MODIFIED_BY="[Empty name]">
<P>We also attempted to collect information on baseline characteristics of the patients, such as the severity of the stroke at randomisation, age of the patients, gender, etc. We hoped to be able to perform subgroup analyses based on these characteristics should the data be sufficient.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2013-01-21 15:56:59 +0000" MODIFIED_BY="[Empty name]">
<P>The main analyses were based on all trials. However, we also planned a priori sensitivity analyses based on:</P>
<OL>
<LI>trials with well-concealed treatment allocation (i.e. allocation was given by telephoning a central office; by first entering the data into a computer; by the pharmacy; by using identical numbered containers; or by sequentially numbered, sealed, opaque envelopes) versus less well concealed allocation;</LI>
<LI>trials with blinded outcome assessment versus unblinded assessment.</LI>
</OL>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2013-03-28 12:18:18 +0000" MODIFIED_BY="jmw ">
<STUDY_DESCRIPTION MODIFIED="2013-03-28 12:14:46 +0000" MODIFIED_BY="jmw ">
<SEARCH_RESULTS MODIFIED="2013-03-28 12:13:14 +0000" MODIFIED_BY="[Empty name]">
<P>The searches of the Cochrane Stroke Group Trials Register, MEDLINE and EMBASE yielded 3672 potentially relevant abstracts but the majority were either completely irrelevant or excluded through being non-randomised comparisons, not testing comparisons relevant to this review, randomised but no relevant outcome reported, or confounded by another drug or intervention. Of these, 71 were relevant enough to be listed in the excluded studies section, five are ongoing, one is awaiting assessment but may prove to be irrelevant and 20 met the inclusion criteria.</P>
<P>Five trials (<LINK REF="STD-BASICS" TYPE="STUDY">BASICS</LINK>; <LINK REF="STD-DIAS_x002d_J" TYPE="STUDY">DIAS-J</LINK>; <LINK REF="STD-ENCHANTED" TYPE="STUDY">ENCHANTED</LINK>; <LINK REF="STD-FRALYSE" TYPE="STUDY">FRALYSE</LINK>; <LINK REF="STD-ITAIS" TYPE="STUDY">ITAIS</LINK>) are classified as ongoing . One further study (<LINK REF="STD-Wadia-2009" TYPE="STUDY">Wadia 2009</LINK>) appears relevant to the topic of this review as it tests two different doses of tenecteplase but it has only been published in abstract so far and further information is required, particularly regarding the method of randomisation, and is therefore classified as awaiting evaluation.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2013-03-28 12:14:37 +0000" MODIFIED_BY="[Empty name]">
<P>We included 20 trials involving 2527 patients, of which 13 trials (1433 patients) were relevant to the comparison of higher dose with lower dose, five trials (875 patients) to one agent versus another and five trials (485 patients) to different routes of administration. Three of these trials (<LINK REF="STD-Abe-1990" TYPE="STUDY">Abe 1990</LINK>; <LINK REF="STD-Parsons-2012" TYPE="STUDY">Parsons 2012</LINK>; <LINK REF="STD-TNK_x002d_S2B" TYPE="STUDY">TNK-S2B</LINK>) compared both different doses (259 patients) and different agents (341 patients). Thus, there was an overlap for the number of included trials and patients. Summary details of the included trials are given in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table including, where available, data on baseline characteristics of the included patients.</P>
<P>Thirteen trials compared a higher dose of a thrombolytic drug with a lower dose of the same drug, of which five trials (<LINK REF="STD-Abe-1990" TYPE="STUDY">Abe 1990</LINK>; <LINK REF="STD-Kikuchi-1994" TYPE="STUDY">Kikuchi 1994</LINK>; <LINK REF="STD-Mori-1992" TYPE="STUDY">Mori 1992</LINK>; <LINK REF="STD-Ohtomo-1988a" TYPE="STUDY">Ohtomo 1988a</LINK>; <LINK REF="STD-Wang-2003" TYPE="STUDY">Wang 2003</LINK>) tested t-PA, three trials (<LINK REF="STD-Abe-1981" TYPE="STUDY">Abe 1981</LINK>; <LINK REF="STD-Atarashi-1985" TYPE="STUDY">Atarashi 1985</LINK>; <LINK REF="STD-Chen-2002" TYPE="STUDY">Chen 2002</LINK>) tested UK, three trials (<LINK REF="STD-DEDAS" TYPE="STUDY">DEDAS</LINK>; <LINK REF="STD-DIAS_x002d_2" TYPE="STUDY">DIAS-2</LINK>; <LINK REF="STD-DIAS-2005" TYPE="STUDY">DIAS 2005</LINK>) tested desmoteplase, and two trials (<LINK REF="STD-Parsons-2012" TYPE="STUDY">Parsons 2012</LINK>; <LINK REF="STD-TNK_x002d_S2B" TYPE="STUDY">TNK-S2B</LINK>) tested tenecteplase. Two trials (<LINK REF="STD-Kikuchi-1994" TYPE="STUDY">Kikuchi 1994</LINK>; <LINK REF="STD-Mori-1992" TYPE="STUDY">Mori 1992</LINK>) compared rt-PA (duteplase) 30 MIU (equivalent to 60 mg alteplase) with 20 MIU (40 mg) given by intravenous infusion for one hour. <LINK REF="STD-Abe-1990" TYPE="STUDY">Abe 1990</LINK> compared rt-PA 2 MU with 1 MU/day intravenously over one hour once per day for seven days. <LINK REF="STD-Ohtomo-1988a" TYPE="STUDY">Ohtomo 1988a</LINK> compared t-PA 60,000 U with 36,000 U/day intravenously over one hour once per day for seven days. <LINK REF="STD-Abe-1981" TYPE="STUDY">Abe 1981</LINK> compared 60,000 U UK/day with 6000 U, <LINK REF="STD-Atarashi-1985" TYPE="STUDY">Atarashi 1985</LINK> compared 240,000 U UK per day with 60,000 U/day - in both trials the UK was given intravenously over one hour once per day for seven days. Only <LINK REF="STD-Chen-2002" TYPE="STUDY">Chen 2002</LINK> used UK in doses of 1 million units compared to 1.5 million units given within 30 minutes, i.e. in a manner compatible with other recent trials testing thrombolysis versus placebo in acute ischaemic stroke. In the case of the DIAS study where more than two regimens were evaluated, only the doses 125 µg/kg versus 90 µg/kg have been included in the analysis. The small numbers in the other dose groups make further statistical analysis meaningless at this stage. In <LINK REF="STD-DEDAS" TYPE="STUDY">DEDAS</LINK> there were 12 protocol violations (six had no perfusion diffusion mismatch and six had internal carotid artery occlusions, which was an exclusion criterion; two in the placebo group, six in the low-dose and four in the high-dose group); for the purpose of this review we included these patients in the analysis. The DIAS study was a phase II dose finding study and several doses were tested; in the data analysis in this review we have only included the doses 125 µg/kg versus 90 µg/kg. In the two trials of tenecteplase (<LINK REF="STD-Parsons-2012" TYPE="STUDY">Parsons 2012</LINK>; <LINK REF="STD-TNK_x002d_S2B" TYPE="STUDY">TNK-S2B</LINK>) the dose 0.25 mg/kg TNK is defined as the high-dose group and the 0.1 mg/kg TNK as the low-dose group. The 0.4 mg/kg TNK group in <LINK REF="STD-TNK_x002d_S2B" TYPE="STUDY">TNK-S2B</LINK> had the lowest numbers, was eliminated early from the trial as inferior to the other two and has not been included in the statistical results.</P>
<P>Five trials tested different drugs - two compared t-PA with UK (<LINK REF="STD-Abe-1990" TYPE="STUDY">Abe 1990</LINK>; <LINK REF="STD-Ohtomo-1988b" TYPE="STUDY">Ohtomo 1988b</LINK>), one compared tissue-cultured UK with UK (<LINK REF="STD-Ohtomo-1985" TYPE="STUDY">Ohtomo 1985</LINK>) and two tested different doses of tenecteplase with rt-PA (<LINK REF="STD-Parsons-2012" TYPE="STUDY">Parsons 2012</LINK>; <LINK REF="STD-TNK_x002d_S2B" TYPE="STUDY">TNK-S2B</LINK>). Abe (<LINK REF="STD-Abe-1990" TYPE="STUDY">Abe 1990</LINK>) compared a higher dose of rt-PA with a lower dose of t-PA and with UK. We have used the data from the higher-dose (2 MU/day) rt-PA group to compare with the UK group (60,000 IU) because of their dose similarity (as judged by dose equivalence for the treatment of acute MI). The tenecteplase trials (<LINK REF="STD-Parsons-2012" TYPE="STUDY">Parsons 2012</LINK>; <LINK REF="STD-TNK_x002d_S2B" TYPE="STUDY">TNK-S2B</LINK>) compared two or three different doses of tenecteplase as well as rt-PA with tenecteplase. We extracted data comparing rt-PA against all doses of TNK as the optimal dose of TNK in the treatment of stroke is not known at this stage and the analysis could be updated in the future in the light of further evidence.</P>
<P>Five trials compared two different routes of administration, four (<LINK REF="STD-EMS-Bridging-Trial" TYPE="STUDY">EMS Bridging Trial</LINK>; <LINK REF="STD-Sen-2008" TYPE="STUDY">Sen 2008</LINK>; <LINK REF="STD-SYNTHESIS" TYPE="STUDY">SYNTHESIS</LINK>; <LINK REF="STD-SYNTHESIS-EXPANSION" TYPE="STUDY">SYNTHESIS EXPANSION</LINK>) tested rt-PA and one (<LINK REF="STD-Ducrocq-2005" TYPE="STUDY">Ducrocq 2005</LINK>) tested UK. The EMS Bridging Trial compared intravenous rt-PA plus intra-arterial rt-PA with intravenous placebo plus intra-arterial rt-PA in a pilot study of 35 patients (<LINK REF="STD-EMS-Bridging-Trial" TYPE="STUDY">EMS Bridging Trial</LINK>). <LINK REF="STD-Ducrocq-2005" TYPE="STUDY">Ducrocq 2005</LINK> is a single-centre, randomised trial comparing intravenous versus intra-arterial UK and had enrolled 27 patients before the study was terminated early due to the high mortality rate. <LINK REF="STD-Sen-2008" TYPE="STUDY">Sen 2008</LINK> conducted a feasibility study comparing intravenous (N = 4) versus intra-arterial (N = 3) rt-PA in patients with acute ischaemic stroke and major vessel occlusion on CT angiogram. <LINK REF="STD-SYNTHESIS" TYPE="STUDY">SYNTHESIS</LINK> was another pilot study evaluating intra-arterial t-PA up to six hours (N = 25 participants randomised, 19 treated) versus intravenous t-PA up to three hours (N = 29 participants randomised, 28 treated). Mechanical thrombus disruption or clot retrieval was allowed (used in 8/19 patients) but not balloon angioplasty. <LINK REF="STD-SYNTHESIS-EXPANSION" TYPE="STUDY">SYNTHESIS EXPANSION</LINK> (N = 362), similar to like <LINK REF="STD-SYNTHESIS" TYPE="STUDY">SYNTHESIS</LINK>, compared intra-arterial with intravenous rt-PA up to 4.5 hours after stroke. Mechanical devices were allowed (in patients allocated intra-arterial therapy, 109/181 had clot fragmentation with a guidewire in addition to rt-PA and a device was used in 56/181 patients). The technique of thrombolytic delivery, mechanical clot disruption or clot extraction and the exact dose of fibrinolytic agent may differ substantially between patients, operators and trials. However, such differences are difficult to account for in the statistical analysis, especially when the data are so scant. The rt-PA in the <LINK REF="STD-SYNTHESIS" TYPE="STUDY">SYNTHESIS</LINK> and <LINK REF="STD-SYNTHESIS-EXPANSION" TYPE="STUDY">SYNTHESIS EXPANSION</LINK> trials was administered as an infusion while in the other two newly included studies the thrombolytic agent was administered with what is described as the 'pulse spray' method. Whether or not this makes a practical difference is not known. Different doses of heparin are routinely administered during the intra-arterial treatment, further confounding the results. Blinding of patients and doctors to treatment is challenging in the interventional studies, increasing the risk for further bias.</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2013-03-28 12:14:46 +0000" MODIFIED_BY="[Empty name]">
<P>We excluded 71 studies because they were either: irrelevant to the current review, lacked randomisation or were confounded by the use of additional agents such as ultrasound or other drugs (see details below and the <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> table). We excluded some studies because they were confounded by different time windows (<LINK REF="STD-Bu-1998" TYPE="STUDY">Bu 1998</LINK>; <LINK REF="STD-Lee-1994" TYPE="STUDY">Lee 1994</LINK>), or confounded by concomitant heparin doses (<LINK REF="STD-Tazaki-1987" TYPE="STUDY">Tazaki 1987</LINK>; <LINK REF="STD-Tsuchiya-1989" TYPE="STUDY">Tsuchiya 1989</LINK>; <LINK REF="STD-Tsuchiya-1990" TYPE="STUDY">Tsuchiya 1990</LINK>), or were stopped after only a few patients had been included (<LINK REF="STD-Riedel-1996" TYPE="STUDY">Riedel 1996</LINK>), or were studies of haematological effects of thrombolysis with no clinical outcome assessments (<LINK REF="STD-Gao-1994" TYPE="STUDY">Gao 1994</LINK>; <LINK REF="STD-Tazaki-1987" TYPE="STUDY">Tazaki 1987</LINK>; <LINK REF="STD-Xu-2000" TYPE="STUDY">Xu 2000</LINK>). The six non-randomised dose-escalation studies were <LINK REF="STD-Del-Zoppo-1989" TYPE="STUDY">Del Zoppo 1989</LINK>, <LINK REF="STD-Morris-2003" TYPE="STUDY">Morris 2003</LINK>, <LINK REF="STD-Qureshi-2002" TYPE="STUDY">Qureshi 2002</LINK>, <LINK REF="STD-ReoPro-Retavase-MRI" TYPE="STUDY">ReoPro Retavase MRI</LINK>, <LINK REF="STD-TASS" TYPE="STUDY">TASS</LINK> and <LINK REF="STD-Yoneda-1998" TYPE="STUDY">Yoneda 1998</LINK>. Two trials (<LINK REF="STD-Konta-1996" TYPE="STUDY">Konta 1996</LINK>; <LINK REF="STD-Wu-1995" TYPE="STUDY">Wu 1995</LINK>), which were awaiting assessment, have now been excluded because, to the best of our knowledge, the data have still not been published in full after five years.</P>
<P>In the process of doing this update we identified several studies that are relevant to the topic of this review but we excluded them because they did not fulfil the inclusion criteria. For example, <LINK REF="STD-TTT_x002d_AIS" TYPE="STUDY">TTT-AIS</LINK> compares two different doses of rt-PA (standard dose 0.90 mg/kg versus 0.72 mg/kg), but it is not a randomised study. <LINK REF="STD-J_x002d_ACT" TYPE="STUDY">J-ACT</LINK> tests the efficacy of 0.6 mg/kg rt-PA in acute stroke in the Japanese population (contrary to the widely used 0.9 mg/kg); we also excluded this single-arm, non-randomised trial, and a further registry (<LINK REF="STD-J_x002d_MARS-2010" TYPE="STUDY">J-MARS 2010</LINK>), from the review. <LINK REF="STD-ITAIS_x002d_II" TYPE="STUDY">ITAIS-II</LINK> is testing the use of CT perfusion and angiography imaging to select patients for thrombolysis but is not a randomised drug comparison. Microplasmin (<LINK REF="STD-MITI_x002d_IV" TYPE="STUDY">MITI-IV</LINK>) is a truncated form of plasmin, has an extremely short half life when given intravenously and is not considered to be a true thrombolytic drug, so we also excluded it.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2013-03-28 12:16:58 +0000" MODIFIED_BY="[Empty name]">
<P>The risk of bias in included studies is summarised in <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>.</P>
<ALLOCATION MODIFIED="2013-01-22 15:37:39 +0000" MODIFIED_BY="[Empty name]">
<P>Details about concealment of randomisation were generally scant, so it is difficult to tell how adequate this was. All older trials used sequentially numbered containers for randomisation except two trials (<LINK REF="STD-Abe-1981" TYPE="STUDY">Abe 1981</LINK>; <LINK REF="STD-Abe-1990" TYPE="STUDY">Abe 1990</LINK>), in which it was unclear whether the containers were sequentially numbered or not. Some of the more recent trials used central telephone randomisation (<LINK REF="STD-DEDAS" TYPE="STUDY">DEDAS</LINK>; <LINK REF="STD-DIAS-2005" TYPE="STUDY">DIAS 2005</LINK>; <LINK REF="STD-TNK_x002d_S2B" TYPE="STUDY">TNK-S2B</LINK>) though others used sealed pre-packed drugs or sequential numbered envelopes.</P>
</ALLOCATION>
<BLINDING MODIFIED="2013-03-28 12:15:00 +0000" MODIFIED_BY="[Empty name]">
<P>Most trials were double-blind so patients and doctors (including the outcome assessors) who treated the patients were blinded. However, some trials were open-label (<LINK REF="STD-Sen-2008" TYPE="STUDY">Sen 2008</LINK>; <LINK REF="STD-SYNTHESIS" TYPE="STUDY">SYNTHESIS</LINK>; <LINK REF="STD-SYNTHESIS-EXPANSION" TYPE="STUDY">SYNTHESIS EXPANSION</LINK>) or conducted in few centres with local outcome assessors (<LINK REF="STD-Ducrocq-2005" TYPE="STUDY">Ducrocq 2005</LINK>), making it difficult to blind the clinical outcomes to treatment allocation even if the assessments were said to be performed without knowledge of treatment allocation. In <LINK REF="STD-SYNTHESIS-EXPANSION" TYPE="STUDY">SYNTHESIS EXPANSION</LINK>, 90-day follow-up was by a single neurologist by telephone blinded to treatment allocation.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2013-01-22 15:41:05 +0000" MODIFIED_BY="[Empty name]">
<P>After consultation with the trial authors, we excluded few studies because of missing data where the data had been collected in the first place. A more major problem was that many trials did not collect data on functional outcome or symptomatic intracerebral haemorrhage and we therefore excluded them. Details of these are listed in the relevant sections. Most of these studies were small and likely to be methodologically weak for other reasons.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2012-12-26 17:40:21 +0000" MODIFIED_BY="[Empty name]">
<P>We did not find any evidence of selective reporting bias.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2013-03-28 12:16:58 +0000" MODIFIED_BY="[Empty name]">
<P>No serious imbalance in baseline prognostic factors was reported between treatment groups, although in two trials there were more male patients in the lower-dose group, and in one trial (<LINK REF="STD-EMS-Bridging-Trial" TYPE="STUDY">EMS Bridging Trial</LINK>) there were more severe strokes and occluded arteries on angiography in the patients randomised to intravenous plus intra-arterial rt-PA than to intravenous placebo plus intra-arterial rt-PA. Intention-to-treat analyses were not reported in all trials but the data in all trials were sufficient to allow us to perform an intention-to-treat analysis in this review.</P>
<SUBSECTION>
<HEADING LEVEL="4">Other methodological factors</HEADING>
<P>There is marked heterogeneity in the included studies as practices have changed over the last 30 years. The trial methodology and published data of the studies included in the last update are more standardised when compared with the earlier studies of this review: they now typically contain basic information on baseline stroke characteristics and the 90-day modified Rankin Scale. Seven of the early trials aimed to include patients with cerebral thrombosis, but most did not define what that was. One trial (<LINK REF="STD-Mori-1992" TYPE="STUDY">Mori 1992</LINK>) aimed to include thromboembolic stroke (source unspecified) of the internal carotid artery territory. Two trials used intra-arterial angiography to document the presence of thrombus in a cerebral artery (<LINK REF="STD-EMS-Bridging-Trial" TYPE="STUDY">EMS Bridging Trial</LINK>; <LINK REF="STD-Mori-1992" TYPE="STUDY">Mori 1992</LINK>). One trial (<LINK REF="STD-Kikuchi-1994" TYPE="STUDY">Kikuchi 1994</LINK>) aimed to include only patients with cerebral embolism (source unspecified). All the patients had a CT brain scan to exclude intracranial haemorrhage prior to randomisation. Most trials (<LINK REF="STD-Chen-2002" TYPE="STUDY">Chen 2002</LINK>; <LINK REF="STD-Ducrocq-2005" TYPE="STUDY">Ducrocq 2005</LINK>; <LINK REF="STD-EMS-Bridging-Trial" TYPE="STUDY">EMS Bridging Trial</LINK>; <LINK REF="STD-Kikuchi-1994" TYPE="STUDY">Kikuchi 1994</LINK>; <LINK REF="STD-Mori-1992" TYPE="STUDY">Mori 1992</LINK>; <LINK REF="STD-Parsons-2012" TYPE="STUDY">Parsons 2012</LINK>; <LINK REF="STD-Sen-2008" TYPE="STUDY">Sen 2008</LINK>; <LINK REF="STD-SYNTHESIS" TYPE="STUDY">SYNTHESIS</LINK>; <LINK REF="STD-TNK_x002d_S2B" TYPE="STUDY">TNK-S2B</LINK>; <LINK REF="STD-Wang-2003" TYPE="STUDY">Wang 2003</LINK>) entered patients within six hours of stroke onset. Three studies (<LINK REF="STD-DEDAS" TYPE="STUDY">DEDAS</LINK>; <LINK REF="STD-DIAS_x002d_2" TYPE="STUDY">DIAS-2</LINK>; <LINK REF="STD-DIAS-2005" TYPE="STUDY">DIAS 2005</LINK>) extended this window to nine hours if there was more than 20% potentially salvageable tissue suggested by perfusion imaging (CT or MR). Five trials entered patients within three to five days and one trial (<LINK REF="STD-Abe-1981" TYPE="STUDY">Abe 1981</LINK>) within 14 days. One trial (<LINK REF="STD-Mori-1992" TYPE="STUDY">Mori 1992</LINK>) excluded patients with visible early infarction on the pre-randomisation CT scan. One tenecteplase trial (<LINK REF="STD-Parsons-2012" TYPE="STUDY">Parsons 2012</LINK>) only included patients with a perfusion lesion on CT perfusion imaging that was 20% larger than the infarct core and an associated arterial occlusion on CT angiography pre-randomisation.</P>
<P>In the early studies, it was not possible to extract much information on the baseline characteristics of the patients or the relation to treatment outcome. For example, <LINK REF="STD-Kikuchi-1994" TYPE="STUDY">Kikuchi 1994</LINK> used the Hemispheric Stroke Scale (HSS) to classify patients at randomisation (32% of the group given 30 MIU t-PA, and 37% of those given 20 MIU t-PA, were HSS 1 to 60), but it was not possible to relate these data to outcome following treatment. However, all the new studies included in the latest update contained baseline and post-treatment characteristics such as stroke severity scores and functional outcome at the end of follow-up for each treatment group. In the <LINK REF="STD-EMS-Bridging-Trial" TYPE="STUDY">EMS Bridging Trial</LINK>, there were more patients with severe strokes (and also more patients with occlusive thrombus in the intracranial arteries on angiography) in the patients randomised to intravenous plus intra-arterial rt-PA than in those randomised to intravenous placebo plus intra-arterial rt-PA (<LINK REF="STD-EMS-Bridging-Trial" TYPE="STUDY">EMS Bridging Trial</LINK>). In <LINK REF="STD-SYNTHESIS" TYPE="STUDY">SYNTHESIS</LINK>, six of the 25 patients randomised to intra-arterial thrombolysis did not receive any treatment (no vessel occlusion, five of the six patients improved spontaneously); this compares with one of the 29 patients randomised to intravenous thrombolysis that improved spontaneously. In <LINK REF="STD-SYNTHESIS-EXPANSION" TYPE="STUDY">SYNTHESIS EXPANSION</LINK>, 15/181 patients allocated to intra-arterial treatment did not receive it (six improved clinically, three had no occlusion, three were dissections, one had a bleeding diathesis, one groin haematoma, one due to the delayed arrival of the interventionist) versus 3/181 allocated to intravenous treatment (one spontaneously improved, two had thrombectomy).</P>
<P>Antithrombotic drugs were not allowed during the whole study period in five trials (<LINK REF="STD-Abe-1981" TYPE="STUDY">Abe 1981</LINK>; <LINK REF="STD-Atarashi-1985" TYPE="STUDY">Atarashi 1985</LINK>; <LINK REF="STD-Ohtomo-1985" TYPE="STUDY">Ohtomo 1985</LINK>; <LINK REF="STD-Ohtomo-1988a" TYPE="STUDY">Ohtomo 1988a</LINK>; <LINK REF="STD-Ohtomo-1988b" TYPE="STUDY">Ohtomo 1988b</LINK>) although an exception could be made if the doctors thought that antithrombotic drugs were needed. Antithrombotic drugs were not allowed within the treatment period but could be allowed thereafter in four trials (<LINK REF="STD-Abe-1990" TYPE="STUDY">Abe 1990</LINK>; <LINK REF="STD-EMS-Bridging-Trial" TYPE="STUDY">EMS Bridging Trial</LINK>; <LINK REF="STD-Kikuchi-1994" TYPE="STUDY">Kikuchi 1994</LINK>; <LINK REF="STD-Mori-1992" TYPE="STUDY">Mori 1992</LINK>). All patients received aspirin 300 mg starting 24 hours after randomisation in <LINK REF="STD-Chen-2002" TYPE="STUDY">Chen 2002</LINK>. No antithrombotics were allowed in the first 24 hours in <LINK REF="STD-Ducrocq-2005" TYPE="STUDY">Ducrocq 2005</LINK> or <LINK REF="STD-DIAS-2005" TYPE="STUDY">DIAS 2005</LINK>. <LINK REF="STD-Sen-2008" TYPE="STUDY">Sen 2008</LINK>, <LINK REF="STD-SYNTHESIS" TYPE="STUDY">SYNTHESIS</LINK> and <LINK REF="STD-SYNTHESIS-EXPANSION" TYPE="STUDY">SYNTHESIS EXPANSION</LINK> mentioned the use a variable amount of intra-arterial heparin either as a bolus (<LINK REF="STD-SYNTHESIS" TYPE="STUDY">SYNTHESIS</LINK>; <LINK REF="STD-SYNTHESIS-EXPANSION" TYPE="STUDY">SYNTHESIS EXPANSION</LINK>) or through heparinised flush solution during the interventional treatment (<LINK REF="STD-Sen-2008" TYPE="STUDY">Sen 2008</LINK>).</P>
<P>Eight trials used the 'overall neurological improvement rating' and side effects as their main outcome measures. Four of the trials assessed 'utility' (as judged by the neurological improvement and side effects). The others used standard stroke outcome measures: modified Rankin scale (mRS), European Stroke Scale (ESS), Barthel Index (BI). The number of patients who died, or had an intra or extracranial haemorrhage, could be extracted from all trials except one (<LINK REF="STD-Kikuchi-1994" TYPE="STUDY">Kikuchi 1994</LINK>) in which extracranial haemorrhage was not reported. Seven trials mentioned activities of daily living (ADL) as part of their overall improvement measure, but most only reported the number of patients with improvements in the ADL score compared with their baseline score. Thus, we were not able to extract the number of dependent patients except from <LINK REF="STD-Chen-2002" TYPE="STUDY">Chen 2002</LINK>, the <LINK REF="STD-EMS-Bridging-Trial" TYPE="STUDY">EMS Bridging Trial</LINK> and <LINK REF="STD-Mori-1992" TYPE="STUDY">Mori 1992</LINK>, which used the BI and mRS to measure functional outcome. <LINK REF="STD-Sen-2008" TYPE="STUDY">Sen 2008</LINK> only describes neurological improvement at three months (defined as reduction in the National Institutes of Health Stroke Scale (NIHSS) score by four or more points) and it was not possible to extract the number of dependent patients at the end of follow-up.</P>
<P>Dependency was differently defined and followed up. <LINK REF="STD-Kikuchi-1994" TYPE="STUDY">Kikuchi 1994</LINK> measured the BI at one month after the stroke, but only reported the mean BI for the two treatment groups, not the actual number of dependent patients. <LINK REF="STD-Chen-2002" TYPE="STUDY">Chen 2002</LINK> used a BI less than 95 and a mRS greater than 1, and the <LINK REF="STD-EMS-Bridging-Trial" TYPE="STUDY">EMS Bridging Trial</LINK> published details of individual patients' mRS. <LINK REF="STD-SYNTHESIS" TYPE="STUDY">SYNTHESIS</LINK> and <LINK REF="STD-SYNTHESIS-EXPANSION" TYPE="STUDY">SYNTHESIS EXPANSION</LINK> defined good clinical outcome as mRS of 0 or 1. Where available, we defined death or dependency at the end of follow-up as mRS 3 to 6 at the latest time interval available.</P>
<P>The duration of follow-up was only one month in eight trials and three months in 12 trials. The one-month functional outcome might not be relevant to the final true outcome because of insufficient time to allow maximum recovery.</P>
</SUBSECTION>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2013-03-28 12:18:18 +0000" MODIFIED_BY="jmw ">
<P>This results section is split into three parts. The first part deals with direct comparisons of different doses of the same drug, the second part with direct comparisons of different drugs, and the third part with direct comparisons of different routes of administration of the same drug. It was not always possible to assess for statistically significant heterogeneity because of a paucity of trials, but where it was possible to test, none of the outcomes showed any statistically significant heterogeneity.</P>
<SUBSECTION>
<HEADING LEVEL="3">1. Comparison of higher dose with lower dose of the same drug</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">(a) Death or dependency at the end of follow-up</HEADING>
<P>Seven trials (<LINK REF="STD-Chen-2002" TYPE="STUDY">Chen 2002</LINK>; <LINK REF="STD-DEDAS" TYPE="STUDY">DEDAS</LINK>; <LINK REF="STD-DIAS_x002d_2" TYPE="STUDY">DIAS-2</LINK>; <LINK REF="STD-DIAS-2005" TYPE="STUDY">DIAS 2005</LINK>; <LINK REF="STD-Mori-1992" TYPE="STUDY">Mori 1992</LINK>; <LINK REF="STD-Parsons-2012" TYPE="STUDY">Parsons 2012</LINK>; <LINK REF="STD-TNK_x002d_S2B" TYPE="STUDY">TNK-S2B</LINK>) provided this outcome (at three months after the stroke, apart from <LINK REF="STD-Mori-1992" TYPE="STUDY">Mori 1992</LINK> where the follow-up was one month) and no statistically significant difference was observed between the higher dose and lower dose groups (OR 0.86, 95% CI 0.62 to 1.19, I²<SUP> </SUP>= 27%) (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>). <LINK REF="STD-Kikuchi-1994" TYPE="STUDY">Kikuchi 1994</LINK> measured the BI and found no statistically significant difference in the mean BI score between the 20 and the 30 MIU treatment groups (mean BI score 46 versus 49 respectively, P = 0.8).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(b) Death (early and late)</HEADING>
<P>Data for this outcome were available in 10 and 12 trials respectively regarding early (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>) and late deaths (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>). There was no statistically significant difference between the higher and lower-dose groups in terms of early (OR 1.09, 95% CI 0.66 to 1.80) or total deaths by the end of follow-up (OR 1.22, 95% CI 0.82 to 1.80, I²<SUP> </SUP>= 32%). In patients allocated to the higher versus lower dose of desmoteplase, there were significantly more deaths at the end of the follow-up (OR 3.21, 95% CI 1.23 to 8.39).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(c) 'Significant' and fatal intracranial haemorrhage</HEADING>
<P>All 13 trials provide data on 'significant' intracranial haemorrhage (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>) and 10 on fatal haemorrhages (<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>). <LINK REF="STD-Kikuchi-1994" TYPE="STUDY">Kikuchi 1994</LINK> provides only the number of non-fatal intracranial haemorrhages but not the total symptomatic intracranial haemorrhages within the first two weeks. The definition of 'significant' haemorrhage is not always clear or standardised across the studies. Some trials define symptomatic intracranial haemorrhage (<LINK REF="STD-DEDAS" TYPE="STUDY">DEDAS</LINK>; <LINK REF="STD-DIAS_x002d_2" TYPE="STUDY">DIAS-2</LINK>; <LINK REF="STD-DIAS-2005" TYPE="STUDY">DIAS 2005</LINK>) as intracranial haemorrhage within 72 hours of treatment that led to an increase by four points or more in the NIHSS score. Others (<LINK REF="STD-TNK_x002d_S2B" TYPE="STUDY">TNK-S2B</LINK>) define symptomatic haemorrhage as any haemorrhage seen on a follow-up CT that can explain any neurological worsening (appearance of new deficit or worsening of previous deficit persisting more than eight hours). Some trials (<LINK REF="STD-Chen-2002" TYPE="STUDY">Chen 2002</LINK>; <LINK REF="STD-Kikuchi-1994" TYPE="STUDY">Kikuchi 1994</LINK>; <LINK REF="STD-Ohtomo-1985" TYPE="STUDY">Ohtomo 1985</LINK>; <LINK REF="STD-Ohtomo-1988a" TYPE="STUDY">Ohtomo 1988a</LINK>; <LINK REF="STD-Ohtomo-1988b" TYPE="STUDY">Ohtomo 1988b</LINK>) did not clearly describe the relationship between clinical deterioration and the CT-confirmed intracranial haemorrhages, but they classified the severity of intracranial haemorrhage as mild, moderate and severe (also not clearly defined). For those studies we collected the number of moderate or worse (or massive or mass effect on CT) as 'significant intracranial haemorrhages'. There were more significant intracranial haemorrhages in the patients allocated to higher doses than lower doses (OR 1.43, 95% CI 0.81 to 2.52, I² = 0%), but the difference was not statistically significant. There were significantly more fatal intracranial haemorrhages in the high-dose group at the end of follow-up (OR 2.71, 95% CI 1.22 to 6.04, I² = 0%) although the confidence intervals were wide because of the small number of events. If confirmed in future large trials, this would be equivalent to 23 more fatal intracranial haemorrhages per 1000 patients treated with high versus low-dose thrombolytic drugs. Despite the failure of some trials to define intracranial haemorrhage in terms of its clinical effect, it was possible to identify important relationships. For example, in <LINK REF="STD-Kikuchi-1994" TYPE="STUDY">Kikuchi 1994</LINK>, eight of the 13 patients in the group treated with 30 MIU rt-PA who died were said to have 'cerebral haemorrhage with mass effect' or 'massive cerebral haemorrhage' compared with only one of the 13 patients in the group treated with 20 MIU rt-PA.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(d) Major extracranial haemorrhage</HEADING>
<P>Nine trials provided these data (<LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>). There were more major extracranial haemorrhages in the patients allocated to the higher than the lower dose (OR 1.72, 95% CI 0.93 to 3.21) but the difference was not statistically significant.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">2. Comparison of one drug with another</HEADING>
<P>Five trials compared one agent with another - one trial of rt-PA versus UK (<LINK REF="STD-Abe-1990" TYPE="STUDY">Abe 1990</LINK>), one trial of t-PA versus UK (<LINK REF="STD-Ohtomo-1988b" TYPE="STUDY">Ohtomo 1988b</LINK>), one trial of tissue-cultured UK versus UK (<LINK REF="STD-Ohtomo-1985" TYPE="STUDY">Ohtomo 1985</LINK>) and two trials of different doses of tenecteplase versus rt-PA (<LINK REF="STD-Parsons-2012" TYPE="STUDY">Parsons 2012</LINK>; <LINK REF="STD-TNK_x002d_S2B" TYPE="STUDY">TNK-S2B</LINK>). With the limitations described above, we included two trials (<LINK REF="STD-Parsons-2012" TYPE="STUDY">Parsons 2012</LINK>; <LINK REF="STD-TNK_x002d_S2B" TYPE="STUDY">TNK-S2B</LINK>) in this section comparing the cumulative outcome from two different doses of tenecteplase versus t-PA.</P>
<SUBSECTION>
<HEADING LEVEL="4">(a) Death or dependency at the end of follow-up</HEADING>
<P>Only the tenecteplase trials contribute to this outcome. There was no significant difference in death or dependency at the end of follow-up between tenecteplase and t-PA (OR 0.58, 95% CI 0.31 to 1.09) (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(b) Death</HEADING>
<P>All trials reported the number of patients who died and the cause. There was no statistically significant difference in the number of deaths between patients treated with UK and another agent within the first two weeks (tissue-cultured UK versus UK, OR 1.37, 95% CI 0.23 to 8.09; rt-PA versus UK, OR 0.90, 95% CI 0.27 to 2.98). The tenecteplase trials did not provide this outcome (<LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>). There were slightly more deaths by the end of follow-up (<LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>) in the patients allocated to tissue-cultured UK-treated then in those allocated to UK (OR 1.81, 95% CI 0.36, to 9.19) and slightly fewer deaths in those allocated to rt-PA than in those allocated to UK (OR 0.72, 95% CI 0.26 to 2.02), but neither comparison was statistically significant. There was a tendency for fewer deaths at the end of follow-up in those allocated to tenecteplase versus those allocated to rt-PA, but this did not reach statistical significance (OR 0.52, 95% CI 0.21 to 1.27).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(c) <I>'</I>Significant' and fatal intracranial haemorrhage (the heading 'significant' has been retained for consistency)</HEADING>
<P>This outcome was available in all trials with the exception of the <LINK REF="STD-TNK_x002d_S2B" TYPE="STUDY">TNK-S2B</LINK> trial where the number of fatal intracranial haemorrhages could not be extracted from the published data. There was a trend to fewer symptomatic intracranial haemorrhages within the first two weeks in the patients allocated to tissue-cultured UK or rt-PA than in those allocated to conventional UK but there were few events (one versus zero and one versus six haemorrhages respectively) and the difference was not statistically significant (OR 0.12, 95% CI 0.0 to 6.21; OR 0.26, 95% CI 0.06 to 1.18 respectively) (<LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>). Similarly, there was no significant difference in significant intracranial haemorrhage between those allocated tenecteplase or t-PA (OR 0.74, 95% CI  0.20 to 2.76). There were no fatal haemorrhages in the tissue-cultured UK versus UK comparison and only one fatal intracranial haemorrhage during the whole study period in the UK versus rt-PA comparison (OR 7.91, 95% CI 0.16 to 399.54) and only two fatal intracerebral haemorrhages in the TNK versus rt-PA comparison in one tenecteplase trial (<LINK REF="STD-Parsons-2012" TYPE="STUDY">Parsons 2012</LINK>; OR 0.47, 95% CI 0.02 to 9.02) (<LINK REF="CMP-002.05" TYPE="ANALYSIS">Analysis 2.5</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(d) Major extracranial haemorrhage</HEADING>
<P>There were no major extracranial haemorrhages in the tissue-cultured UK versus UK comparison (<LINK REF="CMP-002.06" TYPE="ANALYSIS">Analysis 2.6</LINK>). Only one non-fatal event occurred in each group in the UK versus rt-PA comparison (OR 1.07, 95% CI 0.07 to 17.17). There was one major extracranial non-fatal haemorrhage in the tenecteplase group versus none in the rt-PA group in the <LINK REF="STD-TNK_x002d_S2B" TYPE="STUDY">TNK-S2B</LINK> trial (OR 3.99, 95% CI 0.05 to 318.43) but extracranial haemorrhage was not reported in <LINK REF="STD-Parsons-2012" TYPE="STUDY">Parsons 2012</LINK>. No fatal events occurred.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">3. Comparison of different routes of administration of the same drug</HEADING>
<P>There are five studies in this category, four comparing intravenous versus intra-arterial rt-PA (<LINK REF="STD-EMS-Bridging-Trial" TYPE="STUDY">EMS Bridging Trial</LINK>; <LINK REF="STD-Sen-2008" TYPE="STUDY">Sen 2008</LINK>; <LINK REF="STD-SYNTHESIS" TYPE="STUDY">SYNTHESIS</LINK>; <LINK REF="STD-SYNTHESIS-EXPANSION" TYPE="STUDY">SYNTHESIS EXPANSION</LINK>) and one comparing intravenous versus intra-arterial UK (<LINK REF="STD-Ducrocq-2005" TYPE="STUDY">Ducrocq 2005</LINK>). Only one trial compares a combination of intravenous rt-PA plus intra-arterial rt-PA with intravenous placebo plus intra-arterial rt-PA (<LINK REF="STD-EMS-Bridging-Trial" TYPE="STUDY">EMS Bridging Trial</LINK>). The <LINK REF="STD-EMS-Bridging-Trial" TYPE="STUDY">EMS Bridging Trial</LINK> only included 35 patients and had an imbalance in baseline stroke severity which did not reach conventional statistical significance but which may, none the less, have influenced the outcomes in the two treatment arms in favour of intravenous placebo plus intra-arterial rt-PA. <LINK REF="STD-Ducrocq-2005" TYPE="STUDY">Ducrocq 2005</LINK> is a single-centre, randomised trial comparing intravenous versus intra-arterial urokinase: 900,000 units of UK were given within six hours of stroke onset to 27 patients intravenously or intra-arterially (or less in the intra-arterial group if recanalisation had been achieved). The study was terminated early due to a high mortality rate. <LINK REF="STD-Sen-2008" TYPE="STUDY">Sen 2008</LINK> performed a feasibility study comparing intravenous (N = 4) versus intra-arterial (N = 3) t-PA in patients with acute ischaemic stroke who could start treatment within three hours of symptom onset and had evidence of major arterial occlusion on CT angiogram. <LINK REF="STD-SYNTHESIS" TYPE="STUDY">SYNTHESIS</LINK> was another pilot study evaluating intra-arterial t-PA up to six hours (N = 25 patients randomised, 19 treated) versus intravenous t-PA up to three hours (N = 29 patients randomised, 28 treated). Mechanical thrombus disruption or clot retrieval was allowed (used in 8/19 patients) but not balloon angioplasty. <LINK REF="STD-SYNTHESIS-EXPANSION" TYPE="STUDY">SYNTHESIS EXPANSION</LINK> was a larger trial of intravenous (N = 181) versus intra-arterial (N = 181) rt-PA up to 4.5 hours after ischaemic stroke. Mechanical devices were allowed in addition to intra-arterial rt-PA and were used in 56/181 patients.</P>
<SUBSECTION>
<HEADING LEVEL="4">(a) Death or dependency at the end of follow-up</HEADING>
<P>Four trials provided these data (<LINK REF="STD-Ducrocq-2005" TYPE="STUDY">Ducrocq 2005</LINK>; <LINK REF="STD-EMS-Bridging-Trial" TYPE="STUDY">EMS Bridging Trial</LINK>; <LINK REF="STD-SYNTHESIS" TYPE="STUDY">SYNTHESIS</LINK>; <LINK REF="STD-SYNTHESIS-EXPANSION" TYPE="STUDY">SYNTHESIS EXPANSION</LINK>). The fifth study (<LINK REF="STD-Sen-2008" TYPE="STUDY">Sen 2008</LINK>) only describes neurological improvement at three months (defined as reduction in the NIHSS score by four or more points). There was no difference in the number of patients who were dead or dependent between those allocated intra-arterial thrombolysis (combined OR 1.08, 95% CI 0.15 to 1.55). The addition of the recently completed <LINK REF="STD-SYNTHESIS-EXPANSION" TYPE="STUDY">SYNTHESIS EXPANSION</LINK> trial has increased the available data four fold - although the numbers are still small there is little evidence of any benefit of intra-arterial over intravenous therapy (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(b) Death</HEADING>
<P>There were no significant differences in the number of patients who died within the first two weeks between the two groups (OR 0.96, 95% CI 0.51 to 1.79) (<LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>). Similarly, at the end of follow-up, there was no significant difference in the number of patients who had died between the two treatment groups (OR 0.81, 95% CI 0.47 to 1.39) (<LINK REF="CMP-003.03" TYPE="ANALYSIS">Analysis 3.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(c) Symptomatic and fatal intracranial haemorrhage</HEADING>
<P>All five studies provided data on symptomatic and fatal intracranial haemorrhage. The number of incidents is small and the confidence intervals are wide. There was no statistically significant difference between the patients allocated intra-arterial or intravenous treatment in the number of symptomatic (OR 1.10, 95% CI 0.4 to 2.25) (<LINK REF="CMP-003.04" TYPE="ANALYSIS">Analysis 3.4</LINK>) or fatal intracranial haemorrhages (OR 0.67, 95% CI 0.21 to 2.11) (<LINK REF="CMP-003.05" TYPE="ANALYSIS">Analysis 3.5</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(d) Major extracranial haemorrhage</HEADING>
<P>Only two studies (<LINK REF="STD-SYNTHESIS" TYPE="STUDY">SYNTHESIS</LINK>; <LINK REF="STD-SYNTHESIS-EXPANSION" TYPE="STUDY">SYNTHESIS EXPANSION</LINK>) gave details on extracranial haemorrhages describing 4/210 cases with extracranial haemorrhage in those allocated to intravenous therapy and 4/206 patients with groin haematomas two of which required surgical excision in those allocated to intra-arterial therapy. </P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2013-03-28 12:25:31 +0000" MODIFIED_BY="jmw ">
<P>The data from trials comparing different doses of the same thrombolytic agent, two different agents or two routes of administration are limited to only 2527 patients. In contrast to the evidence on thrombolytic therapy versus control, where more than 9000 patients have been randomised to thrombolysis or control (<LINK REF="REF-Wardlaw-2009" TYPE="REFERENCE">Wardlaw 2009</LINK>; <LINK REF="REF-Wardlaw-2010" TYPE="REFERENCE">Wardlaw 2010</LINK>) and more than 6000 between rt-PA and control alone (<LINK REF="REF-Wardlaw-2012" TYPE="REFERENCE">Wardlaw 2012</LINK>), the number of included patients in the group and subgroup analysis of this companion thrombolysis review is very small. Therefore, regrettably, we are not able to report any results that will have any significant impact on everyday clinical practice. The new studies included in this update are mainly &#8216;dose ranging&#8217; studies evaluating new thrombolytic agents such as desmoteplase and tenecteplase, or 'pilot' or larger interventional studies comparing intravenous thrombolysis versus intra-arterial treatment, and therefore are very limited in their conclusions.</P>
<P>Two ongoing trials are comparing intra-arterial with intravenous thrombolysis (<LINK REF="STD-BASICS" TYPE="STUDY">BASICS</LINK>; <LINK REF="STD-ITAIS" TYPE="STUDY">ITAIS</LINK>). There is one other completed but unpublished trial (<LINK REF="STD-FRALYSE" TYPE="STUDY">FRALYSE</LINK>). The amount of data on intravenous versus intra-arterial therapy increased four-fold from 123 to 485 patients with the publication of <LINK REF="STD-SYNTHESIS-EXPANSION" TYPE="STUDY">SYNTHESIS EXPANSION</LINK>. Other ongoing trials are comparing different doses of rt-PA (e.g. <LINK REF="STD-ENCHANTED" TYPE="STUDY">ENCHANTED</LINK>) and should complete in the next five years.</P>
<P>On the early trials of this review there was little evidence on functional outcome - most of these trials did not collect such data, and two that did measure the BI (<LINK REF="STD-Kikuchi-1994" TYPE="STUDY">Kikuchi 1994</LINK>; <LINK REF="STD-Mori-1992" TYPE="STUDY">Mori 1992</LINK>) did it at only one month after the stroke, at which stage patients may still be improving. On a positive note, the published data in the last decade seem now to be more standardised when compared with earlier studies and typically contain basic information on baseline stroke characteristics and 90-day mRS. Hopefully this will bear fruit in future years as larger, better conducted and reported studies become available, enabling more meaningful comparisons and meta-analyses.</P>
<P>Many of the early trials used somewhat unconventional dosing regimens, such as a once daily dose for seven days, and may have started treatment up to several days after the stroke, so it is difficult to extrapolate these results to the sort of dosing regimens used in the recent trials comparing thrombolysis with placebo (<LINK REF="REF-Wardlaw-2009" TYPE="REFERENCE">Wardlaw 2009</LINK>; <LINK REF="REF-Wardlaw-2010" TYPE="REFERENCE">Wardlaw 2010</LINK>). However, most of these early trials do not provide functional outcome data, therefore data on functional outcome come from recent trials (e.g. <LINK REF="STD-EMS-Bridging-Trial" TYPE="STUDY">EMS Bridging Trial</LINK>; <LINK REF="STD-Parsons-2012" TYPE="STUDY">Parsons 2012</LINK>) testing more conventional dosing regimens.</P>
<P>However, these limited data do suggest that there is some evidence that lower doses of thrombolytic agents cause fewer fatal (statistically significant) and 'clinically significant' (not statistically significant) intracranial haemorrhages. But there was no effect on the number of early deaths or total deaths at the end of follow-up, or the death and disability outcome at the end of the follow-up (and too few extracranial haemorrhages to make any comments). In the desmoteplase subgroup, there were significantly fewer deaths in the lower-dose than the high-dose subgroup.</P>
<P>The data on the comparison of different thrombolytic agents (rt-PA, t-PA, tissue-cultured UK, UK and tenecteplase) are extremely limited, with too few patients and outcome events to make any useful conclusions. There are no data comparing the dose of SK or of SK with other thrombolytic drugs. Desmoteplase and tenecteplase are variants of the native t-PA with theoretically improved pharmacokinetic properties. The prematurely terminated <LINK REF="STD-TNK_x002d_S2B" TYPE="STUDY">TNK-S2B</LINK> trial included a subgroup (N = 31) of patients that received t-PA; too small to draw any conclusions. <LINK REF="STD-Parsons-2012" TYPE="STUDY">Parsons 2012</LINK> had 25 patients randomised to rt-PA and only 50 to two different doses of TNK, again rather too small for reliable conclusions.</P>
<P>Recently there has been an emerging interest in the use of interventional devices to treat acute stroke (mechanical devices alone or in addition to pharmacological therapy) and many centres in developed countries worldwide offer intra-arterial thrombolysis/thrombectomy for stroke due to large vessel occlusion (<LINK REF="REF-RECANALISE-2009" TYPE="REFERENCE">RECANALISE 2009</LINK>). This interest is often based on concepts such as that intra-arterial therapy or mechanical devices, or both, increase recanalisation rates, or are safer because they use lower doses of thrombolytic drug (<LINK REF="REF-Ciccone-2007" TYPE="REFERENCE">Ciccone 2007</LINK>). Until the publication of <LINK REF="STD-SYNTHESIS-EXPANSION" TYPE="STUDY">SYNTHESIS EXPANSION</LINK> and <LINK REF="STD-IMS_x002d_III" TYPE="STUDY">IMS-III</LINK>, the use of interventional mechanical devices was based on very limited evidence, mostly registries or case series and virtually none of it randomised (<LINK REF="REF-Galimanis-2012" TYPE="REFERENCE">Galimanis 2012</LINK>). IMS-111 showed no benefit for mechanical intra-arterial devices over intravenous rt-PA, which taken together with the data in <LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK> shows no benefit for intra-arterial/interventional mechanical devices over intravenous rt-PA. There is also increasing interest in the use of adjunctive methods to enhance pharmacological or spontaneous thrombolysis, for example using transcranial ultrasound (<LINK REF="REF-Tsivgoulis-2010" TYPE="REFERENCE">Tsivgoulis 2010</LINK>). At the outset of this update we were interested in evaluating the different interventional techniques and devices. However, it soon became clear that this would be premature as there are no randomised studies comparing the various interventional procedures. It was therefore more important to establish whether intra-arterial treatment works in the first place and if it offers any particular advantage over intravenous treatment. The four randomised studies of intravenous versus intra-arterial treatment that have been conducted so far were small (123 patients in total) and too heterogeneous to draw any definitive conclusions. Differences in stroke severity, intra-arterial techniques, dose and technique of thrombolytic administration, use of mechanical devices, variable doses of heparin, difficulties of blinding and subsequent follow-up assessment are only a few of the factors that may introduce significant bias in these small studies. This review indicates that intra-arterial therapy confers no benefit over intravenous therapy either in terms of reduced dependency or death or reduced haemorrhage. At present, intravenous rt-PA remains best practice and intra-arterial therapy or mechanica devices should only be used in randomised trials or in exceptional situations.</P>
<P>Two trials (<LINK REF="STD-Chen-2002" TYPE="STUDY">Chen 2002</LINK>; <LINK REF="STD-Kikuchi-1994" TYPE="STUDY">Kikuchi 1994</LINK>) contributed most of the data on significant intracranial haemorrhage, yet there were problems in the definition of the intracranial haemorrhage - the authors graded the severity of the haemorrhage on the CT brain scan appearance, not on whether the haemorrhage was associated with clinical deterioration or death. <LINK REF="STD-Chen-2002" TYPE="STUDY">Chen 2002</LINK> used the term 'symptomatic intracranial haemorrhage' without an exact definition. Therefore, in some analyses we have adopted the term 'significant intracerebral haemorrhage' to take account of this. It was possible to extract the number of patients dying with mass effect (on CT brain scan), or 'massive intracranial haemorrhage' where the authors appeared to have attributed the cause of death to the haemorrhage, but nevertheless these data must be regarded with extreme caution. The patients who died of neurological causes but did not have brain imaging or autopsy may have had fatal intracranial haemorrhage, therefore the total number of deaths within the first two weeks (most likely to be of neurological causes) is a more reliable end point than fatal intracranial haemorrhage because of these definition problems.</P>
<P>Thus more, larger trials are needed to answer questions on which drug, or dose of thrombolysis and if there are any situations when intra-arterial thrombolysis with or without mechanical clot removing devices might be best, including collecting data on functional outcome as well as deaths, and intra and extracranial haemorrhages, clearly defined in terms of their clinical effect.</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2013-03-28 12:25:36 +0000" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2013-03-28 12:25:36 +0000" MODIFIED_BY="[Empty name]">
<P>The data provide limited evidence that higher doses of thrombolytic drugs lead to higher rates of fatal intracranial haemorrhage. Apart from that, the data are insufficient to answer questions about which drug or dose might be best for thrombolysis. That is not to say that one drug might be better (or worse) than others, but simply that the randomised evidence does not exist. Data on route of administration are more substantial and do not support routine use of intra-arterial therapy over intravenous therapy. At present intravenous rtPA as licensed should be regarded as best practice. Please refer to the Cochrane review of 'Thrombolysis for acute ischaemic stroke' (<LINK REF="REF-Wardlaw-2009" TYPE="REFERENCE">Wardlaw 2009</LINK>) for conclusions on the broader question of the use of any thrombolytic agent, and of rt-PA specifically (<LINK REF="REF-Wardlaw-2012" TYPE="REFERENCE">Wardlaw 2012</LINK>), in acute ischaemic stroke.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2013-03-28 12:20:02 +0000" MODIFIED_BY="[Empty name]">
<P>More, larger randomised controlled trials are required to answer questions about which drug, or dose is best for thrombolysis, and whether there are any situations in which intra-arterial therapy with or without a mechanical clot extracting device is better than intravenous rt-PA. Such trials should collect data on functional outcome assessed using the modified Rankin Scale or Barthel Index at a minimum of three months after the stroke, and should clearly define intracranial haemorrhage in terms of its clinical effects (for example 'asymptomatic', 'symptomatic' or 'fatal'). Patients dying of neurological causes without immediate prior brain imaging should, wherever possible, undergo autopsy examination.</P>
<P>There are no randomised comparisons of streptokinase with rt-PA or urokinase, only of rt-PA with urokinase or tenecteplase. Larger randomised trials are required to evaluate the newer thrombolytic agents such as desmoteplase and tenecteplase and compare them to the widely used rt-PA. Future trials also need to address whether interventional management of stroke offers any particular advantage and in which group of patients. Future trials could usefully address these areas to try to find ways of reducing the risk (and improving the chance of benefit) with thrombolysis.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2013-02-01 10:36:48 +0000" MODIFIED_BY="jmw ">
<P>We would like to thank Hazel Fraser for providing us with lists of the relevant trials from the Cochrane Stroke Group's Trials Register, Brenda Thomas for considerable assistance with the search strategy, Prof Hideki Origasa for searching and translating Japanese trials, Miss Mami Seki for checking and translating data in Japanese trials, Dr Li He for searching the Chinese journals, Prof Chen for clarifying data from the Chinese UK trial, and Xin Wang for assistance in translating papers published in Chinese. We also thank Dr Carl Counsell for useful comments on the first version and also Dr Orell Mielke for his contribution to a subsequent update. We thank Kirsten Shuler for substantial administrative assistance with data checking and typography for the current version.</P>
<P>If you are aware of any additional trials, please let us know.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2013-02-01 11:15:27 +0000" MODIFIED_BY="[Empty name]">
<P>JMW (and other academic colleagues) was awarded grants to perform the Third International Stroke Trial, a multicentre international randomised controlled trial of rt-PA versus control in acute ischaemic stroke. The funders included the UK Medical Research Council, the Emerging Medicines Evaluation initiative of the National Institutes of Health Research UK, the Stroke Association, and numerous other governmental and charitable funders. These grants were all administered by the University of Edinburgh and funded staff, equipment and consumables. I received no personal salary or other direct funding from any of these.</P>
<P>Many years ago, the University of Edinburgh established a Brain Research Imaging Centre Magnetic Resonance scanner with academic government grants and some collaborative support from industry. The Industry funders were the MR equipment manufacturer Elscint (now taken over by GE) who provided the majority industry investment, Boehringer Ingelheim and Novartis, both of whom provided small contributions worth less than 5% of the total cost of the facility.</P>
<P>PK and ML have no known conflicts of interest.<BR/>
</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2013-02-01 10:36:51 +0000" MODIFIED_BY="jmw ">
<P>JMW and ML contributed to literature searching, collection of data, extraction of data, and interpretation of data of the first version of the review. ML and JMW drafted the review and produced the first version for publication.</P>
<P>Orell Mielke and JMW carried out searches for the first revised review, extracted the data, performed the analyses and, with ML, drafted and updated the review.</P>
<P>PK and JMW carried out searches for the second revised review, extracted the data, performed the analyses, drafted and updated the review and, with ML, checked the final version for submission.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2011-11-21 22:33:31 +0000" MODIFIED_BY="[Empty name]">
<P>Not applicable.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES MODIFIED="2013-01-23 14:56:18 +0000" MODIFIED_BY="[Empty name]"/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2013-03-19 11:55:24 +0000" MODIFIED_BY="jmw ">
<STUDIES MODIFIED="2013-03-19 11:55:24 +0000" MODIFIED_BY="jmw ">
<INCLUDED_STUDIES MODIFIED="2013-03-19 11:47:59 +0000" MODIFIED_BY="jmw ">
<STUDY DATA_SOURCE="PUB" ID="STD-Abe-1981" MODIFIED="2013-01-24 10:56:45 +0000" MODIFIED_BY="Hazel Fraser" NAME="Abe 1981" YEAR="1981">
<REFERENCE MODIFIED="2013-01-24 10:56:45 +0000" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Abe T, Kazama M, Naito I, et al</AU>
<TI>Clinical effect of urokinase (60 000 units/day) on cerebral infarction - comparative study by means of multiple center double blind test</TI>
<SO>Blood and Vessel</SO>
<YR>1981</YR>
<VL>12</VL>
<PG>342-58</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Abe-1990" MODIFIED="2013-02-01 10:40:37 +0000" MODIFIED_BY="Hazel Fraser" NAME="Abe 1990" YEAR="1990">
<REFERENCE MODIFIED="2013-01-24 10:56:36 +0000" MODIFIED_BY="Hazel Fraser" NOTES="&lt;p&gt;&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2013-01-24 10:56:36 +0000" NOTES_MODIFIED_BY="Hazel Fraser" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Abe T, Terashi A, Tohgi H, et al</AU>
<TI>Clinical efficacy of intravenous administration of SM-9527 (t-PA) in cerebral thrombolysis - multi-centre double-blind study in comparison with urokinase</TI>
<SO>Clinical Evaluation</SO>
<YR>1990</YR>
<VL>18</VL>
<PG>39-69</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-02-01 10:40:37 +0000" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Yamaguchi T, Hayakawa T, Kikuchi H, Abe T</AU>
<TI>Thrombolytic therapy in embolic and thrombotic cerebral infarction: a cooperative study</TI>
<SO>Thrombolytic Therapy in Acute Ischaemic Stroke</SO>
<YR>1990</YR>
<PG>168-9</PG>
<EN>1st</EN>
<ED>Hacke W, del Zoppo GJ, Hirschberg M</ED>
<PB>Spinger-Verlag</PB>
<CY>Berlin</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Atarashi-1985" MODIFIED="2013-01-24 10:57:14 +0000" MODIFIED_BY="Hazel Fraser" NAME="Atarashi 1985" YEAR="1985">
<REFERENCE MODIFIED="2013-01-24 10:57:14 +0000" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>UK-BR Study Group (Atarashi J, Ohtomo E, Araki G, Itoh E, Togi H, Matsuda T)</AU>
<TI>Clinical utility of urokinase in the treatment of acute stage of cerebral thrombosis - multi-center double blind study in comparison with placebo</TI>
<SO>Clinical Evaluation</SO>
<YR>1985</YR>
<VL>13</VL>
<PG>659-709</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Chen-2002" MODIFIED="2011-11-24 14:26:17 +0000" MODIFIED_BY="[Empty name]" NAME="Chen 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Chen Q, He M</AU>
<TI>Intravenous thrombolysis with urokinase for acute cerebral infarction. The study group of a 5 year National Project of the People's Republic of China</TI>
<SO>Proceedings of the 7th International Symposium on Thrombolysis and Acute Stroke Therapy, 27-28 May, Lyon, France</SO>
<YR>2002</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-11-24 14:26:17 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Chen Q-T</AU>
<TI>Intravenous fibrinolytic therapy for acute ischaemic stroke</TI>
<SO>In preparation</SO>
<YR>2002</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-DEDAS" MODIFIED="2013-01-24 10:58:22 +0000" MODIFIED_BY="[Empty name]" NAME="DEDAS" YEAR="2006">
<REFERENCE MODIFIED="2013-01-24 10:58:22 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Furlan AJ, Eyding D, Albers GW, Al-Rawi Y, Lees KR, Rowley HA, et al</AU>
<TI>Dose Escalation of Desmoteplase for Acute ischemic Stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset</TI>
<SO>Stroke</SO>
<YR>2006</YR>
<VL>37</VL>
<NO>5</NO>
<PG>1227-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-DIAS_x002d_2" MODIFIED="2013-02-01 10:41:20 +0000" MODIFIED_BY="[Empty name]" NAME="DIAS-2" YEAR="2005">
<REFERENCE MODIFIED="2013-01-24 10:58:54 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fiebach JB, Al-Rawi Y, Wintermark M, Furlan AJ, Hacke W, Rowley HA, et al</AU>
<TI>Vascular occlusion as imaging biomarker in selecting acute ischaemic stroke patients for treatment with desmoteplase</TI>
<SO>Cerebrovascular Diseases</SO>
<YR>2011</YR>
<VL>31 Suppl 2</VL>
<PG>165</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-02-01 10:41:20 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Forest Laboratories</AU>
<TI>Study of Desmoteplase (International Nonproprietary Name [INN]) in Acute Ischemic Stroke (DIAS-2)</TI>
<SO>ClinicalTrials.gov</SO>
<YR>2005</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-02-01 10:41:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hacke W, Furlan AJ, Al-Rawi Y, Davalos A, Fiebach JB, Gruber F, et al</AU>
<TI>Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study</TI>
<SO>Lancet Neurology</SO>
<YR>2009</YR>
<VL>8</VL>
<PG>141-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-DIAS-2005" MODIFIED="2012-01-11 12:38:39 +0000" MODIFIED_BY="jmw " NAME="DIAS 2005" YEAR="2005">
<REFERENCE MODIFIED="2012-01-11 12:38:39 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hacke W, Albers G, Al-Rawi Y, Bogousslavsky J, Davalos A, Eliasziw M, et al</AU>
<TI>The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase</TI>
<SO>Stroke</SO>
<YR>2005</YR>
<VL>36</VL>
<NO>1</NO>
<PG>66-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2011-12-21 15:04:34 +0000" MODIFIED_BY="jmw "/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ducrocq-2005" MODIFIED="2013-02-01 10:41:52 +0000" MODIFIED_BY="[Empty name]" NAME="Ducrocq 2005" YEAR="1997">
<REFERENCE MODIFIED="2011-11-04 14:05:13 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ducrocq X, Anxionnat R, Taillandier L, Lacour JC, Bracard S, Bollaert PE, et al</AU>
<TI>Intravenous versus intra-arterial urokinase thrombolysis in acute ischemic stroke. Randomised study of 27 patients</TI>
<SO>Cerebrovascular Diseases</SO>
<YR>2000</YR>
<VL>10</VL>
<NO>Suppl 2</NO>
<PG>76</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-02-01 10:41:52 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Draft given to Joanna Wardlaw at ESC Lisbon 2001&lt;/p&gt;" NOTES_MODIFIED="2013-02-01 10:41:52 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Ducrocq X, Bracard S, Taillandier L, Anxionnat R, Lacour J-C, Guillemin F, et al</AU>
<TI>Comparison of intravenous and intra-arterial urokinase thrombolysis for acute ischaemic stroke: randomised study of 27 patients</TI>
<SO>Unpublished</SO>
<YR>2001</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-01-24 11:51:52 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ducrocq X, Bracard S, Taillandier, Anxionnat R, Lacour JC, Guillemin F, et al</AU>
<TI>Comparison of intravenous and intra-arterial urokinase thrombolysis for acute ischaemic stroke. Randomised study of 27 patients</TI>
<SO>Journal of Neuroradiology</SO>
<YR>2005</YR>
<VL>32</VL>
<PG>26-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-EMS-Bridging-Trial" MODIFIED="2013-02-01 10:43:18 +0000" MODIFIED_BY="[Empty name]" NAME="EMS Bridging Trial" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Derex L, Tomsick T, Brott TG, Lewandowski CA, Frankel MR, Clark W, et al</AU>
<TI>Outcome of stroke patients without angiographically revealed arterial occlusion within four hours of symptom onset</TI>
<SO>American Journal of Neuroradiology</SO>
<YR>2001</YR>
<VL>22</VL>
<PG>685-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-02-01 10:43:18 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Emergency Management of Stroke (EMS) Investigators</AU>
<TI>Combined intraarterial and intravenous tPA for stroke (abstract)</TI>
<SO>Proceedings of the 21st International Joint Conference on Stroke and Cerebral Circulation; San Antonio, Texas, USA</SO>
<YR>1996</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lewandowski CA, Frankel M, Tomsick T, Broderick J, Frey J, Clark W, et al</AU>
<TI>Combined intravenous and intra-arterial r-TPA versus intra-arterial therapy of acute ischaemic stroke. Emergency Management of Stroke (EMS) Bridging Trial</TI>
<SO>Stroke</SO>
<YR>1999</YR>
<VL>30</VL>
<PG>2598-605</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>The EMS Bridging Trial Investigators</AU>
<TI>Combined intravenous and intra-arterial thrombolysis versus intra-arterial thrombolysis alone: preliminary safety and clot lysis</TI>
<SO>Cerebrovascular Diseases</SO>
<YR>1996</YR>
<VL>6</VL>
<PG>184</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>The EMS Bridging Trial Investigators</AU>
<TI>Combined intravenous/intraarterial thrombolytic therapy: safety, time to treatment, and frequency of clot</TI>
<SO>Stroke</SO>
<YR>1996</YR>
<VL>27</VL>
<NO>1</NO>
<PG>2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kikuchi-1994" MODIFIED="2013-02-01 10:43:44 +0000" MODIFIED_BY="Hazel Fraser" NAME="Kikuchi 1994" YEAR="1994">
<REFERENCE MODIFIED="2013-01-24 11:52:45 +0000" MODIFIED_BY="Hazel Fraser" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kikuchi H, Yamaguchi T, Abe H, et al</AU>
<TI>Thrombolytic therapy of SM-9527 (duteplase; rt-PA) in hyperacute embolic stroke - the clinical efficacy and safety of thrombolytic agent in a randomized double-blind study</TI>
<SO>Clinical Evaluation</SO>
<YR>1994</YR>
<VL>22</VL>
<PG>105-39</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-02-01 10:43:44 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Yamaguchi T, Kikuchi H, Hayakawa T for the Japanese Thrombolysis Study Group</AU>
<TI>Clinical efficacy and safety of intravenous tissue plasminogen activator in acute embolic stroke: a randomised, double-blind, dose-comparison study of duteplase</TI>
<SO>Thrombolytic Therapy in Acute Ischemic Stroke III</SO>
<YR>1995</YR>
<ED>Yamaguchi T, Mori E, Minematsu K, del Zoppo GJ</ED>
<PB>Springer-Verlag</PB>
<CY>Tokyo</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yamaguchi T</AU>
<TI>Randomized dose comparison (20 and 30) million international unit of (t-PA), double blind trial in stroke</TI>
<SO>Stroke</SO>
<YR>1994</YR>
<VL>25</VL>
<PG>253</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mori-1992" MODIFIED="2013-02-01 10:44:04 +0000" MODIFIED_BY="[Empty name]" NAME="Mori 1992" YEAR="1992">
<REFERENCE MODIFIED="2013-02-01 10:44:04 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mori E, Yoneda Y, Tabuchi M, Yoshida T, Ohkawa S, Ohsumi Y, et al</AU>
<TI>Intravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke</TI>
<SO>Neurology</SO>
<YR>1992</YR>
<VL>42</VL>
<PG>976-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ohtomo-1985" MODIFIED="2013-01-24 11:55:20 +0000" MODIFIED_BY="Hazel Fraser" NAME="Ohtomo 1985" YEAR="1985">
<REFERENCE MODIFIED="2013-01-24 11:55:20 +0000" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ohtomo E, Araki G, Itoh E, Toghi H, Matsuda T, Atarashi J</AU>
<TI>Clinical efficacy of urokinase in patients with cerebral thrombosis - multicentre double blind study</TI>
<SO>Kiso-to-Rinshyo (Basic and Clinical)</SO>
<YR>1985</YR>
<VL>19</VL>
<PG>445-78</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ohtomo-1988a" MODIFIED="2013-01-24 11:55:34 +0000" MODIFIED_BY="Hazel Fraser" NAME="Ohtomo 1988a" YEAR="1988">
<REFERENCE MODIFIED="2013-01-24 11:55:34 +0000" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ohtomo E et al</AU>
<TI>Clinical efficacy of AK-124 (tissue plasminogen activator) in the treatment of cerebral thrombosis - dose-finding study by means of multi-center double blind comparison</TI>
<SO>Yakuri to Chiryo (Pharmacology and Therapy)</SO>
<YR>1988</YR>
<VL>16</VL>
<NO>5</NO>
<PG>327-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ohtomo-1988b" NAME="Ohtomo 1988b" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ohtomo E et al</AU>
<TI>Clinical efficacy of AK -124 (tissue plasminogen activator) in the treatment of cerebral thrombosis - study by means of multi-center double blind comparison with urokinase</TI>
<SO>Pharmacology and Therapy</SO>
<YR>1988</YR>
<VL>16</VL>
<NO>9</NO>
<PG>167-213</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Parsons-2012" MODIFIED="2013-02-01 10:44:26 +0000" MODIFIED_BY="[Empty name]" NAME="Parsons 2012" YEAR="2012">
<REFERENCE MODIFIED="2013-01-24 11:56:03 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Parsons M, Spratt N, Bivard A, Campbell B, Chung K, Miteff F, et al</AU>
<TI>A randomised trial of tenecteplase versus alteplase for acute ischemic stroke</TI>
<SO>New England Journal of Medicine</SO>
<YR>2012</YR>
<VL>366</VL>
<PG>1099-107</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-02-01 10:44:26 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Parsons M</AU>
<TI>Low-dose tenecteplase versus standard-dose alteplase for acute ischemic stroke: an imaging-based efficacy trial</TI>
<SO>Australian New Zealand Clinical Trials Registry (ANZCTR) http://www.anzctr.org.au</SO>
<YR>2008</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-01-24 11:56:40 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Parsons MW, Bivard A, Campbell B, Chong KK, Miteff F, Blandin C, et al</AU>
<TI>Tenecteplase versus alteplase for acute ischaemic stroke: an imaging based efficacy trial</TI>
<SO>Cerebrovascular Diseases</SO>
<YR>2011</YR>
<VL>31 Suppl 2</VL>
<PG>86</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sen-2008" MODIFIED="2011-11-24 14:31:10 +0000" MODIFIED_BY="[Empty name]" NAME="Sen 2008" YEAR="2008">
<REFERENCE MODIFIED="2011-11-24 14:31:10 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sen S, Huang DY, Akhaven O, Wilson S, Verro P, Solander S</AU>
<TI>IV vs IA TPA in acute ischemic stroke with CT angiographic evidence of major vessel occlusion: a feasibility study</TI>
<SO>Neurocritical Care</SO>
<YR>2009</YR>
<VL>11</VL>
<PG>76-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-SYNTHESIS" MODIFIED="2013-02-01 10:44:42 +0000" MODIFIED_BY="[Empty name]" NAME="SYNTHESIS" YEAR="">
<REFERENCE MODIFIED="2011-03-14 07:41:53 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Ciccone A, Boccardi E, Coppola C, Gatti A, Guccione A, Santilli I, et al</AU>
<TI>Thrombolytic therapy for acute ischaemic stroke: the SYNTHESIS trial</TI>
<SO>Proceedings of the European Stroke Conference 21-24 May 2003, Valencia, Spain</SO>
<YR>2003</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-02-01 10:44:42 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ciccone A, Valvassori L, Ponzio M, Ballabio E, Gasparotti R, Sessa M, et al</AU>
<TI>Intra-arterial or intravenous thrombolysis for acute ischemic stroke? The SYNTHESIS pilot trial</TI>
<SO>Journal of Neurointerventional Surgery</SO>
<YR>2010</YR>
<VL>2</VL>
<PG>74-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-SYNTHESIS-EXPANSION" MODIFIED="2013-03-19 11:47:59 +0000" MODIFIED_BY="[Empty name]" NAME="SYNTHESIS EXPANSION" YEAR="2008">
<REFERENCE MODIFIED="2013-03-19 00:33:29 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ciccone A, Caputo D, Casoni F, Zini A, Checcarelli N, Muscia F, et al</AU>
<TI>SYNTHESIS Expansion: an ongoing randomized controlled trial on endovascular treatment for acute ischemic stroke. Baseline characteristics of the first 100 patients</TI>
<SO>Cerebrovascular Diseases</SO>
<YR>2010</YR>
<VL>29 Suppl 2</VL>
<PG>121-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-03-19 00:33:29 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ciccone A, Motto C, Sgoifo A, Daolio M, Nichelatti M, Valvassori L, et al</AU>
<TI>Synthesis expansion: an ongoing randomized controlled trial on fast track intra-arterial thrombolysis for acute ischemic stroke. Data on the first 200 patients</TI>
<SO>Cerebrovascular Diseases</SO>
<YR>2011</YR>
<VL>31 Suppl 2</VL>
<PG>134</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-03-19 11:47:59 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ciccone A, Valvassori L, Nichelatti M, Sgoifo A, Ponzia M, Sterzi R, Boccardi E for the Synthesis Expansion Investigators</AU>
<TI>Endovascular therapy for acute ischaemic stroke</TI>
<SO>New England Journal of Medicine</SO>
<YR>2013</YR>
<VL>368</VL>
<NO>10</NO>
<PG>904-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-03-19 00:33:29 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ciccone A, Valvassori L, Nichelatti M</AU>
<TI>SYNTHESIS Expansion: design of a nonprofit, pragmatic, randomized, controlled trial on the best fast-track endovascular treatment vs. standard intravenous alteplase for acute ischemic stroke</TI>
<SO>International Journal of Stroke</SO>
<YR>2011</YR>
<VL>6</VL>
<PG>259-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-03-19 00:33:29 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Ciccone A</AU>
<TI>Intra-arterial versus systemic thrombolysis for acute ischemic stroke (SYNTHESIS EXP)</TI>
<SO>ClinicalTrials.gov</SO>
<YR>2008</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-03-19 00:33:29 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Ciccone A</AU>
<TI>SYNTHESIS. Local versus systemic thrombolysis for acute stroke</TI>
<SO>Personal communication</SO>
<YR>2003</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-TNK_x002d_S2B" MODIFIED="2013-01-24 11:58:49 +0000" MODIFIED_BY="[Empty name]" NAME="TNK-S2B" YEAR="2005">
<REFERENCE MODIFIED="2013-01-24 11:58:49 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Haley EC, Thompson JLP, Grotta JC, Lyden PD, Hemmen TG, Brown DL, et al</AU>
<TI>Phase IIB/III trial of tenecteplase in acute ischemic stroke. Results of a prematurely terminated randomized clinical trial</TI>
<SO>Stroke</SO>
<YR>2010</YR>
<VL>41</VL>
<PG>707-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2003" MODIFIED="2013-01-24 11:59:42 +0000" MODIFIED_BY="[Empty name]" NAME="Wang 2003" YEAR="2003">
<REFERENCE MODIFIED="2013-01-24 11:59:15 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Wang SY, Wang XL, Zeng H, Zuo Y, Hu N, Li  XY, et al</AU>
<TI>Early intravenous thrombolysis with recombinant tissue plasminogen activator for acute cerebral infarction</TI>
<SO>Chinese Critical Care Medicine</SO>
<YR>2003</YR>
<VL>15</VL>
<NO>9</NO>
<PG>542-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-01-24 11:59:26 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang XL, Zeng H, Fan K, Wang KY, Zuo Y, Wang SY, et al</AU>
<TI>Clinical study on early intravenous thrombolysis with rt-PA for acute cerebral infarction</TI>
<SO>Chinese Journal of Neurology</SO>
<YR>2006</YR>
<VL>39</VL>
<NO>10</NO>
<PG>678-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-01-24 11:59:42 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zeng H, Wang X, Qi X, Wang H</AU>
<TI>Thrombolytic therapy using actilyse (rt-PA) in patients with acute cerebral infarction</TI>
<SO>Chinese Journal of Emergency Medicine</SO>
<YR>2006</YR>
<VL>15</VL>
<NO>5</NO>
<PG>457-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2013-03-19 11:55:24 +0000" MODIFIED_BY="jmw ">
<STUDY DATA_SOURCE="PUB" ID="STD-Abciximab-2001" MODIFIED="2013-01-24 12:47:13 +0000" MODIFIED_BY="jmw " NAME="Abciximab 2001" YEAR="2001">
<REFERENCE MODIFIED="2013-01-24 12:47:13 +0000" MODIFIED_BY="jmw " PRIMARY="NO" TYPE="OTHER">
<AU>Qureshi AI</AU>
<TI>Safety and efficacy in intra-arterial reteplase and intravenous Abciximab in patients with acute ischemic stroke</TI>
<SO>http://www.strokecenter.org/trials/clinicalstudies/safety-and-efficacy-of-intra-arterial-reteplase-and-intravenous-abciximab-in-patients-with-acute-ischemic-stroke</SO>
<YR>2006</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Amaro-2007" MODIFIED="2013-01-31 15:43:22 +0000" MODIFIED_BY="[Empty name]" NAME="Amaro 2007" YEAR="2007">
<REFERENCE MODIFIED="2011-11-03 12:03:46 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Amaro S, Obach V, Cervera Z, Urra X, Gomez-Choco M, Planas AM, et al</AU>
<TI>Course of matrix metalloproteinase-9 isoforms after the administration of uric acid in patients with acute stroke</TI>
<SO>Journal of Neurology</SO>
<YR>2009</YR>
<VL>256</VL>
<PG>651-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-11-24 14:31:10 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Amaro S, Soy D, Obach V, Cervera A, Planas AM, Chamorro A</AU>
<TI>A pilot study of dual treatment with recombinant tissue plasminogen activator and uric acid in acute ischemic stroke</TI>
<SO>Stroke</SO>
<YR>2007</YR>
<VL>38</VL>
<PG>2173-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-ARTIS" MODIFIED="2013-01-24 12:00:38 +0000" MODIFIED_BY="[Empty name]" NAME="ARTIS" YEAR="2008">
<REFERENCE MODIFIED="2013-01-24 12:00:38 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zinkstok SM, Vermeulen M, Stam J, de Haan RJ, Roos YB</AU>
<TI>Antiplatelet therapy in combination with rt-PA thrombolysis in ischemic stroke (ARTIS): rationale and design of a randomized controlled trial</TI>
<SO>Cerebrovascular Diseases</SO>
<YR>2010</YR>
<VL>29</VL>
<PG>79-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Australian-UK-Trial" MODIFIED="2013-01-31 16:07:53 +0000" MODIFIED_BY="[Empty name]" NAME="Australian UK Trial" YEAR="">
<REFERENCE MODIFIED="2013-01-24 12:01:16 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Macleod MR, Davis SM, Mitchell PJ, Gerraty RP, Fitt G, Hankey GJ, et al</AU>
<TI>Results of a multicentre, randomised controlled trial of intra-arterial urokinase in the treatment of acute posterior circulation ischaemic stroke</TI>
<SO>Cerebrovascular Diseases</SO>
<YR>2005</YR>
<VL>20</VL>
<PG>12-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brichta-2010" MODIFIED="2013-01-24 12:47:36 +0000" MODIFIED_BY="[Empty name]" NAME="Brichta 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-01-24 12:47:36 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brichta J, Goldemund D, Kara T, Bar M, Reif M, Mikulik R</AU>
<TI>Optimized tPA dosing in correlation with artery status - acute stroke study: preliminary results</TI>
<SO>International Journal of Stroke</SO>
<YR>2010</YR>
<VL>5 Suppl 2</VL>
<PG>189</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bu-1998" MODIFIED="2008-10-14 12:25:28 +0100" MODIFIED_BY="Hazel Fraser" NAME="Bu 1998" YEAR="1998">
<REFERENCE MODIFIED="2008-10-14 12:25:28 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bu X, Huang Y, Zhao Y, Zhang X, Su S, Ping B</AU>
<TI>Study on treatment time window for intravenous thrombolysis of acute ischaemic stroke</TI>
<SO>Modern Diagnosis and Treatment (Xian dai zhen duan yu zhi liao)</SO>
<YR>1998</YR>
<VL>9</VL>
<NO>5</NO>
<PG>267-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-CARNEROS_x002d_1" MODIFIED="2011-11-24 14:31:10 +0000" MODIFIED_BY="[Empty name]" NAME="CARNEROS-1" YEAR="2007">
<REFERENCE MODIFIED="2011-11-24 14:31:10 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Begelman SM</AU>
<TI>Phase 2 proof-of-concept study of the safety and efficacy of alfimeprase to rapidly open arteries and restore brain function following a stroke</TI>
<SO>ClinicalTrials.gov</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Christoforidis-2008" MODIFIED="2013-02-01 10:45:03 +0000" MODIFIED_BY="[Empty name]" NAME="Christoforidis 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-02-01 10:45:03 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Christoforidis G, Mohammed Y, Kontzialis M, Caragine L, Sivka A</AU>
<TI>Does the method for intra-arterial TPA delivery affect reperfusion rate?</TI>
<SO>Stroke</SO>
<YR>2008</YR>
<VL>39</VL>
<PG>591 (Abst P88)</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-CLEAR_x002d_ER" MODIFIED="2013-02-01 10:45:42 +0000" MODIFIED_BY="jmw " NAME="CLEAR-ER" YEAR="">
<REFERENCE MODIFIED="2013-02-01 10:45:19 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Pancioli AM</AU>
<TI>The combined approach to lysis utilizing eptifibatide and rt-PA in acute ischemic stroke - enhanced regimen</TI>
<SO>Proceedings of the International Stroke Conference; 24-26 February 2010</SO>
<YR>2010</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-02-01 10:45:42 +0000" MODIFIED_BY="jmw " PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Pancioli AM</AU>
<TI>The combined approach to lysis utilizing eptifibatide and rt-PA in acute ischemic stroke enhanced regimen (The CLEAR-ER Stroke Trial): an ongoing phase IIb trial</TI>
<SO>Proceedings of the International Stroke Conference 2011; 8-11 February 2011; USA, Los Angeles</SO>
<YR>2011</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Davalos-2003" MODIFIED="2013-01-24 12:03:19 +0000" MODIFIED_BY="[Empty name]" NAME="Davalos 2003" YEAR="2003">
<REFERENCE MODIFIED="2013-01-24 12:03:19 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Study of 122 patients in which a mismatch between the expected lesion according to the clinical deficit and the actual lesion seen on DWI was used to identify patients - some received rt-PA and some abciximab and some both (not absolutely clear). Also not clear from the abstract whether allocation to the treatment groups was random.&lt;/p&gt;" NOTES_MODIFIED="2013-01-24 12:03:19 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Davalos A, Leira R, Pedraza S, Blanco J, Serena J, Silva Y, et al</AU>
<TI>The usefulness of clinical-DWI mismatch in the treatment of acute ischaemic stroke with reperfusion therapies</TI>
<SO>Cerebrovascular Diseases</SO>
<YR>2003</YR>
<VL>16 Suppl 4</VL>
<PG>64</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Del-Zoppo-1989" MODIFIED="2013-01-24 12:03:41 +0000" MODIFIED_BY="Hazel Fraser" NAME="Del Zoppo 1989" YEAR="1989">
<REFERENCE MODIFIED="2013-01-24 12:03:41 +0000" MODIFIED_BY="Hazel Fraser" NOTES="&lt;p&gt;Dose range finding study for t-PA (the original Borroughs Wellcome compound). Not randomised. Never published in full. Excluded.&lt;/p&gt;" NOTES_MODIFIED="2013-01-24 12:03:41 +0000" NOTES_MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Del Zoppo GJ for the rt-PA Acute Stroke Group</AU>
<TI>An open multicenter trial of rt-PA in acute stroke (safety and efficacy): a progress report</TI>
<SO>Fibrinolysis</SO>
<YR>1990</YR>
<VL>4 Suppl 3</VL>
<PG>18 (Abst 47)</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-10-14 12:25:37 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Del Zoppo GJ, Poeck K, Pessin MS, Furlan A, Zivin J, Kase C, et al</AU>
<TI>An open multicentre trial of rt-PA in acute stroke: safety and efficacy</TI>
<SO>Thrombosis and Haemostasis</SO>
<YR>1989</YR>
<VL>62</VL>
<NO>1</NO>
<PG>27</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ding-2006" MODIFIED="2013-01-24 12:47:59 +0000" MODIFIED_BY="[Empty name]" NAME="Ding 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-01-24 12:47:59 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ding Y, Yin XG</AU>
<TI>Small-dose aspirin plus lumbrokinase in improving neurological function of patients with acute cerebral infarction</TI>
<SO>Chinese Journal of Clinical Rehabilitation</SO>
<YR>2006</YR>
<VL>10</VL>
<NO>6</NO>
<PG>60-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dong-2003" MODIFIED="2013-02-01 10:46:20 +0000" MODIFIED_BY="[Empty name]" NAME="Dong 2003" YEAR="2003">
<REFERENCE MODIFIED="2013-02-01 10:46:20 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Dong S, Wu C, Lu X, Wang J, Ma R, Wang H</AU>
<TI>Urokinase used for intra-arterial and intravenous thrombolysis for acute cerebral infarction: a clinical comparison study</TI>
<SO>Proceedings of the 4th International Conference on Research Advances in Cerebrovascular Disease; 13-15 October 2003; China, Chengdu: 2003:179-81</SO>
<YR>2003</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fan-2001" MODIFIED="2011-11-24 14:31:10 +0000" MODIFIED_BY="[Empty name]" NAME="Fan 2001" YEAR="2001">
<REFERENCE MODIFIED="2011-11-24 14:31:10 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fan C, Chen Q, Chang J</AU>
<TI>Antithrombosis enzyme vs dextran-40 in treatment of acute cerebral infarction</TI>
<SO>Henan Journal of Practical Nervous Diseases</SO>
<YR>2001</YR>
<VL>4</VL>
<NO>5</NO>
<PG>10-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gahn-2004" MODIFIED="2013-01-24 12:05:06 +0000" MODIFIED_BY="[Empty name]" NAME="Gahn 2004" YEAR="2004">
<REFERENCE MODIFIED="2013-01-24 12:05:06 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gahn G, Kunz A, Putz V, Becker U, Goldhagen T, Hahn G, et al</AU>
<TI>Recanalisation of middle cerebral artery occlusion after either t-PA or t-PA combined with abciximab</TI>
<SO>Stroke</SO>
<YR>2004</YR>
<VL>35</VL>
<NO>1</NO>
<PG>291</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gao-1994" MODIFIED="2013-01-31 15:45:44 +0000" MODIFIED_BY="[Empty name]" NAME="Gao 1994" YEAR="1994">
<REFERENCE MODIFIED="2013-01-31 15:45:44 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;This study is a comparison of i.v. versus i.a. urokinase (40,000 units into a peripheral vein or the carotid artery per day for seven days) in 50 patients (25 per group). However the randomisation method is not given, follow up is only to seven days with no longer term outcome, and no actual numbers of patients are given. Therefore it has not been possible to use these data. However the paper comments that &amp;quot;there was no significant difference between the two groups (p&amp;lt;0.05) but that injection into the carotid has side effects while injection into a peripheral vein is easier and has less pain and complications.&lt;/p&gt;" NOTES_MODIFIED="2013-01-31 15:45:44 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gao QL, Han QY, Li BS</AU>
<TI>Comparative observation of urokinase injected by carotid and peripheral vein treating brain infarction</TI>
<SO>Journal of Clinical Medicine (Lin chuang nei ke za zhi)</SO>
<YR>1994</YR>
<VL>11</VL>
<NO>2</NO>
<PG>38-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Geng-1998" MODIFIED="2013-01-24 12:05:26 +0000" MODIFIED_BY="[Empty name]" NAME="Geng 1998" YEAR="1998">
<REFERENCE MODIFIED="2013-01-24 12:05:26 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Geng JG, Wang YK, Wang YM</AU>
<TI>A comparison of efficacy of alternative thrombolysis intra-arterially by DSA with small dose of urokinase in the treatment of cerebral infarction</TI>
<SO>Journal of Apoplexy and Nervous Diseases</SO>
<YR>1998</YR>
<VL>15</VL>
<NO>4</NO>
<PG>242-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Huang-1996" MODIFIED="2011-11-24 14:31:10 +0000" MODIFIED_BY="[Empty name]" NAME="Huang 1996" YEAR="1996">
<REFERENCE MODIFIED="2011-11-24 14:31:10 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Huang R, Fang Y, Su Z</AU>
<TI>Clinical report of 31 cases of acute cerebral infarction treated with snake venom Svate-IV</TI>
<SO>Chinese Journal of Nervous &amp; Mental Diseases</SO>
<YR>1996</YR>
<VL>22</VL>
<NO>6</NO>
<PG>378</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-ICTUS_x002d_L" MODIFIED="2011-11-24 14:31:10 +0000" MODIFIED_BY="[Empty name]" NAME="ICTUS-L" YEAR="">
<REFERENCE MODIFIED="2011-11-24 14:31:10 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Guluma KZ, Hemmen TM, Olsen SE, Rapp KS, Lyden PD</AU>
<TI>A trial of therapeutic hypothermia via endovascular approach in awake patients with acute ischemic stroke: methodology</TI>
<SO>Academic Emergency Medicine</SO>
<YR>2006</YR>
<VL>13</VL>
<NO>8</NO>
<PG>820-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-IMS-I-_x0026_-II" MODIFIED="2013-01-24 12:48:23 +0000" MODIFIED_BY="[Empty name]" NAME="IMS I &amp; II" YEAR="2004">
<REFERENCE MODIFIED="2011-11-04 13:39:36 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Broderick JP, Tomsick T, Palesch Y</AU>
<TI>Pooled analysis of the IMS I and IMS II trials</TI>
<SO>Stroke</SO>
<YR>2007</YR>
<VL>38</VL>
<NO>2</NO>
<PG>505</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-11-04 13:40:44 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>The IMS II Trial Investigators</AU>
<TI>The Interventional Management of Stroke (IMS) II study</TI>
<SO>Stroke</SO>
<YR>2007</YR>
<VL>38</VL>
<PG>2127-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-01-24 12:48:23 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>The IMS Study Investigators</AU>
<TI>Combined intravenous and intra-arterial recanalization for acute ischemic stroke: the Interventional Management of Stroke study</TI>
<SO>Stroke</SO>
<YR>2004</YR>
<VL>35</VL>
<PG>904-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-IMS_x002d_III" MODIFIED="2013-03-19 11:55:24 +0000" MODIFIED_BY="[Empty name]" NAME="IMS-III" YEAR="2006">
<REFERENCE MODIFIED="2013-03-19 11:55:24 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Broderick JP, Palesch YY, Demchuk AM, Yeatts SD, Khatri P, Hill MD, et al.</AU>
<TI>Endovascular therapy after intravenous t-PA versus t-PA alone for stroke</TI>
<SO>New England Journal of Medicine</SO>
<YR>2013</YR>
<VL>368</VL>
<NO>10</NO>
<PG>893-903</PG>
<IDENTIFIERS MODIFIED="2013-03-19 00:36:52 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2013-03-19 00:33:55 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Broderick JP, Tomsick TA</AU>
<TI>The Interventional Management of Stroke (IMS) III Trial: an ongoing phase III trial</TI>
<SO>Proceedings of the International Stroke Conference; 24-26 February 2010</SO>
<YR>2010</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-03-19 00:33:55 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Broderick JP, Tomsick TA</AU>
<TI>The Interventional Management of Stroke (IMS) III trial: an ongoing phase III trial</TI>
<SO>Proceedings of the 20th European Stroke Conference 2011; 24-27 May 2011; Germany, Hamburg</SO>
<YR>2011</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-03-19 00:33:55 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Broderick JP, Tomsick TA</AU>
<TI>The Interventional Management of Stroke (IMS) III trial: an ongoing phase III trial</TI>
<SO>International Journal of Stroke</SO>
<YR>2010</YR>
<VL>5 Suppl 2</VL>
<PG>83-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-03-19 00:33:55 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sohn JA, Broderick JP, Spilker JA, Tomsick TA, Hill MD, Jauch EC, et al</AU>
<TI>Sedation practice patterns in acute stroke endovascular therapy: The IMS III Trial experience</TI>
<SO>Stroke</SO>
<YR>2011</YR>
<VL>42</VL>
<NO>3</NO>
<PG>e229-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-03-19 00:33:55 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Tomsick TA, Broderick JP</AU>
<TI>The Interventional Management of Stroke (IMS) III Trial: an ongoing phase III trial</TI>
<SO>Proceedings of the International Stroke Conference 2011; 8-11 February 2011;  USA, Los Angeles</SO>
<YR>2011</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-ITAIS_x002d_II" MODIFIED="2012-12-28 18:19:06 +0000" MODIFIED_BY="jmw " NAME="ITAIS-II" YEAR="2009">
<REFERENCE MODIFIED="2012-12-28 18:19:06 +0000" MODIFIED_BY="jmw " PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang Y, Liao X, Zhao X, Wang C, Liu L, Zhou Y, et al</AU>
<TI>Imaging-based thrombolysis trial in acute ischemic stroke-II (ITAIS-II)</TI>
<SO>International Journal of Stroke</SO>
<YR>2009</YR>
<VL>4</VL>
<PG>49-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Itoh-1998" MODIFIED="2013-01-24 12:07:07 +0000" MODIFIED_BY="[Empty name]" NAME="Itoh 1998" YEAR="1998">
<REFERENCE MODIFIED="2013-01-24 12:07:07 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Itoh H, Yamatani K, Oshida N, Shioi M, Takaba M, Kamiyama H, et al</AU>
<TI>Clinical effects of sodium ozagrel and urokinase in patients with acute cerebral infarction in the territory of the internal carotid artery</TI>
<SO>Brain and Nerve/No To Shinkei</SO>
<YR>1998</YR>
<VL>50</VL>
<NO>2</NO>
<PG>147-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-J_x002d_ACT" MODIFIED="2013-01-24 12:07:25 +0000" MODIFIED_BY="[Empty name]" NAME="J-ACT" YEAR="2006">
<REFERENCE MODIFIED="2013-01-24 12:07:25 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yamaguchi T, Mori E, Minematsu K, Nakagawara J, Hashi K, Saito I, et al</AU>
<TI>Alteplase at 0.6 mg/kg for acute ischemic stroke within 3 hours of onset: Japan Alteplase Clinical Trial (J-ACT)</TI>
<SO>Stroke</SO>
<YR>2006</YR>
<VL>37</VL>
<NO>7</NO>
<PG>1810-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-J_x002d_MARS-2010" MODIFIED="2011-12-21 15:19:15 +0000" MODIFIED_BY="jmw " NAME="J-MARS 2010" YEAR="2010">
<REFERENCE MODIFIED="2011-12-21 15:19:15 +0000" MODIFIED_BY="jmw " PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nakagawara J, Minematsu K, Okada Y, Tanahashi N, Nagahiro S, Mori E, et al</AU>
<TI>Thrombolysis with 0.6 mg/kg intravenous alteplase for acute ischemic stroke in routine clinical practice: the Japan post-Marketing Alteplase Registration Study (J-MARS)</TI>
<SO>Stroke</SO>
<YR>2010</YR>
<VL>41</VL>
<PG>1984-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kim-2007" MODIFIED="2013-01-24 12:07:50 +0000" MODIFIED_BY="[Empty name]" NAME="Kim 2007" YEAR="2007">
<REFERENCE MODIFIED="2013-01-24 12:07:50 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kim OJ, Koo YH, Kim DG, Kim WC, Kim HS</AU>
<TI>Intra-arterial tirofiban therapy in ischemic stroke [Abstract]</TI>
<SO>European Journal of Neurology</SO>
<YR>2007</YR>
<VL>14 Suppl 1</VL>
<PG>41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kim-2008" MODIFIED="2013-01-24 12:08:18 +0000" MODIFIED_BY="jmw " NAME="Kim 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-01-24 12:08:18 +0000" MODIFIED_BY="jmw " PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kim GM, Bang OY, Chung CS, Lee KH</AU>
<TI>Partial recanalization after intraarterial thrombolysis: angiographic consequences and clinical outcome</TI>
<SO>Stroke</SO>
<YR>2008</YR>
<VL>39</VL>
<NO>2</NO>
<PG>589-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Konta-1996" NAME="Konta 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;No trial found 10/2001 Medline&lt;br&gt;No further details published by Sept 2003 therefore exclude.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Konta Y, Aizu K, Fuziwara, Matsui T</AU>
<TI>Evaluation of intravenous urokinase, ozagrel sodium and low molecular dextran therapy in acute ischaemic stroke - comparison of infusion methods of urokinase</TI>
<SO>Cerebrovascular Diseases</SO>
<YR>1996</YR>
<VL>6</VL>
<PG>187</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lavallee-2007" MODIFIED="2012-01-11 12:40:42 +0000" MODIFIED_BY="jmw " NAME="Lavallee 2007" YEAR="2007">
<REFERENCE MODIFIED="2012-01-11 12:40:42 +0000" MODIFIED_BY="jmw " PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lavallee PC, Mazighi M, Saint-Maurice JP, Meseguer E, Abboud H, Klein IF, et al</AU>
<TI>Stent-assisted endovascular thrombolysis versus intravenous thrombolysis in internal carotid artery dissection with tandem internal carotid and middle cerebral artery occlusion</TI>
<SO>Stroke</SO>
<YR>2007</YR>
<VL>38</VL>
<PG>2270-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lee-1994" NAME="Lee 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lee JH, Seo DC, Kim JS, Lee MC</AU>
<TI>Therapeutic efficacy of urokinase and heparin in acute ischaemic stroke</TI>
<SO>Stroke</SO>
<YR>1994</YR>
<VL>25</VL>
<PG>268</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Leker-2007" MODIFIED="2013-02-01 10:46:35 +0000" MODIFIED_BY="[Empty name]" NAME="Leker 2007" YEAR="2007">
<REFERENCE MODIFIED="2013-02-01 10:46:35 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Leker RR</AU>
<TI>Study of aspirin and tPA in acute ischemic stroke</TI>
<SO>ClinicalTrials.gov</SO>
<YR>2007</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-2000f" MODIFIED="2013-01-24 12:09:18 +0000" MODIFIED_BY="[Empty name]" NAME="Li 2000f" YEAR="2000">
<REFERENCE MODIFIED="2013-01-24 12:09:18 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li P, Yan LJ, Kang H</AU>
<TI>The control study on thrombolysis through artery and vein in treatment of acute cerebral infarction</TI>
<SO>Chinese Journal of Practical Internal Medicine</SO>
<YR>2000</YR>
<VL>20</VL>
<NO>3</NO>
<PG>166-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-2003b" MODIFIED="2013-02-01 10:47:00 +0000" MODIFIED_BY="[Empty name]" NAME="Li 2003b" YEAR="2003">
<REFERENCE MODIFIED="2013-02-01 10:47:00 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Li J, Peng Y, Yang F, Liu K, Du X, Huang C</AU>
<TI>Treatment of acute cerebral infarction with acupuncture therapy Tong-nao-huo-luo during super-acute phase and acute phase: clinical and experiment study</TI>
<SO>Proceedings of the 4th International Conference on Research Advances in Cerebrovascular Disease; 13-15 October 2003</SO>
<YR>2003</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-2003e" MODIFIED="2013-01-24 12:09:34 +0000" MODIFIED_BY="[Empty name]" NAME="Li 2003e" YEAR="2003">
<REFERENCE MODIFIED="2013-01-24 12:09:34 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li JY, Peng YZ, Yang F, et al</AU>
<TI>Clinical observation on effect of tongnao huoluo acupuncture therapy in treating acute cerebral infarction at ultra-early or acute stage</TI>
<SO>Chinese Journal of Integrated Traditional and Western Medicine/Chung-kuo Chung Hsi</SO>
<YR>2003</YR>
<VL>23</VL>
<NO>10</NO>
<PG>736-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liu-1991a" MODIFIED="2011-11-04 13:46:34 +0000" MODIFIED_BY="[Empty name]" NAME="Liu 1991a" YEAR="1991">
<REFERENCE MODIFIED="2011-11-04 13:46:33 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liu CX</AU>
<TI>Efficacy analysis of DUM infusion interventionally on 33 cases of cerebral thrombosis</TI>
<SO>Chinese Journal of Practical Internal Medicine</SO>
<YR>1991</YR>
<VL>11</VL>
<NO>6</NO>
<PG>303-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liu-2000b" MODIFIED="2011-11-24 14:31:10 +0000" MODIFIED_BY="[Empty name]" NAME="Liu 2000b" YEAR="2000">
<REFERENCE MODIFIED="2011-11-24 14:31:10 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liu X, Zhan G, Zheng Z</AU>
<TI>The clinical efficacy and safety of thrombolytic therapy with urokinase in patients with acute cerebral infarction</TI>
<SO>Chinese Journal of Geriatric Cardiovascular and Cerebrovascular Diseases</SO>
<YR>2000</YR>
<VL>2</VL>
<NO>3</NO>
<PG>177-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Luo-1997" MODIFIED="2011-11-24 14:31:10 +0000" MODIFIED_BY="[Empty name]" NAME="Luo 1997" YEAR="1997">
<REFERENCE MODIFIED="2011-11-24 14:31:10 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Luo HW, Geng J, Liu YH</AU>
<TI>Clinical analysis of treating 50 patients with cerebral infarction by drugs through carotid artery</TI>
<SO>Chinese Journal of Practical Internal Medicine (Zhongguo shi yong nei ke za zhi)</SO>
<YR>1997</YR>
<VL>17</VL>
<NO>6</NO>
<PG>376</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lyden-2003" MODIFIED="2013-02-01 10:47:19 +0000" MODIFIED_BY="[Empty name]" NAME="Lyden 2003" YEAR="2003">
<REFERENCE MODIFIED="2013-02-01 10:47:19 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Lyden P</AU>
<TI>Intravenous thrombolysis plus hypothermia for acute treatment of ischemic stroke</TI>
<SO>Stroke Trials Registry, Internet Stroke Center: www.strokecenter.org/trials/</SO>
<YR>2003</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lyden-2003a" MODIFIED="2013-02-01 10:47:31 +0000" MODIFIED_BY="[Empty name]" NAME="Lyden 2003a" YEAR="2003">
<REFERENCE MODIFIED="2011-11-04 13:49:13 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Haley EC, Lyden PD, Johnston KC, Hemmen TM, the TNK in Stroke Investigators</AU>
<TI>A pilot dose-escalation safety study of tenecteplase in acute ischemic stroke</TI>
<SO>Stroke</SO>
<YR>2005</YR>
<VL>36</VL>
<PG>607-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-02-01 10:47:31 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Haley EC</AU>
<TI>Pilot study of TNK-TPA in acute ischemic stroke</TI>
<SO>CRISP Database</SO>
<YR>(accessed 12 December 2002)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-01-24 12:10:04 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lyden P, on behalf of the TNK for Stroke Investigators</AU>
<TI>Pilot study of tenecteplase (TNK) in acute ischemic stroke: preliminary report</TI>
<SO>Stroke</SO>
<YR>2003</YR>
<VL>34</VL>
<PG>246</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Macleod-2005" MODIFIED="2013-01-24 12:10:48 +0000" MODIFIED_BY="[Empty name]" NAME="Macleod 2005" YEAR="2005">
<REFERENCE MODIFIED="2013-01-24 12:10:48 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Macleod MR, Davis SM, Mitchell PJ, Gerraty RP, Fitt G, Hankey GJ, et al</AU>
<TI>Results of a multicentre, randomised controlled trial of intra-arterial urokinase in the treatment of acute posterior circulation ischaemic stroke</TI>
<SO>Cerebrovascular Diseases</SO>
<YR>2005</YR>
<VL>20</VL>
<NO>1</NO>
<PG>12-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-MELT" MODIFIED="2013-01-24 12:11:03 +0000" MODIFIED_BY="[Empty name]" NAME="MELT" YEAR="2002">
<REFERENCE MODIFIED="2013-01-24 12:11:03 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ogawa A, Mori E, MinematsuK, Taki W, Takahashi A, Nemoto S, et al</AU>
<TI>Randomized trial of intraarterial infusion of urokinase within 6 hours of middle cerebral artery stroke. The Middle Cerebral Artery Embolism Local Fibrinolytic Intervention Trial (MELT) Japan</TI>
<SO>Stroke</SO>
<YR>2007</YR>
<VL>38</VL>
<PG>2633-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-MITI_x002d_IV" MODIFIED="2012-01-11 12:39:20 +0000" MODIFIED_BY="jmw " NAME="MITI-IV" YEAR="2009">
<REFERENCE MODIFIED="2012-01-11 12:39:20 +0000" MODIFIED_BY="jmw " PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thijs VN, Peeters A, Vosko M, Aichner F, Schellinger PD, Schneider D, et al</AU>
<TI>Randomized, placebo-controlled, dose-ranging clinical trial of intravenous microplasmin in patients with acute ischemic stroke</TI>
<SO>Stroke</SO>
<YR>2009</YR>
<VL>40</VL>
<NO>12</NO>
<PG>3789-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Morris-2003" MODIFIED="2013-02-01 10:48:04 +0000" MODIFIED_BY="[Empty name]" NAME="Morris 2003" YEAR="2003">
<REFERENCE MODIFIED="2013-02-01 10:48:04 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Open lable phase 1 dose escalation study of reduced dose rt-PA (0.45, 0.60 or 0.75 mg/kg) with full dose abciximab. 42 patients to be enrolled in three dose cohorts with 14 patients in each group, beginning with the lowest dose (ie not randomised). Primary outcome is intracerebral haemorrhage. The dose will be raised if no ICHs are observed in the lowest dose group. No long term outcomes planned. Started 3/9/02, and two patients had been enrolled by Feb 2003.&lt;/p&gt;" NOTES_MODIFIED="2013-02-01 10:48:04 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Morris DC, Mitsias P, Silver B, Zhang L, Daley S, Lewandowski C, et al</AU>
<TI>Abciximab and rt-PA in acute ischaemic stroke treatment</TI>
<SO>Proceedings of the 28th AHA International Stroke Conference; February 13-15 2003; USA, Phoenix, Arizona: The American Stroke Association. Abstract CTP16</SO>
<YR>2003</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Qiang-2001" MODIFIED="2013-01-24 12:12:00 +0000" MODIFIED_BY="[Empty name]" NAME="Qiang 2001" YEAR="2001">
<REFERENCE MODIFIED="2013-01-24 12:12:00 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Qiang D</AU>
<TI>The dynamic study of stroke MRI in hyperacute stroke patients with thrombolysis</TI>
<SO>Hong Kong Medical Journal</SO>
<YR>2001</YR>
<VL>7</VL>
<NO>4</NO>
<PG>16</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Qureshi-2002" MODIFIED="2008-10-14 12:25:47 +0100" MODIFIED_BY="Hazel Fraser" NAME="Qureshi 2002" YEAR="2002">
<REFERENCE MODIFIED="2008-10-14 12:25:47 +0100" MODIFIED_BY="Hazel Fraser" NOTES="&lt;p&gt;Expected start date 01/01 and finish date 12/01.&lt;br&gt;Prospective, non-random, open-labled, dose-escalation study of abciximab standard iv dose and one of four doses of i.a. reteplase. &lt;br&gt;Purpose: To evaluate the safety and efficacy of escalating reteplase i.a. used in conjunction with abciximab in recanalising occluded cerebral arteries in patients with acute ischaemic stroke.&lt;br&gt;Eligible patients: those presenting within 3 to 6 hours of ischaemic stroke.&lt;br&gt;Follow-up at one month. Primary outcome is degree of recanalisation categorised by the TIMI classification. Secondary outcome MRS at 1 month, incidental and symptomatic intracranial haemorrhage, systemic haemorrhage.&lt;br&gt;Trial sponsored by Centocor Inc from Dept of Neurosurgery, Millard Fillmore Hospital, 3 Gates Circle, Buffalo, NY 14209-1194. Contact aiqureshi@hotmail.com&lt;br&gt;Also presented at the 26th and 27th AHA International Stroke Conferences (2001 and 2002).&lt;/p&gt;" NOTES_MODIFIED="2008-10-14 12:25:47 +0100" NOTES_MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="OTHER">
<AU>Qureshi AI</AU>
<TI>Safety and efficacy of intra-arterial reteplase and intravenous abciximab in patients with acute ischaemic stroke</TI>
<SO>www.strokecenter.org</SO>
<YR>2002</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Qureshi-2006" MODIFIED="2013-01-24 12:12:26 +0000" MODIFIED_BY="[Empty name]" NAME="Qureshi 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-01-24 12:12:26 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Qureshi AI, Harris-Lane P, Kirmani JF, Janjua N, Divani AA, Mohammad YM, et al</AU>
<TI>Intra-arterial reteplase and intravenous abciximab in patients with acute ischemic stroke: an open-label, dose-ranging, phase I study</TI>
<SO>Neurosurgery</SO>
<YR>2006</YR>
<VL>59</VL>
<PG>789-97</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-ReoPro-Retavase-MRI" MODIFIED="2008-10-14 12:25:52 +0100" MODIFIED_BY="Hazel Fraser" NAME="ReoPro Retavase MRI" YEAR="2002">
<REFERENCE MODIFIED="2008-10-14 12:25:52 +0100" MODIFIED_BY="Hazel Fraser" NOTES="&lt;p&gt;NIH-NINDS sponsored open-lable, dose escalation safety and proof of concept study of abciximab i.v. and retavase. Inclusion criteria: patients presenting within 3 to 24 hours of acute ischaemic stroke with a disabling stroke of NIHSS score &amp;lt;16 with a perfusion deficit on MR perfusion imaging. Exclusion criteria: those of thrombolysis plus any contraindication to MR, or DWI lesion greater than 1/3 of the MCA territory. &lt;br&gt;Trial treatment: 0.25 mg/kg abciximab (max 30 mg) followed by 0.125 ug/kg/min infusion (max 10 ug/min) for 12 hours; five reteplase dose groups (0 units, 2.5 U, 5.0 U, 7.5 U or 10.0 U) iv.&lt;br&gt;Follow-up MR at 24 hours.&lt;br&gt;Primary outcome : MR evidence of reperfusion at 24 hours, symptomatic ICH, major systemic haemorrhage, death within 48 hours of treatment.&lt;br&gt;Further information - Clinicaltrials.gov website.&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2008-10-14 12:25:52 +0100" NOTES_MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="OTHER">
<AU>Patient Recruitment and Public Liaison Office</AU>
<TI>ReoPro Retavase Reperfusion of Stroke Safety Study - Imaging Evaluation</TI>
<SO>www.strokecenter.org (Internet Stroke Center)</SO>
<YR>2002</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Riedel-1996" NAME="Riedel 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;Study was prematurely terminated because of lack of patients&lt;/p&gt;" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Riedel A</AU>
<TI>Phase II pilot study of pro-urokinase (Saruplase) in acute stroke with angiographically-proven occlusion of the middle cerebral artery</TI>
<SO>Unpublished</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sakamoto-1996" MODIFIED="2011-11-24 14:31:10 +0000" MODIFIED_BY="[Empty name]" NAME="Sakamoto 1996" YEAR="1996">
<REFERENCE MODIFIED="2011-11-24 14:31:10 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sakamoto T, Harimoto K, Inoue S, Konishi A</AU>
<TI>Clinical effects of urokinase and sodium ozagrel in patients with acute symptomatic lacunar infarction</TI>
<SO>Brain and Nerve/No To Shinkei</SO>
<YR>1996</YR>
<VL>48</VL>
<NO>9</NO>
<PG>805-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Seitz-2004" MODIFIED="2011-11-24 14:31:10 +0000" MODIFIED_BY="[Empty name]" NAME="Seitz 2004" YEAR="2004">
<REFERENCE MODIFIED="2011-11-24 14:31:10 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Seitz RJ, Meisel S, Moll M, Wittsack H-J, Junghans U, Siebler M</AU>
<TI>The effect of combined thrombolysis with rtPA and tirofiban on ischemic brain lesions</TI>
<SO>Neurology</SO>
<YR>2004</YR>
<VL>62</VL>
<PG>2110-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Song-2000" MODIFIED="2013-01-31 15:49:51 +0000" MODIFIED_BY="[Empty name]" NAME="Song 2000" YEAR="2000">
<REFERENCE MODIFIED="2013-01-31 15:49:51 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Song JY, Zhang Y, Zhan JS, et al</AU>
<TI>A comparison of efficacy of carotid artery thrombolysis and venous thrombolysis with urokinase in acute cerebral infarction</TI>
<SO>Chinese Journal of Critical Care Medicine - Zhongguo Ji Jiu Yi Xue</SO>
<YR>2000</YR>
<VL>12</VL>
<NO>5</NO>
<PG>287-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Song-2003" MODIFIED="2013-02-01 10:48:35 +0000" MODIFIED_BY="[Empty name]" NAME="Song 2003" YEAR="2003">
<REFERENCE MODIFIED="2013-02-01 10:48:35 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Song X, Xu G, Zhu R, Yu M, Wu X, Yu S, et al</AU>
<TI>Intracarotid thrombolysis in treatment of acute cerebral infarction</TI>
<SO>Proceedings of the 4th International Conference on Research Advances in Cerebrovascular Disease; 13-15 October 2003; China, Chengdu: 2003:171-3</SO>
<YR>2003</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-TASS" MODIFIED="2013-01-24 12:20:18 +0000" MODIFIED_BY="[Empty name]" NAME="TASS" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="OTHER">
<AU>Haley EC</AU>
<TI>Pilot study of TNK-TPA in acute ischaemic stroke, treated within 3 hours</TI>
<SO>CRISP Database (electronic), also Internet Stroke Trials Directory www.strokecenter.org</SO>
<YR>2002</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-01-24 12:20:18 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Open lable, dose escalation study of tenecteplase. Acute ischaemic stroke, within three hours, with inclusion/exclusion as in the NINDS rt-PA Stroke Trial 1995. Each dose teir will include 25 patients. Stopping rules based on intracerebral haemorrhage. Initial dose calculated to be bioequivalent to the licenced dose of rt-PA for stroke (but other two dose tiers not mentioned). Follow-up at 24 hours, discharge, 3 months with NIH Stroke Scale, Rankin, Glasgow Outcome and Barthel Scales. All three dose tiers complete with 25 patients in July 2002, no symptomatic intracranial haemorrhages had occurred. Asymptomatic ICH (detected on CT) occurred in 2/25 and 8/25 in the first two does tiers.&lt;/p&gt;" NOTES_MODIFIED="2013-01-24 12:20:18 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lyden P, on behalf of the TNK for Stroke Investigators</AU>
<TI>Pilot study of tenecteplase (TNK) in acute ischaemic stroke: preliminary report</TI>
<SO>Stroke</SO>
<YR>2003</YR>
<VL>34</VL>
<PG>246</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tazaki-1987" NAME="Tazaki 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tazaki Y, Kobayashi S, Togi H, Ohtomo E, Goto F, Araki G, et al</AU>
<TI>Therapeutic effect of thrombin inhibitor MD-805 in cerebral thrombosis - double blinded comparative study with tissue cultured urokinase</TI>
<SO>Igaku no Ayumi</SO>
<YR>1987</YR>
<VL>141</VL>
<PG>499-515</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-TNK_x002d_TPA" MODIFIED="2013-01-24 12:21:34 +0000" MODIFIED_BY="jmw " NAME="TNK-TPA" YEAR="2008">
<REFERENCE MODIFIED="2013-01-24 12:21:34 +0000" MODIFIED_BY="jmw " PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Molina CA, Ribo M, Rubiera M, Santamarina E, Delgado-Mederos R, Maisterra O, et al</AU>
<TI>TNK induces faster MCA recanalization and leads to better short- and long-term clinical outcomes than native tPA. The TNK-TPA reperfusion stroke study</TI>
<SO>Stroke</SO>
<YR>2008</YR>
<VL>39</VL>
<NO>2</NO>
<PG>563</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tsuchiya-1989" MODIFIED="2013-01-24 12:21:51 +0000" MODIFIED_BY="Hazel Fraser" NAME="Tsuchiya 1989" YEAR="1989">
<REFERENCE MODIFIED="2013-01-24 12:21:51 +0000" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tsuchiya T, Fujikake K, Oku K</AU>
<TI>Effects of urokinase and heparin on hemorrhagic infarction, recanalization, recurrence - analysis of 111 cases with middle cerebral artery occlusion on an acute stage in a prospective controlled trial</TI>
<SO>Japanese Journal of Stroke</SO>
<YR>1989</YR>
<VL>11</VL>
<PG>500-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tsuchiya-1990" NAME="Tsuchiya 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tsuchiya T, Fujikake K, Oku K</AU>
<TI>A study on clinical effects of the combinated therapy of urokinase and heparin for acute lacunar infarcts in a prospective controlled trial</TI>
<SO>Japanese Journal of Stroke</SO>
<YR>1990</YR>
<VL>11</VL>
<PG>177-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-TTT_x002d_AIS" MODIFIED="2013-01-24 12:22:14 +0000" MODIFIED_BY="[Empty name]" NAME="TTT-AIS" YEAR="2010">
<REFERENCE MODIFIED="2013-01-24 12:22:14 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chao AC, Hsu HY, Chung CP, Liu CH, Chen CH, Teng MM, et al</AU>
<TI>Outcomes of thrombolytic therapy for acute ischemic stroke in Chinese patients: the Taiwan Thrombolytic Therapy for Acute Ischemic Stroke (TTT-AIS) study</TI>
<SO>Stroke</SO>
<YR>2010</YR>
<VL>41</VL>
<NO>5</NO>
<PG>885-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-URICO_x002d_ICTUS" MODIFIED="2013-01-24 12:22:40 +0000" MODIFIED_BY="[Empty name]" NAME="URICO-ICTUS" YEAR="2010">
<REFERENCE MODIFIED="2013-01-24 12:22:40 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Amaro S, Canovas D, Castellanos M, Gallego J, Marti-Fabregas J, Segura T, et al</AU>
<TI>The URICO-ICTUS study, a phase 3 study of combined treatment with uric acid and rtPA administered intravenously in acute ischaemic stroke patients within the first 4.5 hours of onset of symptoms</TI>
<SO>International Journal of Stroke</SO>
<YR>2010</YR>
<VL>5</VL>
<PG>325-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-VASTT" MODIFIED="2013-02-01 10:48:51 +0000" MODIFIED_BY="[Empty name]" NAME="VASTT" YEAR="">
<REFERENCE MODIFIED="2013-02-01 10:48:51 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hill M, Demaerschalk B, Teal P, Pawsey S, Kwiatkowski K, Stratton G</AU>
<TI>VASTT - the V10153 acute stroke thrombolysis trial</TI>
<SO>International Journal of Stroke</SO>
<YR>2008</YR>
<VL>3 Suppl 1</VL>
<PG>133</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-1999a" MODIFIED="2011-11-24 14:31:10 +0000" MODIFIED_BY="[Empty name]" NAME="Wang 1999a" YEAR="1999">
<REFERENCE MODIFIED="2011-11-24 14:31:10 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang Y</AU>
<TI>Observations of effect of defibrase in treatment of 30 cases with acute cerebral thrombosis</TI>
<SO>Chinese Journal of Critical Care Medicine - Zhongguo Ji Jiu Yi Xue</SO>
<YR>1999</YR>
<VL>19</VL>
<NO>8</NO>
<PG>485</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2007h" MODIFIED="2011-11-03 12:09:35 +0000" MODIFIED_BY="[Empty name]" NAME="Wang 2007h" YEAR="2007">
<REFERENCE MODIFIED="2011-11-03 12:09:34 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang F, Yang H, Chu L-Z, Hu Y-C, Sui J-M, Liu J</AU>
<TI>Combined intravenous and intra-arterial infusion of recombinant tissue plasminogen activator for treatment of acute ischemic stroke</TI>
<SO>Chinese Journal of Cerebrovascular Diseases</SO>
<YR>2007</YR>
<VL>4</VL>
<NO>4</NO>
<PG>160-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Won-2010" MODIFIED="2013-01-24 12:49:45 +0000" MODIFIED_BY="[Empty name]" NAME="Won 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-01-24 12:49:45 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Won YD, Yoo DS, Park JW, Shin HE, Huh PW, Kim KT</AU>
<TI>Clinical significance of perfusion/diffusion mismatching in additional intraarterial thrombolytic therapy after full dose i.v.-tPA administration</TI>
<SO>International Journal of Stroke</SO>
<YR>2010</YR>
<VL>5 Suppl 2</VL>
<PG>110</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wu-1995" MODIFIED="2013-01-24 12:23:49 +0000" MODIFIED_BY="Hazel Fraser" NAME="Wu 1995" YEAR="1995">
<REFERENCE MODIFIED="2013-01-24 12:23:49 +0000" MODIFIED_BY="Hazel Fraser" NOTES="&lt;p&gt;no publication found 10/2001 (medline)&lt;br&gt;No further details found/published by Sept 2003 therefore exclude.&lt;/p&gt;" NOTES_MODIFIED="2013-01-24 12:23:49 +0000" NOTES_MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Wu X</AU>
<TI>Urokinase therapy in acute ischaemic stroke</TI>
<SO>Proceedings of the 4th Chinese Stroke Conference, Chengdu, China</SO>
<YR>1995</YR>
<PG>149-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Xiao-2002" MODIFIED="2011-11-24 14:31:10 +0000" MODIFIED_BY="[Empty name]" NAME="Xiao 2002" YEAR="2002">
<REFERENCE MODIFIED="2011-11-24 14:31:10 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Xiao KT, Xu KE</AU>
<TI>Observation of efficacy of intra-arterial thrombolysis and intravenous thrombolysis in 54 cases with acute cerebral infarction</TI>
<SO>Chinese Journal of Critical Care Medicine - Zhongguo Ji Jiu Yi Xue</SO>
<YR>2002</YR>
<VL>22</VL>
<NO>10</NO>
<PG>607</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Xu-2000" NAME="Xu 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Xu H-Q, Shao B, Zhou C-Y</AU>
<TI>Comparison of the curative effects between ahylsantinfarctase and defibrinogenase on cerebral infarction</TI>
<SO>Journal of Wenzhou Medical College</SO>
<YR>2000</YR>
<VL>30</VL>
<NO>2</NO>
<PG>124-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yan-1997" MODIFIED="2011-11-24 14:31:10 +0000" MODIFIED_BY="[Empty name]" NAME="Yan 1997" YEAR="1997">
<REFERENCE MODIFIED="2011-11-24 14:31:10 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yan LJ, Ma R, Li P</AU>
<TI>Clinical study of thrombolysis with gene-recombinant streptokinase on treatment of acute cerebral infarction</TI>
<SO>Chinese Journal of Practical Internal Medicine (Zhongguo shi yong nei ke za zhi)</SO>
<YR>1997</YR>
<VL>17</VL>
<NO>11</NO>
<PG>667-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yoneda-1998" MODIFIED="2008-10-14 12:26:18 +0100" MODIFIED_BY="Hazel Fraser" NAME="Yoneda 1998" YEAR="1998">
<REFERENCE MODIFIED="2008-10-14 12:26:18 +0100" MODIFIED_BY="Hazel Fraser" NOTES="&lt;p&gt;Non-random, open lable, dose escalation study. 5, 10 or 20 MIU (approx 10, 20 or 40 mg) in 100 ml saline continuously over 1 hour through a catheter with its tip in the proximal ICA. ICA or MCA occlusion on angiography and major hemisoheric stroke syndrome. 19 pts (6;6;7); mean time to treatment 192 mins; recanalisation similar between the groups, no stroke recurrence; 2 (11%) died; 2, 2, and 4 had any HTI, and 1, 0 and 1 had cerebral haematoma in the 10, 20, 40 mg groups respect.&lt;/p&gt;" NOTES_MODIFIED="2008-10-14 12:26:18 +0100" NOTES_MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yoneda Y, Mori E, Uehara T, Tabuchi M</AU>
<TI>Intracarotid regional infusion of recombinant tissue plasminogen activator for acute hemispheric stroke</TI>
<SO>Cerebrovascular Diseases</SO>
<YR>1998</YR>
<VL>8</VL>
<PG>357-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhang-2001e" MODIFIED="2013-01-24 12:24:52 +0000" MODIFIED_BY="[Empty name]" NAME="Zhang 2001e" YEAR="2001">
<REFERENCE MODIFIED="2013-01-24 12:24:52 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhang HX, Gu JQ, Han B</AU>
<TI>A study on alternative thrombolysis intra-arterially in the treatment of cerebral infarction</TI>
<SO>Chinese Journal of Practical Internal Medicine (Zhongguo shi yong nei ke za zhi)</SO>
<YR>2001</YR>
<VL>21</VL>
<NO>11</NO>
<PG>656-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhang-2006c" MODIFIED="2013-01-24 12:25:19 +0000" MODIFIED_BY="[Empty name]" NAME="Zhang 2006c" YEAR="2006">
<REFERENCE MODIFIED="2013-01-24 12:25:19 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhang XY, Li XG, Fan DS, Wang LP, Zhang Y, Sun AP, et al</AU>
<TI>Combined intravenous recombinant tissue plasminogen activator (rt-PA) and free radical scavenger (edaravone) for acute ischemic stroke</TI>
<SO>International Journal of Stroke</SO>
<YR>2006</YR>
<VL>1 Suppl 1</VL>
<PG>146</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhou-1996b" MODIFIED="2011-11-24 14:31:10 +0000" MODIFIED_BY="[Empty name]" NAME="Zhou 1996b" YEAR="1996">
<REFERENCE MODIFIED="2011-11-24 14:31:10 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhou Y, Gao H, Ma R</AU>
<TI>Functions changes of VEC and therapeutic effect on VEC in patients with acute cerebral infarct</TI>
<SO>Stroke and Nervous Diseases</SO>
<YR>1996</YR>
<VL>3</VL>
<NO>4</NO>
<PG>191-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2013-01-24 12:26:31 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="UNPUB" ID="STD-Wadia-2009" MODIFIED="2013-01-24 12:26:31 +0000" MODIFIED_BY="[Empty name]" NAME="Wadia 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-01-24 12:26:31 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Wadia RS</AU>
<TI>Clinical trial to assess the efficacy and safety of TNK-TPA in acute ischemic stroke</TI>
<SO>Clinical Trials Registry - India (CTRI) http://www.ctri.in</SO>
<YR>2009</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES MODIFIED="2013-03-19 00:33:55 +0000" MODIFIED_BY="jmw ">
<STUDY DATA_SOURCE="UNPUB" ID="STD-BASICS" MODIFIED="2011-09-19 01:42:04 +0100" MODIFIED_BY="[Empty name]" NAME="BASICS" YEAR="2011">
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-DIAS_x002d_J" MODIFIED="2013-02-01 10:49:21 +0000" MODIFIED_BY="[Empty name]" NAME="DIAS-J" YEAR="2010">
<REFERENCE MODIFIED="2013-01-24 12:27:22 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Lundbeck Japan KK</AU>
<TI>Clinical study of desmoteplase in Japanese patients with acute ischemic stroke (DIAS-J)</TI>
<SO>ClinicalTrials.gov</SO>
<YR>2010</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-01-24 12:50:09 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Mori E</AU>
<TI>Desmoteplase in Japanese patients with acute ischaemic stroke (DIAS-J): study objectives of a randomised, double-blind, placebo-controlled, dose escalation trial</TI>
<SO>International Journal of Stroke</SO>
<YR>2010</YR>
<VL>5 Suppl 2</VL>
<PG>192</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-01-24 12:27:31 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Penner R</AU>
<TI>Paion's partner Lundbeck initiates Japanese clinical phase II trial with desmoteplase in ischaemic stroke</TI>
<SO>http://www.paion.de/images/stories/investoren/finanznachrichten/2010/en/pm_dias-j_enfinal.pdf</SO>
<YR>2010</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-02-01 10:49:21 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>von Kummer R, Albers GW, on behalf of the DIAS Steering Committee</AU>
<TI>Desmoteplase in Acute Ischaemic Stroke: status updated on the DIAS clinical trial programme</TI>
<SO>Poster presented at the 2011 European Stroke Conference; May 24-27, 2011; Hamburg, Germany</SO>
<YR>2011</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-ENCHANTED" MODIFIED="2013-01-24 12:50:24 +0000" MODIFIED_BY="[Empty name]" NAME="ENCHANTED" YEAR="2011">
<REFERENCE MODIFIED="2013-01-24 12:50:24 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Lindley R</AU>
<TI>ENCHANTED</TI>
<SO>Powerpoint presentation</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-FRALYSE" MODIFIED="2013-02-01 10:49:38 +0000" MODIFIED_BY="[Empty name]" NAME="FRALYSE" YEAR="2002">
<REFERENCE MODIFIED="2013-02-01 10:49:38 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Comparison of 0.9 mg/kg rt-PA and 0.8 mg/kg rt-PA given i.v. over 60 minutes. All types of cerebral infarcts ; exclude hypodensity on CT; heparin i.v. started after 243 hours. Independent follow-up at 3 months to assess neurological score. Five french centres participating, with an MRI substudy in the Lyon centre. Sample size not give. Progress unknown.&lt;/p&gt;" NOTES_MODIFIED="2013-02-01 10:49:38 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Trouillas P, Nighoghossian N, Derex L, Adeleine P</AU>
<TI>FRALYSE, a randomised blind multicenter study comparing 0.9mg/kg for 60 minutes and 0.8mg/kg for 90 minutes in a 7 hour window</TI>
<SO>Proceedings of the 7th International Symposium on Thrombolysis and Acute Stroke Therapy; 27-28 May 2002; Lyon, France</SO>
<YR>2002</YR>
<PG>74</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-ITAIS" MODIFIED="2013-02-01 10:50:38 +0000" MODIFIED_BY="[Empty name]" NAME="ITAIS" YEAR="2005">
<REFERENCE MODIFIED="2013-02-01 10:50:38 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Wang Y, Jiang W, Liao X, Du B, Zhao X, Dong K, et al</AU>
<TI>Comparison of intravenous and intra-arterial with tPA within 3-6 hours guided by multi-MRI: randomised study of 36 patients</TI>
<SO>Stroke</SO>
<YR>2008</YR>
<VL>39</VL>
<PG>602</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-11-04 15:01:50 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Wang Y, Jiang W, Zhao X, Du B, Dong K, Liao X, et al</AU>
<TI>Imaging-based thrombolysis trial in acute ischemic stroke</TI>
<SO>http://www.abstractsonline.com/arch/RecordPrintView.aspx?LookupKey=12345&amp;RecordID=17703</SO>
<YR>2007</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-11-04 14:55:00 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Wang Y</AU>
<TI>ITAIS. Imaging-based thrombolysis trial in acute ischemic stroke</TI>
<SO>Internet Stroke Center</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2013-02-01 10:50:38 +0000" MODIFIED_BY="jmw ">
<ADDITIONAL_REFERENCES MODIFIED="2013-02-01 10:50:38 +0000" MODIFIED_BY="jmw ">
<REFERENCE ID="REF-APT-1994" NAME="APT 1994" TYPE="JOURNAL_ARTICLE">
<AU>Antiplatelet Trialists&#8217; Collaboration</AU>
<TI>Collaborative overview of randomised trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients</TI>
<SO>BMJ</SO>
<YR>1994</YR>
<VL>308</VL>
<PG>81-106</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ciccone-2007" MODIFIED="2012-12-28 09:50:56 +0000" MODIFIED_BY="[Empty name]" NAME="Ciccone 2007" TYPE="JOURNAL_ARTICLE">
<AU>Ciccone A, Valvassori L, Gasparotti R, Scomazzoni F, Ballabio E, Sterzi R</AU>
<TI>Debunking 7 myths that hamper the realization of randomized controlled trials on intra-arterial thrombolysis for acute ischemic stroke</TI>
<SO>Stroke</SO>
<YR>2007</YR>
<VL>38</VL>
<PG>2191-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Galimanis-2012" MODIFIED="2013-01-24 12:32:30 +0000" MODIFIED_BY="[Empty name]" NAME="Galimanis 2012" TYPE="JOURNAL_ARTICLE">
<AU>Galimanis A, Jung S, Mono ML, Fischer U, Findling O, Weck A, et al</AU>
<TI>Endovascular therapy of 623 patients with anterior circulation stroke</TI>
<SO>Stroke</SO>
<YR>2012</YR>
<VL>43</VL>
<PG>1052-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hacke-2004" MODIFIED="2013-01-24 12:32:48 +0000" MODIFIED_BY="[Empty name]" NAME="Hacke 2004" TYPE="JOURNAL_ARTICLE">
<AU>Hacke W, Donnan G, Fieschi C, Kaste M, von Kummer R, Broderick JP, et al</AU>
<TI>Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials</TI>
<SO>Lancet</SO>
<YR>2004</YR>
<VL>363</VL>
<PG>768-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2012-12-28 09:58:53 +0000" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="BOOK_SECTION">
<AU>Higgins JPT, Altman DG</AU>
<TI>Chapter 8: Assessing risk of bias in included studies</TI>
<SO>Cochrane Handbook of Systematic Reviews of Interventions</SO>
<YR>2011</YR>
<EN>5.1</EN>
<ED>Higgins JPT, Green S</ED>
<PB>The Cochrane Collaboration</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lee-2010" MODIFIED="2011-11-04 13:22:19 +0000" MODIFIED_BY="[Empty name]" NAME="Lee 2010" TYPE="JOURNAL_ARTICLE">
<AU>Lee M, Hong KS, Saver JL</AU>
<TI>Efficacy of intra-arterial fibrinolysis for acute ischemic stroke: meta-analysis of randomized controlled trials</TI>
<SO>Stroke</SO>
<YR>2010</YR>
<VL>41</VL>
<PG>932-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lees-2010" MODIFIED="2012-01-11 12:50:30 +0000" MODIFIED_BY="[Empty name]" NAME="Lees 2010" TYPE="JOURNAL_ARTICLE">
<AU>Lees KR, Bluhmki E, Von Kummer R, Brott TG, Toni D, Grotta JC; the ECASS, ATLANTIS, NINDS and EPITHET rt-PA Study Group Investigators</AU>
<TI>Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS and EPITHET trials</TI>
<SO>Lancet</SO>
<YR>2010</YR>
<VL>375</VL>
<PG>1695-703</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lindsberg-2006" MODIFIED="2011-11-04 13:25:08 +0000" MODIFIED_BY="[Empty name]" NAME="Lindsberg 2006" TYPE="JOURNAL_ARTICLE">
<AU>Lindsberg PJ, Mattle HP</AU>
<TI>Therapy of basilar artery occlusion: a systematic analysis comparing intra-arterial and intravenous thrombolysis</TI>
<SO>Stroke</SO>
<YR>2006</YR>
<VL>37</VL>
<PG>922-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lisboa-2002" NAME="Lisboa 2002" TYPE="JOURNAL_ARTICLE">
<AU>Lisboa RC, Jovanovic BD, Alberts MJ</AU>
<TI>Analysis of the safety and efficacy of intraarterial thrombolytic therapy in ischaemic stroke</TI>
<SO>Stroke</SO>
<YR>2002</YR>
<VL>33</VL>
<PG>2866-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RECANALISE-2009" MODIFIED="2011-12-21 15:10:05 +0000" MODIFIED_BY="jmw " NAME="RECANALISE 2009" TYPE="JOURNAL_ARTICLE">
<AU>Mazighi M, Serfaty JM, Labreuche J, Laissy JP, Meseguer E, Lavallée PC, et al</AU>
<TI>Comparison of intravenous alteplase with a combined intravenous-endovascular approach in patients with stroke and confirmed arterial occlusion (RECANALISE study): a prospective cohort study</TI>
<SO>Lancet</SO>
<YR>2010</YR>
<VL>8</VL>
<PG>802-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2011" MODIFIED="2013-01-21 15:43:24 +0000" MODIFIED_BY="Hazel Fraser" NAME="RevMan 2011" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2011</YR>
<EN>5.1</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tsivgoulis-2010" MODIFIED="2011-11-04 13:20:08 +0000" MODIFIED_BY="[Empty name]" NAME="Tsivgoulis 2010" TYPE="JOURNAL_ARTICLE">
<AU>Tsivgoulis G, Eggers J, Ribo M, Perren F, Saqqur M, Rubiera M, et al</AU>
<TI>Safety and efficacy of ultrasound-enhanced thrombolysis: a comprehensive review and meta-analysis of randomized and nonrandomized studies</TI>
<SO>Stroke</SO>
<YR>2010</YR>
<VL>41</VL>
<PG>280-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wardlaw-2009" MODIFIED="2013-01-21 14:20:50 +0000" MODIFIED_BY="jmw " NAME="Wardlaw 2009" TYPE="COCHRANE_REVIEW">
<AU>Wardlaw JM, Murray V, Berge E, del Zoppo GJ</AU>
<TI>Thrombolysis for acute ischaemic stroke</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2013-01-21 14:20:50 +0000" MODIFIED_BY="jmw ">
<IDENTIFIER MODIFIED="2013-01-21 14:20:50 +0000" MODIFIED_BY="Hazel Fraser" TYPE="DOI" VALUE="10.1002/14651858.CD000213.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wardlaw-2010" MODIFIED="2011-11-03 12:02:05 +0000" MODIFIED_BY="[Empty name]" NAME="Wardlaw 2010" TYPE="JOURNAL_ARTICLE">
<AU>Wardlaw JM, Murray V, Berge E, delZoppo GJ</AU>
<TI>Thrombolysis for acute ischemic stroke</TI>
<SO>Stroke</SO>
<YR>2010</YR>
<VL>41</VL>
<PG>e445-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wardlaw-2012" MODIFIED="2013-02-01 10:50:38 +0000" MODIFIED_BY="[Empty name]" NAME="Wardlaw 2012" TYPE="JOURNAL_ARTICLE">
<AU>Wardlaw JM, Murray V, Berge E, del Zoppo G, Sandercock P, Lindley RL, et al</AU>
<TI>Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis</TI>
<SO>Lancet</SO>
<YR>2012</YR>
<VL>379</VL>
<PG>2364-72</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES MODIFIED="2011-11-03 11:24:00 +0000" MODIFIED_BY="[Empty name]"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2013-03-19 01:03:27 +0000" MODIFIED_BY="jmw ">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2013-03-19 01:01:33 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2013-02-01 11:15:53 +0000" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Abe-1981">
<CHAR_METHODS MODIFIED="2013-02-01 11:15:53 +0000" MODIFIED_BY="Hazel Fraser">
<P>Sequentially numbered identical containers<BR/>Blinding: double<BR/>Lost to follow-up: 1 in high-dose group, 5 in control group</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-01-23 14:57:32 +0000" MODIFIED_BY="Hazel Fraser">
<P>Japan<BR/>101 patients<BR/>71% &lt; 70 years, 61% male<BR/>Cerebral thrombosis<BR/>100% pre-entry CT (probably)<BR/>Time since stroke: &lt; 2 weeks<BR/>Comparability of groups: age, sex, severity similar<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-02-01 10:36:57 +0000" MODIFIED_BY="Hazel Fraser">
<P>Higher dose: UK (manufactured by Green Cross, Japan) 60 000 U/day intravenously over 1 hour for 7 days<BR/>Lower dose: UK 6000 U/day intravenously over 1 hour for 7 days<BR/>Antithrombotic drugs were not allowed within the 7 days of treatment period, but could be used thereafter</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-01-23 14:58:55 +0000" MODIFIED_BY="Hazel Fraser">
<P>Overall improvement rating at 1 week and 4 weeks after treatment start<BR/>Death<BR/>Intracranial haemorrhage<BR/>Extracranial haemorrhage<BR/>Utility</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-01-23 15:00:32 +0000" MODIFIED_BY="Hazel Fraser">
<P>Exclusion criteria: embolic stroke, severe strokes, bleeding tendency<BR/>Follow-up: 1 month</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-02-01 11:16:02 +0000" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Abe-1990">
<CHAR_METHODS MODIFIED="2013-02-01 11:16:02 +0000" MODIFIED_BY="Hazel Fraser">
<P>Sequentially numbered identical containers<BR/>Blinding: double<BR/>Lost to follow-up: 1 in treatment group, 1 in control group</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-01-23 15:02:50 +0000" MODIFIED_BY="Hazel Fraser">
<P>Japan<BR/>230 patients in total (71 versus 76 for higher dose versus lower dose, 71 versus 83 for rt-PA versus UK)<BR/>63% &lt; 70 years, 66% male<BR/>Cerebral thrombosis<BR/>100% pre-entry CT<BR/>Time since stroke: &lt; 3 days in most<BR/>Comparability of groups: age, sex, severity similar, more hypertension and diabetes in control group, more heart disease in treatment group</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-02-01 10:37:04 +0000" MODIFIED_BY="Hazel Fraser">
<P>Higher dose (rt-PA): rt-PA (SM-9527) 2 MU/day intravenously over 1 hour for 7 days<BR/>Lower dose (rt-PA): rt-PA (SM-9527) 1 MU/day intravenously over 1 hour for 7 days<BR/>UK group: UK 60,000 IU/day intravenously over 1 hour for 7 days<BR/>Antithrombotic drugs were not allowed all the time, but could have exception</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-02-01 10:37:09 +0000" MODIFIED_BY="[Empty name]">
<P>Global improvement rating in 3 days, 1, 2 and 4 weeks<BR/>Activity of daily living<BR/>Death<BR/>Intracranial haemorrhage<BR/>Extracranial haemorrhage<BR/>ELT, plasma FDP, fibrinogen, plasminogen and a2-plasmin inhibitor</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-01-23 15:00:49 +0000" MODIFIED_BY="Hazel Fraser">
<P>Exclusion criteria: embolic stroke, bleeding tendency, severe strokes<BR/>Follow-up: 4 weeks</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-02-01 10:37:15 +0000" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Atarashi-1985">
<CHAR_METHODS MODIFIED="2013-02-01 10:37:14 +0000" MODIFIED_BY="Hazel Fraser">
<P>Sequentially numbered identical containers<BR/>Blinding: double<BR/>Lost to follow-up: 4 in low-dose group</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-01-23 15:03:02 +0000" MODIFIED_BY="Hazel Fraser">
<P>Japan<BR/>195 patients<BR/>64% &lt; 70 years, 72% male<BR/>Cerebral thrombosis<BR/>100% pre-entry CT<BR/>Time since stroke: 5 days<BR/>Comparability of groups: age, sex, severity similar</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-02-01 10:37:15 +0000" MODIFIED_BY="Hazel Fraser">
<P>Higher dose UK 240,000 U/day intravenously over 3 hours for 7 days<BR/>Lower dose UK 60,000 U/day intravenously over 3 hours for 7 days<BR/>Placebo group<BR/>Antithrombotic drugs were not allowed all the time, but could have exception</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Final global improvement rating<BR/>Utility<BR/>Activity of daily living<BR/>Death<BR/>Intracranial haemorrhage<BR/>Extracranial haemorrhage<BR/>Plasma fibrinogen and FDP levels</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-01-23 15:00:50 +0000" MODIFIED_BY="Hazel Fraser">
<P>Exclusion criteria: embolic stroke, ICH, severe strokes<BR/>Follow-up: 4 weeks</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-02-01 10:37:19 +0000" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Chen-2002">
<CHAR_METHODS MODIFIED="2013-01-23 15:09:43 +0000" MODIFIED_BY="Hazel Fraser">
<P>Randomisation numbers<BR/>Blind: double<BR/>Intention-to-treat</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-01-23 15:09:47 +0000" MODIFIED_BY="Hazel Fraser">
<P>China (51 hospitals)<BR/>511 patients. 35 to 75 years. 347 for comparison of different doses</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-02-01 10:37:19 +0000" MODIFIED_BY="Hazel Fraser">
<P>In 170 patients: UK 1.5 mµ intravenously<BR/>In 177 patients: UK 1.0 mµ intravenously</P>
<P>In 164 patients: placebo (saline) within 6 hours of stroke onset</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-01-23 15:10:55 +0000" MODIFIED_BY="Hazel Fraser">
<P>ESS day 1, 3, 7 and 30, BI, mRS at 90 days, symptomatic ICH, mortality, extracranial haemorrhage</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-01-23 15:03:04 +0000" MODIFIED_BY="Hazel Fraser">
<P>Exclusion criteria: &lt; 35 or &gt; 75 years, comatose, &gt; 3 muscle weakness. All received aspirin starting at 24 hours post randomisation. Heparin not specifically mentioned</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-02-01 10:37:23 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-DEDAS">
<CHAR_METHODS MODIFIED="2013-02-01 10:37:23 +0000" MODIFIED_BY="[Empty name]">
<P>Multicentre, double-blind, randomised, placebo-controlled, dose-escalation study of desmoteplase at 3 to 9 hours post stroke: phase II study</P>
<P>Interactive voice response randomisation system, no stratification</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-01-23 15:11:58 +0000" MODIFIED_BY="[Empty name]">
<P>Multicentre trial (US and Germany) March 2003 to October 2004</P>
<P>3 to 9 hours post stroke onset with &gt; 20% perfusion/diffusion mismatch</P>
<P>NIHSS 4 to 20</P>
<P>Isolated ICA occlusion without coexisting separate MCA occlusion excluded due to difficulty distinguishing acute from chronic ICA occlusion</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-01-23 15:18:34 +0000" MODIFIED_BY="[Empty name]">
<P>Participants randomised to desmoteplase 90 µg/kg (N = 14) versus 125 µg/kg (N = 15) versus placebo (N = 8)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-01-23 15:18:45 +0000" MODIFIED_BY="[Empty name]">
<P>Symptomatic ICH, death, anaphylaxis, major systemic bleeding</P>
<P>Reperfusion at 4 to 8 hours post treatment</P>
<P>Clinical outcome at 90 days</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-01-23 15:21:21 +0000" MODIFIED_BY="[Empty name]">
<P>MRI performed at presentation, 4 to 8 hours after treatment and at 30 days. CT at 24 hours</P>
<P>12 protocol violations (6 had no mismatch, 6 had isolated ICA occlusion)</P>
<P>Baseline DWI lesion volumes (larger in placebo) and baseline NIHSS (highest in placebo) not balanced</P>
<P>Anticoagulants or antiplatelets not allowed first 24 hours</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-02-01 10:37:30 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-DIAS-2005">
<CHAR_METHODS MODIFIED="2013-02-01 10:37:28 +0000" MODIFIED_BY="[Empty name]">
<P>Placebo-controlled, double-blind, randomised, multicentre phase II trial</P>
<P>Randomisation by interactive voice response system, no stratification</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-01-23 15:22:10 +0000" MODIFIED_BY="[Empty name]">
<P>Patients with acute stroke, 3 to 9 hours from onset with &gt; 20% perfusion diffusion mismatch on MRI</P>
<P>44 centres in 12 countries between January 2001 and October 2003</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-01-23 15:23:07 +0000" MODIFIED_BY="[Empty name]">
<P>Dose finding study. Intravenous desmoteplase bolus over 1 to 2 minutes</P>
<P>Part 1: 25 mg (N = 17) versus 37.5/50 mg (N = 13) versus placebo (N = 16)</P>
<P>Part 1 stopped due to high symptomatic ICH rate (8/30)</P>
<P>Part 2 : 62.5 µg/kg (N = 15) versus 90 µg/kg (N = 15) versus 125 µg/kg (N = 15) versus placebo (N = 11)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-01-23 15:28:18 +0000" MODIFIED_BY="[Empty name]">
<P>Rate of symptomatic ICH, major systemic bleeding, anaphylaxis, death</P>
<P>mRS, BI, NIHSS at 90 days</P>
<P>Reperfusion at 4 to 8 hours post treatment, change in infarct volume at 30 days</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-02-01 10:37:30 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" NOTES_MODIFIED="2013-02-01 10:37:30 +0000" NOTES_MODIFIED_BY="[Empty name]">
<P>MRI at screening, 4 to 8 hours post-treatment and 30 days</P>
<P>Anticoagulants and antiplatelets not allowed in the first 24 hours</P>
<P>37.5 mg and 50 mg due to the low numbers were analysed together</P>
<P>In the data analysis in this review only the doses 125 µg/kg versus 90 µg/kg have been included</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-02-01 10:37:35 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-DIAS_x002d_2">
<CHAR_METHODS MODIFIED="2013-02-01 10:37:35 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised, placebo-controlled, double-blind, dose ranging study phase III study</P>
<P>Testing the effect of 2 doses of desmoteplase at 3 to 9 hours post stroke</P>
<P>Computer-generated randomisation codes, stratified by centre, double-blinded</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-01-24 12:43:07 +0000" MODIFIED_BY="[Empty name]">
<P>Multicentre trial (Europe, North America, Australia, China) June 2005 to March 2007</P>
<P>3 to 9 hour post onset with &gt; 20% potentially salvageable tissue as defined by perfusion study (CT or MR)</P>
<P>18 to 85 years old, NIHSS 4 to 24</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-01-23 15:30:06 +0000" MODIFIED_BY="[Empty name]">
<P>Participants randomised to 90 µg/kg (N = 57) or 125 µg/kg (N = 66) of desmoteplase or placebo (N = 63) 1 intravenous bolus over 1 to 2 minutes</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-01-23 15:30:29 +0000" MODIFIED_BY="[Empty name]">
<P>Good clinical outcome at 90 days = improvement in NIHSS &gt; 8 points and BI 75 to 100 and mRS 0 to 2</P>
<P>Intracranial haemorrhage (symptomatic or asymptomatic), major haemorrhagic event, death</P>
<P>Change in infarct volume between baseline and 30 days</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-01-23 15:31:16 +0000" MODIFIED_BY="[Empty name]">
<P>Baseline study and follow-up by same modality at 30 days. CT at 24 to 72 hours to assess for haemorrhage</P>
<P>Less severe strokes than <LINK REF="STD-DIAS-2005" TYPE="STUDY">DIAS 2005</LINK>/<LINK REF="STD-DEDAS" TYPE="STUDY">DEDAS</LINK> studies</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-02-01 10:37:38 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ducrocq-2005">
<CHAR_METHODS MODIFIED="2013-02-01 10:37:38 +0000" MODIFIED_BY="[Empty name]">
<P>Single-centre, randomised study comparing intravenous versus intra-arterial UK</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-01-23 15:31:53 +0000" MODIFIED_BY="[Empty name]">
<P>27 patients, France</P>
<P>Stroke onset &lt; 6 hours. Hypodensity in &gt; 1/3 of the MCA not an exclusion criterion</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-01-23 15:32:24 +0000" MODIFIED_BY="[Empty name]">
<P>900,000 IU intravenous (N = 14) versus 900,000 units intra-arterially (N = 13)</P>
<P>Intravenous group: 300,000 IU bolus over 10 minutes, 600,000 IU over 50 minutes</P>
<P>Intra-arterial group pulsed spray injections, 20,000 IU per minute up to 900,000 in 45 minutes or until complete recanalisation</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-01-23 15:32:58 +0000" MODIFIED_BY="[Empty name]">
<P>Number of patients with mRS 0 to 2 at 90 days</P>
<P>Death in first 90 days</P>
<P>Symptomatic intracranial haemorrhage (fatal or not)</P>
<P>Scandinavian Score Scale at 7, 30, 90 days</P>
<P>BI at 90 days</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-01-23 15:33:40 +0000" MODIFIED_BY="[Empty name]">
<P>December 1995 to August 1997</P>
<P>Prematurely terminated due to high mortality rate</P>
<P>No diagnostic procedure to determine the presence of vessel occlusion in the intravenous group</P>
<P>Treatment in the intra-arterial group began significantly later than the intravenous group (mean of 68 minutes). 1 protocol violation in the intra-arterial group</P>
<P>No heparin or aspirin in the first 24 hours</P>
<P>Method of randomisation not described</P>
<P>Evaluation by investigator not blinded to the treatment allocation</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-02-01 10:37:42 +0000" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-EMS-Bridging-Trial">
<CHAR_METHODS MODIFIED="2013-02-01 10:37:41 +0000" MODIFIED_BY="Hazel Fraser">
<P>Randomisation - stratified block scheme by clinical centre<BR/>Double-blind, placebo-controlled, intention-to-treat</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-01-23 15:34:24 +0000" MODIFIED_BY="Hazel Fraser">
<P>USA, multicentre</P>
<P>35 patients</P>
<P>Upper age 84 years; within 3 hours of CT proven ischaemic stroke; NIHSS &gt; 5</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-01-23 15:35:02 +0000" MODIFIED_BY="Hazel Fraser">
<P>(1) Intravenous rt-PA (0.6 mg/kg, 60 mg maximum, 10% as bolus over 1 minute and the rest over 30 minutes) followed immediately by angiography and intra-arterial rt-PA if clot seen - 1 mg beyond the thrombus, 1 mg into the thrombus then 10 mg/hour infused for 2 hours maximum<BR/>(2) Intravenous placebo matched in appearance to rt-PA followed by intra-arterial rt-PA as in group 1. Amount of intra-arterial rt-PA and duration of intra-arterial infusion not given</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-02-01 10:37:42 +0000" MODIFIED_BY="Hazel Fraser">
<P>7-point or more improvement on the NIHSS by 7 to 10 days or NIHSS 0 or 1 at 7 days; life-threatening bleeding; mRS, Barthel, GOS at 90 days; arterial patency at 2 hours as measured with the TIMI scale</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-01-23 15:35:35 +0000" MODIFIED_BY="Hazel Fraser">
<P>Done from February 1995 to March 1996. No heparin or aspirin within 24 hours</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-02-01 10:37:44 +0000" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Kikuchi-1994">
<CHAR_METHODS MODIFIED="2013-01-23 14:57:09 +0000" MODIFIED_BY="Hazel Fraser">
<P>Sequentially numbered identical containers<BR/>Blinding: double<BR/>Lost to follow-up: 1 in treatment group, 1 in control group</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-02-01 10:37:44 +0000" MODIFIED_BY="Hazel Fraser">
<P>Japan<BR/>132 patients<BR/>74% &lt; 70 years, 58% male<BR/>Cerebral embolism<BR/>100% pre-entry CT<BR/>Time since stroke: &lt; 6 hours<BR/>Comparability of groups: age, sex, severity and associated diseases similar</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-01-23 15:36:23 +0000" MODIFIED_BY="Hazel Fraser">
<P>Higher dose rt-PA (duteplase, SM 9527) 30 MIU intravenous infusion for 1 hour<BR/>Lower dose rt-PA (duteplase, SM 9527) 20 MIU intravenous infusion for 1 hour<BR/>Drugs which might have interactions with thrombolysis were not allowed within 7 days of treatment period, but could be used thereafter</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Neurological impairment scale at 4 weeks<BR/>Disability (BI) at 4 weeks<BR/>Global improvement rating scale<BR/>Death<BR/>Intracranial haemorrhage<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-01-23 15:00:50 +0000" MODIFIED_BY="Hazel Fraser">
<P>Exclusion criteria: severe stroke, bleeding tendency, pregnancy, severe high blood pressure<BR/>Follow-up: 4 weeks</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-01-23 15:37:25 +0000" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Mori-1992">
<CHAR_METHODS MODIFIED="2013-01-23 14:57:10 +0000" MODIFIED_BY="Hazel Fraser">
<P>Sequentially numbered identical containers<BR/>Blinding: double<BR/>Lost to follow-up: 0</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-01-23 15:03:05 +0000" MODIFIED_BY="Hazel Fraser">
<P>Japan<BR/>19 patients<BR/>Mean age 67 years, 53% male<BR/>Thromboembolic stroke in internal carotid artery territory<BR/>100% pre-entry CT and angiography<BR/>Time since stroke: &lt; 6 hours<BR/>Comparability of groups: age, associated diseases similar, more males in the lower dose group (78% versus 30%)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-01-23 15:07:16 +0000" MODIFIED_BY="Hazel Fraser">
<P>Higher dose rt-PA (duteplase supplied by Sumitomo Pharmaceuticals, Tokyo) 30 MIU (60 mg) intravenous infusion for 1 hour<BR/>Lower dose rt-PA (duteplase ) 20 MIU (40 mg) intravenous infusion for 1 hour<BR/>Placebo group<BR/>Antithrombotic drugs were not allowed within 24 hours after infusion, but could be allowed thereafter<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-01-23 15:37:20 +0000" MODIFIED_BY="Hazel Fraser">
<P>Angiographic recanalisation<BR/>Death<BR/>Neurological improvement<BR/>Intracranial haemorrhage<BR/>Extracranial haemorrhage<BR/>BI at 1 month</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-01-23 15:37:25 +0000" MODIFIED_BY="Hazel Fraser">
<P>Exclusion criteria: pre-entry CT abnormality related to ischaemic events, &gt; 80 years, severe strokes, bleeding tendency<BR/>Follow-up: 1 month</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-02-01 10:37:53 +0000" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Ohtomo-1985">
<CHAR_METHODS MODIFIED="2013-01-23 14:57:10 +0000" MODIFIED_BY="Hazel Fraser">
<P>Sequentially numbered identical containers<BR/>Blinding: double<BR/>Lost to follow-up: 1 in UK group</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-01-23 15:03:07 +0000" MODIFIED_BY="Hazel Fraser">
<P>Japan<BR/>170 patients<BR/>58% &lt; 70 years, 64% male<BR/>Cerebral thrombosis<BR/>100% pre-entry CT<BR/>Time since stroke: &lt; 5 days<BR/>Comparability of groups: age, sex, severity similar</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-02-01 10:37:53 +0000" MODIFIED_BY="Hazel Fraser">
<P>UK: 60,000 U/day intravenously over 1 hour for 7 days<BR/>T-UK: 60,000 U/day intravenously over 1 hour for 7 days<BR/>Antithrombotic drugs were not allowed all the time, but could have exception</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Symptoms and signs<BR/>General improvement<BR/>Utility<BR/>Death<BR/>Intracranial haemorrhage<BR/>Extracranial haemorrhage<BR/>Activity of daily living</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-01-23 15:38:05 +0000" MODIFIED_BY="Hazel Fraser">
<P>Exclusion criteria: embolic stroke, ICH, severe strokes, bleeding tendency<BR/>Follow-up: 4 weeks</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-02-01 10:37:59 +0000" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Ohtomo-1988a">
<CHAR_METHODS MODIFIED="2013-02-01 10:37:57 +0000" MODIFIED_BY="Hazel Fraser">
<P>Sequentially numbered identical containers<BR/>Blinding: double<BR/>Lost to follow-up: 2 in treatment group, 4 in control group</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-01-23 15:03:08 +0000" MODIFIED_BY="Hazel Fraser">
<P>Japan<BR/>131 patients<BR/>64% &lt; 70 years, 65% male<BR/>Cerebral thrombolysis<BR/>100% pre-entry CT<BR/>Time since stroke: &lt; 3 days<BR/>Comparability of groups: age, severity similar, more male in the control group (76% versus 53%)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-02-01 10:37:59 +0000" MODIFIED_BY="Hazel Fraser">
<P>Higher dose t-PA (AK-124) 60,000 U/day intravenously over 1 hour for 7 days<BR/>Lower dose t-PA (AK-124) 36,000 U/day intravenously over 1 hour for 7 days<BR/>Antithrombotic drugs were not allowed all the time, but could have exception</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Symptoms and signs<BR/>General improvement<BR/>Death<BR/>Intracranial haemorrhage<BR/>Extracranial haemorrhage<BR/>Utility<BR/>Activity of daily living</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-01-23 15:38:41 +0000" MODIFIED_BY="Hazel Fraser">
<P>Exclusion criteria: embolic stroke, haemorrhagic stroke, severe strokes, bleeding tendency<BR/>Follow-up: 4 weeks</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-02-01 10:38:04 +0000" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Ohtomo-1988b">
<CHAR_METHODS MODIFIED="2013-01-23 14:57:11 +0000" MODIFIED_BY="Hazel Fraser">
<P>Sequentially numbered identical containers<BR/>Blinding: double<BR/>Lost to follow-up: 7 for 14 days, 2 for 4 weeks in t-PA group, 6 for 14 days, 7 for 4 weeks in UK group</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-01-23 15:03:08 +0000" MODIFIED_BY="Hazel Fraser">
<P>Japan<BR/>364 patients<BR/>62% &lt; 70 years, 66% male<BR/>Cerebral thrombosis<BR/>100% pre-entry CT<BR/>Time since stroke: &lt; 3 days in most<BR/>Comparability of groups: age, sex, severity similar</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-02-01 10:38:04 +0000" MODIFIED_BY="Hazel Fraser">
<P>t-PA: (AK-124) 36,000 AKU/day intravenously over 1 hour for 7 days<BR/>UK: 60 000 IU/day intravenously over 1 hour for 7 days<BR/>Antithrombotic drugs were not allowed all the time, but could have exception</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Symptoms and signs<BR/>General improvement<BR/>Death<BR/>Intracranial haemorrhage<BR/>Extracranial haemorrhage<BR/>Activity of daily living<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-01-23 15:39:22 +0000" MODIFIED_BY="Hazel Fraser">
<P>Exclusion criteria: embolic stroke, unconsciousness, severe strokes, ICH, bleeding tendency<BR/>Follow-up: 4 weeks</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-02-01 10:38:17 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Parsons-2012">
<CHAR_METHODS MODIFIED="2013-02-01 10:38:12 +0000" MODIFIED_BY="[Empty name]">
<P>Acute ischaemic stroke patients with symptom onset &lt; 6 hours randomised 1:1:1 to standard dose intravenous t-PA (0.9 mg/kg) or 0.1 mg/kg TNK or 0.25 TNK</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-02-01 10:38:13 +0000" MODIFIED_BY="[Empty name]">
<P>Acute ischaemic stroke patients with symptom onset &lt; 6 hours randomised into blocks of 15 patients. Recruitment completed with 75 patients randomised at 3 Australian University Hospitals</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-02-01 10:38:17 +0000" MODIFIED_BY="[Empty name]">
<P>Tenecteplase: given as a single intravenous bolus (over 1 minute), on one of 2 doses (0.1 mg/kg or 0.25 mg/kg) or alteplase: given intravenously 0.9 mg/kg, 10% as bolus (over 1 minute) and the remaining 90% as a 1-hour infusion immediately following the bolus</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-01-23 15:41:27 +0000" MODIFIED_BY="[Empty name]">
<P>Blinded measurement extent of reperfusion of the MTT lesion at 24 hours</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-12-26 17:44:04 +0000" MODIFIED_BY="[Empty name]">
<P>Abstract and trial database entry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-02-01 10:38:26 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sen-2008">
<CHAR_METHODS MODIFIED="2013-02-01 10:38:24 +0000" MODIFIED_BY="[Empty name]">
<P>Feasibility study comparing intravenous versus intra-arterial rt-PA in acute ischaemic stroke with major vessel occlusion</P>
<P>Computer-generated randomisation</P>
<P>Open-label study, blinded follow-up</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-02-01 10:38:25 +0000" MODIFIED_BY="[Empty name]">
<P>Single-centre study, North Carolina.</P>
<P>&lt; 3 hours from stroke onset<BR/>NIHSS &gt; 4</P>
<P>Evidence of major vessel occlusion on CTA (M1/M2, ICA, VA/BA). Acute hypodensity &gt; 1/3 of the MCA territory excluded</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-02-01 10:38:26 +0000" MODIFIED_BY="[Empty name]">
<P>Intravenous t-PA (N = 4) 0.9 mg/kg as per NINDS protocol versus intra-arterial t-PA (N = 3) delivered by microcatheter 1 mg in thrombus, 1 mg beyond thrombus and the pulse spray method proximal to thrombus up to maximal dose of 20 mg or until TIMI 3 vessel patency</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-01-23 15:43:44 +0000" MODIFIED_BY="[Empty name]">
<P>Time to clinical/radiological assessment, time from eligibility to treatment</P>
<P>Proportion of patients receiving timely assessments and treatment</P>
<P>Symptomatic ICH at 24 hours, all haemorrhages within 90 days</P>
<P>Reduction of NIHSS &gt; 4 at 90 days</P>
<P>Recanalisation on 24 hour MRA</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-01-23 15:43:55 +0000" MODIFIED_BY="[Empty name]">
<P>Consecutive patients presenting between October 2004 to December 2006 (7/9 eligible patients randomised)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-02-01 10:38:34 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-SYNTHESIS">
<CHAR_METHODS MODIFIED="2013-02-01 10:38:34 +0000" MODIFIED_BY="[Empty name]">
<P>Open-label randomised controlled trial with blinded follow-up. Pilot study</P>
<P>Random assignment by opaque envelops, stratified per centre</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-01-23 15:45:03 +0000" MODIFIED_BY="[Empty name]">
<P>Stroke of any ischaemic type, within 3 hours of onset, age over 18 years</P>
<P>4 Italian centres between January 2004 and February 2008</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-01-23 15:46:38 +0000" MODIFIED_BY="[Empty name]">
<P>intra-arterial rt-PA up to 6 hours (N = 25 patients randomised, 19 treated) versus intravenous rt-PA up to 3 hours (N = 29 patients randomised, 28 treated)</P>
<P>Up to 0.9 mg/kg rt-PA (mean dose 50 mg (45 to 70 mg)) over 60 minutes intra-arterially into the thrombus within 6 hours versus 0.9 mg/kg (maximum 90 mg) over 60 minutes intravenously within 3 hours of onset (median time from stroke to onset of infusion 195 minutes for intra-arterial versus 155 minutes for intravenous)</P>
<P>Mechanical thrombus disruption or clot retrieval were allowed (used in 8/19 patients) but not balloon angioplasty</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-01-23 15:47:29 +0000" MODIFIED_BY="[Empty name]">
<P>7-day neurological deficit (NIHSS); CT at 2 to 4 days; 3 months survival free of disability (mRS 0 or 1), 3-month mRS assessment by telephone call</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-01-23 15:47:33 +0000" MODIFIED_BY="[Empty name]">
<P>Aspirin to be avoided for first 24 hours. Intravenous heparin during angiography</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-03-19 00:57:59 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-SYNTHESIS-EXPANSION">
<CHAR_METHODS MODIFIED="2013-03-19 00:33:29 +0000" MODIFIED_BY="[Empty name]">
<P>Multicentre randomised trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-03-19 00:33:29 +0000" MODIFIED_BY="[Empty name]">
<P>Acute stroke patients able to initiate intravenous rt-PA within 3 hours and intra-arterial thrombolysis within 6 hours of stroke onset</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-03-19 00:57:39 +0000" MODIFIED_BY="[Empty name]">
<P>Intra-arterial alteplase and/or mechanical thrombectomy versus 0.9 mg/kg intravenous rt-PA; ia rt-PA alone used in 109/181 and rt-PA + device in 59 patients</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-03-19 00:33:29 +0000" MODIFIED_BY="[Empty name]">
<P>mRS at 90 days, intracerebral haemorrhage, death</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-03-19 00:57:59 +0000" MODIFIED_BY="[Empty name]">
<P>Recruitment completed 17 April 2012 with 362 patients.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-02-01 10:38:39 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-TNK_x002d_S2B">
<CHAR_METHODS MODIFIED="2013-02-01 10:38:38 +0000" MODIFIED_BY="[Empty name]">
<P>Multicentre, double-blind, randomised controlled trial, comparing 3 different doses of TNK versus rt-PA</P>
<P>Web-based randomisation</P>
<P>Phase IIb trial that was planned to continue with a phase III part but was prematurely terminated</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-01-23 15:48:43 +0000" MODIFIED_BY="[Empty name]">
<P>USA, 8 centres, 112 patients, &lt; 3 hours from stroke</P>
<P>2006 to 2008</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-02-01 10:38:38 +0000" MODIFIED_BY="[Empty name]">
<P>0.1 mg/kg TNK (N = 31) versus 0.25 mg/kg TNK (N = 31) versus 0.4 mg/kg TNK (N = 19) versus rt-PA (N = 31)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-01-23 15:49:09 +0000" MODIFIED_BY="[Empty name]">
<P>mRS at 90 days</P>
<P>Symptomatic and asymptomatic ICH</P>
<P>Major systemic bleeding</P>
<P>Death within 90 days</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-02-01 10:38:39 +0000" MODIFIED_BY="[Empty name]">
<P>March 2006 to December 2008</P>
<P>24-hour neurological status/symptomatic ICH used to define early the best dose of TNK</P>
<P>0.4 mg/kg dose 'dropped' early as inferior to the other 2</P>
<P>Prematurely terminated due to slow enrolment - 'post-specified' statistical analysis</P>
<P>Patients in the rt-PA group had more severe stroke</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-02-01 10:38:43 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-2003">
<CHAR_METHODS MODIFIED="2013-01-23 15:50:22 +0000" MODIFIED_BY="[Empty name]">
<P>Patients with acute cerebral infarction randomly allocated to 3 treatment groups, method of randomisation not described</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-02-01 10:38:43 +0000" MODIFIED_BY="[Empty name]">
<P>Single-centre study, China</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-02-01 10:38:43 +0000" MODIFIED_BY="[Empty name]">
<P>rt-PA 0.9 mg/kg (N = 34) versus rt-PA 0.7 mg/kg (N = 33) versus no treatment</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-01-31 14:18:12 +0000" MODIFIED_BY="[Empty name]">
<P>Clinical outcomes at 24 hours and 90 days: Chinese Stroke Scale and BI</P>
<P>ICH and deaths</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-11-21 22:36:36 +0000" MODIFIED_BY="[Empty name]">
<P>Number of dependent patients at 90 days or definition of dependency on the BI not given</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>BI: Barthel Index<BR/>C: concealment of allocation<BR/>CT: computed tomography<BR/>CTA: CT angiography<BR/>DWI: diffusion-weighted imaging<BR/>ELT: euglobulin clot lysis time<BR/>ESS: European Stroke Scale<BR/>FDP: fibrin degradation products<BR/>GOS: Glasgow Outcome Scale<BR/>ICA: internal carotid artery<BR/>ICH: intracranial haemorrhage<BR/>MCA: middle cerebral artery<BR/>MRA: magnetic resonance angioplasty<BR/>MRI: magnetic resonance imaging<BR/>mRS: modified Rankin Scale<BR/>MTT: mean transit time<BR/>NIHSS: National Institutes of Neurological Disorders and Stroke Scale<BR/>NINDS: National Institute of Neurological Disorders and Stroke<BR/>rt-PA: recombinant t-PA<BR/>TNK: tenecteplase<BR/>t-PA: tissue plasminogen activator<BR/>T-UK: tissue-cultured urokinase<BR/>TIMI scale: Thrombolysis In Myocardial Infarction scale<BR/>UK: urokinase<BR/>Utility: effect judged from improvement and side effects</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2013-03-19 01:03:27 +0000" MODIFIED_BY="jmw " SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2013-01-23 15:55:00 +0000" MODIFIED_BY="jmw " STUDY_ID="STD-Abciximab-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-23 15:55:00 +0000" MODIFIED_BY="jmw ">
<P>Not a trial of a thrombolytic agent</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-23 15:55:34 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Amaro-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-23 15:55:34 +0000" MODIFIED_BY="[Empty name]">
<P>Evaluates the effect of addition of uric acid to rt-PA as a neuroprotective agent</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-23 15:56:17 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-ARTIS">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-23 15:56:17 +0000" MODIFIED_BY="[Empty name]">
<P>Evaluates the effect of intravenous aspirin in addition to rt-PA in acute stroke</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-23 15:57:24 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Australian-UK-Trial">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-23 15:57:24 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised trial. Compares intra-arterial UK + anticoagulation versus anticoagulation alone in posterior circulation stroke. Excluded because it does not compare 2 direct thrombolytic agents</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-02-01 10:38:54 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Brichta-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-02-01 10:38:54 +0000" MODIFIED_BY="[Empty name]">
<P>Abstract only. Dose range-finding stopped prematurely. Non-random, open-label study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-23 15:57:47 +0000" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Bu-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-23 15:57:47 +0000" MODIFIED_BY="Hazel Fraser">
<P>Patients treated early (within 3 hours) or late (about 12 hours) after acute ischaemic stroke but on the basis of time of admission so not actually randomised. Treatment was mannitol + intravenous UK + aspirin</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-31 16:07:05 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-CARNEROS_x002d_1">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-31 16:07:05 +0000" MODIFIED_BY="[Empty name]">
<P>Dose-escalation study, not a randomised study. Company ended further clinical development of alfimeprase</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-23 15:58:06 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Christoforidis-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-23 15:58:06 +0000" MODIFIED_BY="[Empty name]">
<P>Not a randomised study. Retrospective angiographic evaluation of intra-arterial thrombolysis results depending on the technique of thrombolytic delivery</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-23 15:58:13 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-CLEAR_x002d_ER">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-23 15:58:13 +0000" MODIFIED_BY="[Empty name]">
<P>Confounded by the use of eptifibatide</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-23 15:58:17 +0000" MODIFIED_BY="jmw " STUDY_ID="STD-Davalos-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-23 15:58:17 +0000" MODIFIED_BY="jmw ">
<P>No longer relevant - trial never started</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-02-01 10:39:02 +0000" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Del-Zoppo-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-02-01 10:39:02 +0000" MODIFIED_BY="Hazel Fraser">
<P>This was the original Burrough's Wellcome dose range-finding study of t-PA. It was not randomised. Either 0.12, 0.20, 0.29 or 0.37 x 10,000,000 U/kg/60 minutes intravenous t-PA within 8 hours of ischaemic stroke. Follow-up was at 72 hours. The full results have never been published</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-23 16:00:06 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ding-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-23 16:00:06 +0000" MODIFIED_BY="[Empty name]">
<P>Relevant to <LINK REF="REF-Wardlaw-2009" TYPE="REFERENCE">Wardlaw 2009</LINK>. Testing aspirin + lumbrokinase versus aspirin alone after stroke</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-02-01 10:39:03 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dong-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-02-01 10:39:03 +0000" MODIFIED_BY="[Empty name]">
<P>Study comparing intra-arterial versus intravenous UK. Excluded because not a randomised study. Follow-up 2 weeks</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-02-01 10:39:04 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fan-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-02-01 10:39:04 +0000" MODIFIED_BY="[Empty name]">
<P>Antithrombosis enzyme (reptilase) versus dextran-40 for 10 days in acute ischaemic stroke. Not related to thrombolytic treatment dosology in hyperacute stroke</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-23 16:01:12 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gahn-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-23 16:01:12 +0000" MODIFIED_BY="[Empty name]">
<P>Compares rt-PA (0.9 mg/kg) versus rt-PA (0.45 mg/kg) + abciximab (0.125 mg/kg bolus + 12 hour infusion 0.125 micro g/kg x minute) in acute ischaemic stroke. Excluded because it is confounded by the use of abciximab and not randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-02-01 10:39:07 +0000" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Gao-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-02-01 10:39:07 +0000" MODIFIED_BY="Hazel Fraser">
<P>UK (40,000 UI for 7 days) intra-arterially into the carotid artery versus UK (40,000 UI for 7 days) intravenously. No data were given on functional outcome, only on blood count and ESR. 25 patients per group. The authors did comment that injection into the carotid artery had side effects while injection into a peripheral vein is easier, has less pain and complications. Excluded due to lack of relevant data</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-23 16:05:51 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Geng-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-23 16:05:51 +0000" MODIFIED_BY="[Empty name]">
<P>Evaluates intra-arterial UK by DSA (20,000 to 40,000 units) versus intravenous UK (10,000 to 20,000 on day 1 then 20,000 to 40,000 for 4 days) in acute ischaemic stroke. Excluded because not a randomised study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-23 16:07:21 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Huang-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-23 16:07:21 +0000" MODIFIED_BY="[Empty name]">
<P>Evaluates intravenous venom (Svate-IV). Not a thrombolytic agent so not relevant to this the review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-23 16:07:29 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-ICTUS_x002d_L">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-23 16:07:29 +0000" MODIFIED_BY="[Empty name]">
<P>Not relevant to this review. Testing hypothermia as an adjunct to rt-PA</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-23 16:07:39 +0000" MODIFIED_BY="jmw " STUDY_ID="STD-IMS-I-_x0026_-II">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-23 16:07:39 +0000" MODIFIED_BY="jmw ">
<P>Non-random comparison</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-03-19 01:03:27 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-IMS_x002d_III">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-03-19 01:03:27 +0000" MODIFIED_BY="[Empty name]">
<P>RCT of mechanical device versus iv rt-PA, not ia v iv rt-PA</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-23 16:07:44 +0000" MODIFIED_BY="jmw " STUDY_ID="STD-ITAIS_x002d_II">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-23 16:07:44 +0000" MODIFIED_BY="jmw ">
<P>Non-randomised multicentre study of CT perfusion and angiography imaging in patients treated with rt-PA</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-23 16:08:18 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Itoh-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-23 16:08:18 +0000" MODIFIED_BY="[Empty name]">
<P>Sodium ozagrel versus UK in patients with acute cerebral infarction in the territory of the internal carotid artery. Testing antiplatelet agent (ozagrel), not active thrombolysis. Not relevant to this review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-02-01 10:39:08 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-J_x002d_ACT">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-02-01 10:39:08 +0000" MODIFIED_BY="[Empty name]">
<P>Single-arm, non-randomised study testing 0.6 mg/kg of rt-PA</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-23 16:08:30 +0000" MODIFIED_BY="jmw " STUDY_ID="STD-J_x002d_MARS-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-23 16:08:30 +0000" MODIFIED_BY="jmw ">
<P>Non-random registry of treated patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-24 12:44:33 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kim-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-24 12:44:33 +0000" MODIFIED_BY="[Empty name]">
<P>Intra-arterial tirofiban following intra-arterial UK versus intra-arterial UK alone in acute ischaemic stroke. Excluded because testing antiplatelet agent (tirofiban) as adjunct to intra-arterial UK versus UK alone</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-02-01 10:39:09 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kim-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-02-01 10:39:09 +0000" MODIFIED_BY="[Empty name]">
<P>Evaluates mechanical thrombolysis (MT) versus MT + intra-arterial t-PA (20 mg) versus MT + intra-arterial UK (300,000) in patients with MCA or ICA occlusion. Excluded because not a randomised study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-23 16:09:45 +0000" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Konta-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-23 16:09:45 +0000" MODIFIED_BY="Hazel Fraser">
<P>Abstract presented but no further information forthcoming. UK 240,000 IU day 1, 120,000 IU day 2, 60,000 IU day 3 versus UK 420,000 IU on day 1. 28 patients. Neurological outcome assessed at discharge. Stated that divided infusion produced "better" result than bolus but details not given</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-23 16:10:28 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lavallee-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-23 16:10:28 +0000" MODIFIED_BY="[Empty name]">
<P>Stent-assisted intra-arterial thrombolysis and/or thrombectomy versus intravenous thrombolysis (0.9 mg/kg) in patients with tandem internal carotid and MCA occlusion with ICA dissection. Excluded because not a randomised study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-23 16:10:43 +0000" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Lee-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-23 16:10:43 +0000" MODIFIED_BY="Hazel Fraser">
<P>Confounded by different time windows, e.g. intravenous UK versus intravenous heparin (begun within 12 hours of stroke onset) versus intra-arterial UK (begun within 6 hours of stroke onset)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-23 16:10:55 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Leker-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-23 16:10:55 +0000" MODIFIED_BY="[Empty name]">
<P>Not relevant to this review. t-PA (0.9 mg/kg infused over 1 hour) + aspirin (500 mg) versus t-PA alone in acute ischaemic stroke patients &lt; 4.5 hours from onset </P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-23 16:11:02 +0000" MODIFIED_BY="jmw " STUDY_ID="STD-Li-2000f">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-23 16:11:02 +0000" MODIFIED_BY="jmw ">
<P>Non-randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-23 16:04:24 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Li-2003b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-23 16:04:24 +0000" MODIFIED_BY="[Empty name]">
<P>Not testing thrombolysis dosology. Evaluating acupuncture versus UK</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-24 12:44:41 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Li-2003e">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-24 12:44:41 +0000" MODIFIED_BY="[Empty name]">
<P>Tongnao huoluo acupuncture versus UK (12 million units) versus placebo in acute ischaemic stroke (within 6 hours of onset). Not testing thrombolysis, evaluating acupuncture</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-23 16:11:19 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Liu-1991a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-23 16:11:19 +0000" MODIFIED_BY="[Empty name]">
<P>Non-random. Confounded by dextran and other agents</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-23 16:11:41 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Liu-2000b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-23 16:11:41 +0000" MODIFIED_BY="[Empty name]">
<P>Intravenous UK versus dextran from 2 to 12 hours after onset of stroke. Not relevant to this review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-23 16:11:52 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Luo-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-23 16:11:52 +0000" MODIFIED_BY="[Empty name]">
<P>Intra-arterial UK 100,000U every other day via carotid artery versus dextran (500 ml) in acute ischaemic stroke. Patients may also receive ahylsantinfarctase + venorutin. Not relevant to this review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-02-01 10:39:11 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lyden-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-02-01 10:39:11 +0000" MODIFIED_BY="[Empty name]">
<P>Hypothermia + t-PA versus hypothermia versus t-PA versus control in acute ischaemic stroke patients 3 to 6 hours after stroke. Patients less than 3 hours from stroke onset will receive either t-PA or t-PA + hypothermia. Not relevant to this review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-23 16:12:19 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lyden-2003a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-23 16:12:19 +0000" MODIFIED_BY="[Empty name]">
<P>Trial of hypothermia not thrombolysis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-23 16:13:08 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Macleod-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-23 16:13:08 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised trial, evaluates the efficacy of intra-arterial UK versus control (no thrombolysis) in posterior circulation stroke. All patients received heparin/warfarin. Not relevant to this review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-23 16:13:13 +0000" MODIFIED_BY="jmw " STUDY_ID="STD-MELT">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-23 16:13:13 +0000" MODIFIED_BY="jmw ">
<P>Trial of thrombolysis versus placebo - included in <LINK REF="REF-Wardlaw-2009" TYPE="REFERENCE">Wardlaw 2009</LINK>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-23 16:13:40 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-MITI_x002d_IV">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-23 16:13:40 +0000" MODIFIED_BY="[Empty name]">
<P>Intravenous microplasmin (3 dose regimens) versus placebo in ischaemic stroke patients within 12 hours of onset; follow-up 90 days. This study was excluded because microplasmin has a very short half life and when given intravenously it does not have a direct thrombolytic effect</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-02-01 10:39:12 +0000" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Morris-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-02-01 10:39:12 +0000" MODIFIED_BY="Hazel Fraser">
<P>Open-label phase 1 safety study. 3 dose tiers of intravenous rt-PA (0.45, 0.60 and 0.75 mg/kg) plus full-dose abciximab. 42 patients to be enrolled. Primary outcome intracranial haemorrhage. Started September 2002. Excluded because not randomised or blinded</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-24 12:44:57 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Qiang-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-24 12:44:57 +0000" MODIFIED_BY="[Empty name]">
<P>Thrombolysis versus low-molecular-weight heparin (4100 IU subcutaneously 2 times per day) in patients within 6 hours of acute ischaemic stroke; follow-up 7 days. Not testing two thrombolytic agents</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-23 16:15:28 +0000" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Qureshi-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-23 16:15:28 +0000" MODIFIED_BY="Hazel Fraser">
<P>Excluded because non-random dose-escalation study of retavase in the presence of abciximab</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-02-01 10:39:12 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Qureshi-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-02-01 10:39:12 +0000" MODIFIED_BY="[Empty name]">
<P>Comparison of 4 doses of intra-arterial reteplase (0.5, 1, 1.5 and 2 units) in acute ischaemic stroke (3 to 6 hours after onset). All patients received intravenous abciximab. Excluded because not a randomised study and also confounded by the use of abciximab</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-23 16:15:43 +0000" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-ReoPro-Retavase-MRI">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-23 16:15:43 +0000" MODIFIED_BY="Hazel Fraser">
<P>Excluded because non-random dose-escalation study of retavase in the presence of abciximab</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-02-01 10:39:13 +0000" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Riedel-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-02-01 10:39:13 +0000" MODIFIED_BY="Hazel Fraser">
<P>Study was terminated because of recruitment problems. According to Gruenenthal, Germany, fewer than 10 patients were recruited for this study. No results were published</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-23 16:16:10 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sakamoto-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-23 16:16:10 +0000" MODIFIED_BY="[Empty name]">
<P>UK 420,000 units over 2 days versus sodium ozagrel 160 mg/d for 2 weeks in patients with acute lacunar infarction; follow-up 1 month. Testing ozagrel, not a direct thrombolytic (antiplatelet). Not relevant to this review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-02-01 10:39:14 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Seitz-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-02-01 10:39:14 +0000" MODIFIED_BY="[Empty name]">
<P>Excluded as it is testing tirobifan (antiplatelet) as adjunct to t-PA</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-23 16:16:24 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Song-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-23 16:16:24 +0000" MODIFIED_BY="[Empty name]">
<P>Excluded as method of randomisation unclear. Only 21 days follow-up, no dependency data</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-23 16:16:35 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Song-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-23 16:16:35 +0000" MODIFIED_BY="[Empty name]">
<P>Unclear method of randomisation, 14 days follow-up, no dependency data</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-31 16:07:08 +0000" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-TASS">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-31 16:07:08 +0000" MODIFIED_BY="Hazel Fraser">
<P>Excluded because not randomised. This is an open-label dose-escalation study of TNK</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-23 16:17:11 +0000" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Tazaki-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-23 16:17:11 +0000" MODIFIED_BY="Hazel Fraser">
<P>Not relevant to this review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-02-01 10:39:14 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-TNK_x002d_TPA">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-02-01 10:39:14 +0000" MODIFIED_BY="[Empty name]">
<P>Evaluating the effect of intravenous t-PA 0.9 mg/kg versus intravenous TNK 0.4 mg/kg in acute stroke patients with MCA occlusion. Excluded because it is a prospective case series, not a randomised study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-02-01 10:39:18 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tsuchiya-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-02-01 10:39:18 +0000" MODIFIED_BY="[Empty name]">
<P>Confounded by heparin dose, e.g. higher-dose group plus heparin 2500 to 5000 U/day versus lower-dose group plus heparin 2500 U/day</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-02-01 10:39:21 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tsuchiya-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-02-01 10:39:21 +0000" MODIFIED_BY="[Empty name]">
<P>Confounded by heparin dose, e.g. higher-dose group plus heparin 2500 to 5000 U/day versus lower-dose group plus heparin 2500 U/day</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-02-01 10:39:22 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-TTT_x002d_AIS">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-02-01 10:39:22 +0000" MODIFIED_BY="[Empty name]">
<P>Observational, not a randomised study. Evaluates 2 different doses of rt-PA</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-02-01 10:39:23 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-URICO_x002d_ICTUS">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-02-01 10:39:23 +0000" MODIFIED_BY="[Empty name]">
<P>Intravenous uric acid (1 g) versus placebo control in acute ischaemic stroke patients treated with rt-PA and &lt; 4.5 hours from onset.  Effect of combined treatment on clinical outcome and infarction volume. Excluded as not testing thrombolysis, uric acid as adjunct to t-PA</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-02-01 10:39:25 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-VASTT">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-02-01 10:39:25 +0000" MODIFIED_BY="[Empty name]">
<P>Phase IIA open-label dose-escalation study testing V10153. To the best of our knowledge this is not a randomised study. Study completed but no results published by the end of 2010</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-24 12:45:24 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-1999a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-24 12:45:24 +0000" MODIFIED_BY="[Empty name]">
<P>Intravenous defibrase 10 U for 7 days versus ahylsantinfarctase 2 U/d for 21 days in acute ischaemic stroke. Not a direct thrombolytic agent</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-23 16:19:04 +0000" MODIFIED_BY="jmw " STUDY_ID="STD-Wang-2007h">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-23 16:19:04 +0000" MODIFIED_BY="jmw ">
<P>Retrospective analysis of non-randomised case series</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-02-01 10:39:25 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Won-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-02-01 10:39:25 +0000" MODIFIED_BY="[Empty name]">
<P>Abstract only. Observational - non-randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-24 12:45:45 +0000" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Wu-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-24 12:45:45 +0000" MODIFIED_BY="Hazel Fraser">
<P>Published as abstract in 1995. Trial of UK 300,000 IU/day for 3 days, then 100,000 IU/day for 7 days versus intravenous cerebrolysin (amount unspecified). No information on type of patients (N = 132), mode of randomisation or outcome measures or timing. Authors state that "curative rate, effective rate according to neurological deficit." Not possible to extract further data from the abstract. As far as we can see, never published in full. Therefore not usable</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-02-01 10:39:27 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Xiao-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-02-01 10:39:27 +0000" MODIFIED_BY="[Empty name]">
<P>Intra-arterial carotid artery UK 300,000 U for 7 days versus intravenous UK 300,000 U for 7 days in acute ischaemic stroke patients. Only 21-day follow-up. No dependency data. Method of randomisation unclear</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-23 16:21:22 +0000" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Xu-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-23 16:21:22 +0000" MODIFIED_BY="Hazel Fraser">
<P>Intravenous ahylsantinfarctase (20 U day 1, 10 U on 3rd and 5th day) plus from 6th day saliva miltiorrhiza (20 ml) versus intravenous defibrinogenase (10 U 1st day, 5 U on 3rd and 5th day) plus from 6th day saliva miltiorrhiza (20 ml) in ischaemic stroke. Neurological status and blood clotting monitored to 14 days. No functional outcome data. Excluded because of lack of relevant data and unclear whether randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-23 16:21:31 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yan-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-23 16:21:31 +0000" MODIFIED_BY="[Empty name]">
<P>Streptokinase (1 million units over 1 hour) versus citicoline in acute ischaemic stroke. Citicoline is not a thrombolytic agent</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-02-01 10:39:29 +0000" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Yoneda-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-02-01 10:39:29 +0000" MODIFIED_BY="Hazel Fraser">
<P>Open-label, dose escalating study of rt-PA (duteplase) 5, 10 or 20 MIU intra-arterially within 6 hours, acute major hemispheric syndrome, age under 80, angiographically proved MCA or ICA occlusion, exclude CT hypodensity, outcomes recanalisation at end of infusion, haemorrhage on CT, neurological status on hemispheric stroke scale at 1 month. No dependency data. Excluded because non-random, no long-term follow-up, no dependency data. 19 patients included in total</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-02-01 10:39:30 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhang-2001e">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-02-01 10:39:30 +0000" MODIFIED_BY="[Empty name]">
<P>Intra-arterial UK using Seldinger method (500,000 units) versus intravenous UK (750,000 units) in acute ischaemic stroke. Effect on recanalisation rate. The randomisation method is unclear. Only 21-day follow-up. No clinical outcomes available</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-23 16:22:27 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhang-2006c">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-23 16:22:27 +0000" MODIFIED_BY="[Empty name]">
<P>Edaravone + intravenous rt-PA versus rt-PA alone in acute ischaemic stroke. Not relevant to this review. Not testing thrombolysis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-23 16:22:29 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhou-1996b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-23 16:22:29 +0000" MODIFIED_BY="[Empty name]">
<P>Not relevant to this review. Not testing direct thrombolytic agent</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>CT: computed tomography<BR/>DSA: digital subtraction angiography<BR/>ESR: erythrocyte sedimentation rate<BR/>ICA: internal carotid artery<BR/>MCA: middle cerebral artery<BR/>rt-PA: recombinant t-PA<BR/>TNK: tenecteplase<BR/>t-PA: tissue plasminogen activator<BR/>UK: urokinase<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2013-02-01 10:39:33 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR MODIFIED="2013-02-01 10:39:33 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wadia-2009">
<CHAR_METHODS MODIFIED="2013-02-01 10:39:33 +0000" MODIFIED_BY="[Empty name]">
<P>Open-label, single-arm, multicentre, randomised trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-01-24 10:32:48 +0000" MODIFIED_BY="[Empty name]">
<P>Acute ischaemic stroke within 4.5 hours of stroke onset</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-01-24 10:33:02 +0000" MODIFIED_BY="[Empty name]">
<P>Injection of tenecteplase (TNK-TPA) ) 0.1 or 0.2 mg/kg bolus intravenously</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-01-24 10:33:36 +0000" MODIFIED_BY="[Empty name]">
<P>Improvement at 24 hours. Symptomatic/asymptomatic haemorrhage at 36/48 hours. Outcomes at 7 days, 1 month, 3 months</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-12-28 23:22:33 +0000" MODIFIED_BY="[Empty name]"/>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2013-03-19 00:33:55 +0000" MODIFIED_BY="jmw " SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2013-02-01 10:39:33 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-BASICS">
<CHAR_STUDY_NAME MODIFIED="2011-11-21 22:42:30 +0000" MODIFIED_BY="[Empty name]">
<P>BASICS</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2013-02-01 10:39:33 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised, multicentre, open-label, controlled phase III, treatment trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-01-24 10:36:30 +0000" MODIFIED_BY="[Empty name]">
<P>Patients with CTA or MRA confirmed basilar occlusion after completion of intravenous thrombolysis aged 18 to 85 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-01-24 12:45:59 +0000" MODIFIED_BY="[Empty name]">
<P>Patients will be randomised between additional intra-arterial therapy followed by maximum supportive care versus maximum supportive care alone. Intravenous thrombolysis has to be initiated within 4.5 hours from estimated time of basilar artery occlusion and intra-arterial therapy within 6 hours</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-01-24 10:37:34 +0000" MODIFIED_BY="[Empty name]">
<P>Favourable outcome at day 90 defined as a mRS &#8211; functional scale of 0 to 3</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2013-01-24 10:37:40 +0000" MODIFIED_BY="[Empty name]">
<P>To be confirmed</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2013-01-24 10:37:46 +0000" MODIFIED_BY="[Empty name]">
<P>Wouter J Schonewille, St Antonius Hospital, University Medical Center Utrecht, The Netherlands</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES/>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2013-02-01 10:39:34 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-DIAS_x002d_J">
<CHAR_STUDY_NAME MODIFIED="2013-01-24 12:46:04 +0000" MODIFIED_BY="[Empty name]">
<P>Clinical study of desmoteplase in Japanese patients with acute ischaemic stroke (DIAS-J)</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2013-02-01 10:39:34 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, placebo-controlled, dose-escalation phase II trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-01-24 10:39:39 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis of acute ischaemic stroke, age 20 to 85 years, NIHSS 4 to 24, vessel occlusion of high-grade stenosis on angiography (MRA or CTA) in proximal cerebral arteries (TIMI 0 to 1)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-02-01 10:39:34 +0000" MODIFIED_BY="[Empty name]">
<P>Single intravenous bolus of 70 or 90 µg/kg desmoteplase (dose-escalation design) within 3 to 9 hours after the onset of stroke symptoms</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-01-24 10:45:09 +0000" MODIFIED_BY="[Empty name]">
<P>To evaluate the safety and tolerability of desmoteplase doses of 70 µg/kg and 90 µg/kg in Japanese patients with acute ischaemic stroke as measured by the presence of SICH within 72 hours after investigational medicinal product; evaluate the clinical improvement at day 90 after administration of investigational medicinal product as measured by the mRS; evaluate the clinical improvement at days 7 and 30 after administration of investigational medicinal product as measured by the mRS; evaluate recanalisation at 18 ± 6 hours after administration of investigational medicinal product; evaluate change in infarct size at 18 ± 6 hours relative to pre-treatment infarct size; evaluate the pharmacokinetics and pharmacodynamics of desmoteplase at 0.5 to 9 hours; evaluate the immunogenicity of desmoteplase at day 7, day 30, day 90; explore the predictive value of different volumes of absolute mismatch for the clinical response and other objectives at day 90</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2011-11-24 09:50:18 +0000" MODIFIED_BY="[Empty name]">
<P>1 August 2010</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2011-11-24 09:50:48 +0000" MODIFIED_BY="[Empty name]">
<P>Rudiger von Kummer, Dresden, Germany, kummer-r@rcs.urz.tu-dresden.de OR H. Lundbeck A/S, LundbeckClinicalTrials@lundbeck.com</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES/>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2013-01-24 12:46:35 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-ENCHANTED">
<CHAR_STUDY_NAME MODIFIED="2013-01-24 10:46:05 +0000" MODIFIED_BY="[Empty name]">
<P>Enhanced control of hypertension and thrombolysis stroke study (ENCHANTED)</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2013-01-24 10:46:12 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial, 2 arms</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-01-24 12:46:35 +0000" MODIFIED_BY="[Empty name]">
<P>Age &#8805; 18 years, fulfil local criteria for use of intravenous rt-PA, &lt; 3 or &lt; 4.5 hours of definite time of stroke onset, systolic BP &#8804; 185 mmHg, provide written informed consent or approved surrogate and no definite indication/contraindication for either dose of rt-PA (Arm A) or systolic BP &#8805; 150 mm HG and no definite indication/contraindication to intensive BP lowering to 140 to 150 mmHg range over next 72 hours (Arm B)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-01-24 10:50:05 +0000" MODIFIED_BY="[Empty name]">
<P>Arm A: low-dose rt-PA (0.6 mg/kg intravenous alteplase, 15% bolus, 85% infusion over 60 minutes); standard-dose rt-PA (0.9 mg/kg intravenous alteplase, 10% bolus, 90% infusion over 60 minutes)</P>
<P>Arm B: intensive BP lowering (aim for target BP of 140 to 150 mmHg, to be achieved within 30 minutes, to be sustained for at least 72 hours, use locally available agents, patient to be monitored in an appropriate facility such as neurointensive care unit, acute stroke unit, high dependency unit)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-01-24 10:50:20 +0000" MODIFIED_BY="[Empty name]">
<P>mRS of 0 to 1 at 90 days; combined death and any disability mRS of 2 to 6 at 90 days</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2011-11-24 10:22:00 +0000" MODIFIED_BY="[Empty name]">
<P>October 2011</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2011-11-24 11:01:08 +0000" MODIFIED_BY="[Empty name]">
<P>Craig Anderson, canderson@georgeinstitute.org.au; Richard Lindley, richard.lindley@sydney.edu.au</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2011-11-24 10:40:32 +0000" MODIFIED_BY="[Empty name]"/>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2013-02-01 10:39:35 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-FRALYSE">
<CHAR_STUDY_NAME>
<P>FRALYSE</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2013-01-24 10:50:33 +0000" MODIFIED_BY="[Empty name]">
<P>Single-blinded randomised trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-01-24 10:50:42 +0000" MODIFIED_BY="[Empty name]">
<P>All types of cerebral infarction &lt; 7 hours from stroke onset. Exclude patients with hypodense infarct on CT</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-01-24 10:51:01 +0000" MODIFIED_BY="[Empty name]">
<P>0.9 mg/kg intravenously over 60 minutes versus 0.8 mg/kg intravenously over 90 minutes</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-02-01 10:39:35 +0000" MODIFIED_BY="Hazel Fraser">
<P>3-month neurological score; haemorrhage on 24-hour CT</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2013-01-24 10:51:15 +0000" MODIFIED_BY="[Empty name]">
<P>2001 to 2008: 373 patients had been included.</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2013-01-24 10:51:26 +0000" MODIFIED_BY="Hazel Fraser">
<P>P Trouillas, Cerebrovascular Disease Centre, Lyon, France.</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2013-01-24 10:51:39 +0000" MODIFIED_BY="[Empty name]">
<P>Heparin not allowed until 24 hours after treatment. An MR substudy arm with 65 patients. 5 French centres involved. 80% of patients treated &gt; 3 hours after onset</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2013-01-24 10:53:39 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-ITAIS">
<CHAR_STUDY_NAME MODIFIED="2011-11-21 22:42:59 +0000" MODIFIED_BY="[Empty name]">
<P>Imaging-based Thrombolysis trial in Acute Ischemic Stroke (ITAIS)</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS MODIFIED="2013-01-24 10:53:20 +0000" MODIFIED_BY="[Empty name]">
<P>Multicentre trial, China</P>
<P>3 to 6 hours post stroke onset with perfusion/diffusion mismatch on MRI</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-01-24 10:53:27 +0000" MODIFIED_BY="[Empty name]">
<P>Intravenous versus intra-arterial rt-PA</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-01-24 10:53:39 +0000" MODIFIED_BY="[Empty name]">
<P>mRS at 90 days, intracerebral haemorrhage</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2011-11-21 22:43:04 +0000" MODIFIED_BY="[Empty name]">
<P>2005</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION/>
<CHAR_NOTES/>
</ONGOING_CHAR>
<FOOTNOTES>
<P>BP: blood pressure<BR/>CT: computed tomography<BR/>CTA: CT angiography<BR/>MR: magnetic resonance<BR/>MRA: magnetic resonance angioplasty<BR/>MRI: magnetic resonance imaging<BR/>mRS: modified Rankin Score<BR/>NIHSS: National Institutes of Neurological Disorders and Stroke Scale<BR/>rt-PA: recombinant tissue plasminogen activator<BR/>SICH: symptomatic intracranial haemorrhage<BR/>TIMI scale: Thrombolysis In Myocardial Infarction scale</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2013-03-19 01:01:33 +0000" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2013-03-19 00:58:54 +0000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-23 15:01:55 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Abe-1981">
<DESCRIPTION>
<P>Sequentially numbered envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-23 15:08:46 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Abe-1990">
<DESCRIPTION>
<P>Sequentially numbered envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-23 15:09:22 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Atarashi-1985">
<DESCRIPTION>
<P>Sequentially numbered envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-23 15:11:08 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chen-2002">
<DESCRIPTION>
<P>Randomisation method unclear - sounds like sequential numbers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-23 15:21:24 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-DEDAS">
<DESCRIPTION>
<P>Central randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-23 15:28:49 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-DIAS-2005">
<DESCRIPTION>
<P>Central randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-23 15:31:20 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-DIAS_x002d_2">
<DESCRIPTION>
<P>Central randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-23 15:33:43 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Ducrocq-2005">
<DESCRIPTION>
<P>Method unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-23 15:35:39 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-EMS-Bridging-Trial">
<DESCRIPTION>
<P>Method unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-23 15:36:38 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kikuchi-1994">
<DESCRIPTION>
<P>Method unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-23 15:37:30 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mori-1992">
<DESCRIPTION>
<P>Central telephone randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-01 10:37:54 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ohtomo-1985">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-01 10:38:00 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ohtomo-1988a">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-01 10:38:04 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ohtomo-1988b">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-23 15:41:34 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Parsons-2012">
<DESCRIPTION>
<P>Method unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-23 15:47:38 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-SYNTHESIS">
<DESCRIPTION>
<P>Stratified randomisation but sealed envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-19 00:58:54 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-SYNTHESIS-EXPANSION">
<DESCRIPTION>
<P>central simple randomisation system</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-01 10:38:28 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sen-2008">
<DESCRIPTION>
<P>Reported that computer-generated although minimisation, etc. not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-24 12:44:07 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-TNK_x002d_S2B">
<DESCRIPTION>
<P>Web-based randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-23 15:51:01 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wang-2003">
<DESCRIPTION>
<P>No details of randomisation methods</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2013-03-19 00:59:03 +0000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-23 15:01:58 +0000" MODIFIED_BY="Hazel Fraser" RESULT="UNKNOWN" STUDY_ID="STD-Abe-1981">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-23 15:08:48 +0000" MODIFIED_BY="Hazel Fraser" RESULT="UNKNOWN" STUDY_ID="STD-Abe-1990">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-23 15:09:25 +0000" MODIFIED_BY="Hazel Fraser" RESULT="UNKNOWN" STUDY_ID="STD-Atarashi-1985">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-23 15:11:11 +0000" MODIFIED_BY="Hazel Fraser" RESULT="UNKNOWN" STUDY_ID="STD-Chen-2002">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-23 15:21:26 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-DEDAS">
<DESCRIPTION>
<P>Central randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-23 15:28:51 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-DIAS-2005">
<DESCRIPTION>
<P>Central randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-23 15:31:22 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-DIAS_x002d_2">
<DESCRIPTION>
<P>Central randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-23 15:33:45 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ducrocq-2005">
<DESCRIPTION>
<P>Method unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-23 15:35:42 +0000" MODIFIED_BY="Hazel Fraser" RESULT="UNKNOWN" STUDY_ID="STD-EMS-Bridging-Trial">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-23 15:36:41 +0000" MODIFIED_BY="Hazel Fraser" RESULT="UNKNOWN" STUDY_ID="STD-Kikuchi-1994">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-01 10:37:47 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Mori-1992">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-23 15:38:11 +0000" MODIFIED_BY="Hazel Fraser" RESULT="UNKNOWN" STUDY_ID="STD-Ohtomo-1985">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-23 15:38:48 +0000" MODIFIED_BY="Hazel Fraser" RESULT="UNKNOWN" STUDY_ID="STD-Ohtomo-1988a">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-23 15:39:28 +0000" MODIFIED_BY="Hazel Fraser" RESULT="UNKNOWN" STUDY_ID="STD-Ohtomo-1988b">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-01 10:38:19 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Parsons-2012">
<DESCRIPTION>
<P>Central telephone randomisation but trial treatment given open-label; 3 centres; intensive baseline imaging; centralised image analysis; hard to blind clinical outcome assessors to allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-12-27 12:25:42 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-SYNTHESIS">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-19 00:59:03 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-SYNTHESIS-EXPANSION">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-23 15:44:20 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sen-2008">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-02-01 10:38:39 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-TNK_x002d_S2B">
<DESCRIPTION>
<P>Double-blind, web-based</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-23 15:51:04 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wang-2003">
<DESCRIPTION>
<P>Method of randomisation not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2013-03-19 01:00:10 +0000" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-02-01 10:36:58 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Abe-1981">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-02-01 10:37:11 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Abe-1990">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-02-01 10:37:16 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Atarashi-1985">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-02-01 10:37:20 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chen-2002">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-02-01 10:37:24 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-DEDAS">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-02-01 10:37:31 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-DIAS-2005">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-02-01 10:37:36 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-DIAS_x002d_2">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-02-01 10:37:39 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Ducrocq-2005">
<DESCRIPTION>
<P>Single-centre; not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-02-01 10:37:43 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-EMS-Bridging-Trial">
<DESCRIPTION>
<P>Double-blind elements</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-02-01 10:37:45 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kikuchi-1994">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-02-01 10:37:47 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mori-1992">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-02-01 10:37:55 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ohtomo-1985">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-02-01 10:38:01 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ohtomo-1988a">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-02-01 10:38:09 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ohtomo-1988b">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-02-01 10:38:20 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Parsons-2012">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-02-01 10:38:35 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-SYNTHESIS">
<DESCRIPTION>
<P>Central blinded outcome assessment but open-label</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-03-19 01:00:10 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-SYNTHESIS-EXPANSION">
<DESCRIPTION>
<P>90 day follow up done by central blinded assesor. early assessments may be biased by knowledge of treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-02-01 10:38:29 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sen-2008">
<DESCRIPTION>
<P>Open-label</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-02-01 10:38:40 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-TNK_x002d_S2B">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-02-01 10:38:44 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wang-2003">
<DESCRIPTION>
<P>Unclear; single-centre study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2013-03-19 01:00:30 +0000" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-02-01 10:36:59 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Abe-1981">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-02-01 10:37:12 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Abe-1990">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-02-01 10:37:17 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Atarashi-1985">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-02-01 10:37:21 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chen-2002">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-02-01 10:37:25 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-DEDAS">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-02-01 10:37:32 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-DIAS-2005">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-02-01 10:37:37 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-DIAS_x002d_2">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-02-01 10:37:39 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Ducrocq-2005">
<DESCRIPTION>
<P>Single-centre; not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-01-23 15:35:58 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-EMS-Bridging-Trial">
<DESCRIPTION>
<P>Some elements blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-02-01 10:37:45 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kikuchi-1994">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-02-01 10:37:48 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mori-1992">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-02-01 10:37:55 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ohtomo-1985">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-02-01 10:38:01 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ohtomo-1988a">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-02-01 10:38:10 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ohtomo-1988b">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-02-01 10:38:20 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Parsons-2012">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-02-01 10:38:36 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-SYNTHESIS">
<DESCRIPTION>
<P>Open-label</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-03-19 01:00:30 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-SYNTHESIS-EXPANSION">
<DESCRIPTION>
<P>patients and operators unblind to IA v iv therapy</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-02-01 10:38:31 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sen-2008">
<DESCRIPTION>
<P>Reported that blinded outcome but difficult in single-centre study if open-label</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-02-01 10:38:41 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-TNK_x002d_S2B">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-02-01 10:38:45 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wang-2003">
<DESCRIPTION>
<P>Unclear; single-centre study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2013-03-19 01:00:39 +0000" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-02-01 10:37:00 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Abe-1981">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-02-01 10:37:13 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Abe-1990">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-02-01 10:37:18 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Atarashi-1985">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-02-01 10:37:21 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chen-2002">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-02-01 10:37:25 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-DEDAS">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-02-01 10:37:32 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-DIAS-2005">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-02-01 10:37:37 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-DIAS_x002d_2">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-02-01 10:37:40 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Ducrocq-2005">
<DESCRIPTION>
<P>Single-centre; not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-01-23 15:36:01 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-EMS-Bridging-Trial">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-02-01 10:37:46 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kikuchi-1994">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-02-01 10:37:49 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mori-1992">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-02-01 10:37:56 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ohtomo-1985">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-02-01 10:38:02 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ohtomo-1988a">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-02-01 10:38:11 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ohtomo-1988b">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-02-01 10:38:22 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Parsons-2012">
<DESCRIPTION>
<P>Central image adjudication but unclear if follow-up images analysed separately from baseline; plus hard to blind effectively in a small data set</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-01-23 15:47:55 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-SYNTHESIS">
<DESCRIPTION>
<P>Reported to be blinded follow-up; 4 centres</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-03-19 01:00:39 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-SYNTHESIS-EXPANSION">
<DESCRIPTION>
<P>central blinded assesser</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-02-01 10:38:32 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sen-2008">
<DESCRIPTION>
<P>Reported that blinded outcome but difficult in single-centre study if open-label</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-02-01 10:38:41 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-TNK_x002d_S2B">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-02-01 10:38:46 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wang-2003">
<DESCRIPTION>
<P>Unclear; single-centre study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2013-03-19 01:01:18 +0000" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-01-23 15:02:07 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Abe-1981">
<DESCRIPTION>
<P>Minimal</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-01-23 15:08:56 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Abe-1990">
<DESCRIPTION>
<P>Minimal losses</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-01-23 15:09:35 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Atarashi-1985">
<DESCRIPTION>
<P>Few losses</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-12-26 20:06:24 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chen-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-12-26 20:07:21 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-DEDAS">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" RESULT="UNKNOWN" STUDY_ID="STD-DIAS-2005">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-12-26 20:08:40 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-DIAS_x002d_2">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-02-01 10:37:40 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ducrocq-2005">
<DESCRIPTION>
<P>Losses unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-01-23 15:36:03 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-EMS-Bridging-Trial">
<DESCRIPTION>
<P>Few losses</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-01-23 15:36:48 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kikuchi-1994">
<DESCRIPTION>
<P>Few losses</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-01-23 15:37:42 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mori-1992">
<DESCRIPTION>
<P>No losses</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-01-23 15:38:19 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ohtomo-1985">
<DESCRIPTION>
<P>Minimal losses</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-01-23 15:38:56 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ohtomo-1988a">
<DESCRIPTION>
<P>Few losses</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-01-23 15:39:35 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Ohtomo-1988b">
<DESCRIPTION>
<P>More losses</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-01-23 15:41:58 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Parsons-2012">
<DESCRIPTION>
<P>Dead patients not counted in primary outcome as did not undergo repeat imaging</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-01-23 15:47:58 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-SYNTHESIS">
<DESCRIPTION>
<P>Few missing outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-03-19 01:01:18 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-SYNTHESIS-EXPANSION">
<DESCRIPTION>
<P>no loss to follow up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-01-23 15:44:36 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sen-2008">
<DESCRIPTION>
<P>Small study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-01-23 15:50:11 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-TNK_x002d_S2B">
<DESCRIPTION>
<P>No losses evident</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-01-23 15:51:16 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wang-2003">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2013-03-19 01:01:33 +0000" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-23 15:02:09 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Abe-1981">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Abe-1990">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Atarashi-1985">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Chen-2002">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-12-26 20:07:25 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-DEDAS">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-DIAS-2005">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-12-26 20:08:47 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-DIAS_x002d_2">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Ducrocq-2005">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-EMS-Bridging-Trial">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-12-26 20:13:48 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kikuchi-1994">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-23 15:37:45 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mori-1992">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Ohtomo-1985">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Ohtomo-1988a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Ohtomo-1988b">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Parsons-2012">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-23 15:48:01 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-SYNTHESIS">
<DESCRIPTION>
<P>None evident</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-03-19 01:01:33 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-SYNTHESIS-EXPANSION">
<DESCRIPTION>
<P>no evidence of selective reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Sen-2008">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-23 15:50:13 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-TNK_x002d_S2B">
<DESCRIPTION>
<P>Stopped early</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Wang-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2012-01-11 12:28:33 +0000" MODIFIED_BY="jmw "/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2013-03-20 01:04:43 +0000" MODIFIED_BY="jmw ">
<COMPARISON ID="CMP-001" MODIFIED="2013-01-31 16:03:22 +0000" MODIFIED_BY="jmw " NO="1">
<NAME>Thrombolysis: higher dose versus lower dose of the same agent</NAME>
<DICH_OUTCOME CHI2="8.263906928652458" CI_END="1.1872217693332332" CI_START="0.6193735238085566" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.8575160236486278" ESTIMABLE="YES" EVENTS_1="116" EVENTS_2="124" I2="27.395116476966653" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.07453185139066158" LOG_CI_START="-0.20804736325046716" LOG_EFFECT_SIZE="-0.0667577559299028" METHOD="PETO" MODIFIED="2013-01-31 16:03:22 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.2193994745129919" P_Q="0.983947279087284" P_Z="0.35441428278199316" Q="0.15881255432634694" RANDOM="NO" SCALE="16.82" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="317" TOTAL_2="313" WEIGHT="100.0" Z="0.9260610160410634">
<NAME>Death or dependency at end of follow-up</NAME>
<GROUP_LABEL_1>Higher dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Lower dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Higher dose better</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Lower dose better</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.014938814904625" CI_START="0.20137479690555857" DF="0" EFFECT_SIZE="1.188541913083564" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="0.8460238874149589" LOG_CI_START="-0.695994884575654" LOG_EFFECT_SIZE="0.07501450141965248" MODIFIED="2011-02-24 13:45:11 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.8487665011164807" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="9" WEIGHT="3.3581578492699977" Z="0.19069251784911825">
<NAME>t-PA</NAME>
<DICH_DATA CI_END="7.014938814904625" CI_START="0.20137479690555857" EFFECT_SIZE="1.188541913083564" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.8460238874149589" LOG_CI_START="-0.695994884575654" LOG_EFFECT_SIZE="0.07501450141965248" ORDER="13655" O_E="0.21052631578947345" SE="0.9057894597833127" STUDY_ID="STD-Mori-1992" TOTAL_1="10" TOTAL_2="9" VAR="1.2188365650969528" WEIGHT="3.3581578492699977"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3207488898179252" CI_START="0.5211364493831235" DF="0" EFFECT_SIZE="0.829632681954138" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="58" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="0.12082025430415837" LOG_CI_START="-0.28304855029828824" LOG_EFFECT_SIZE="-0.0811141479970649" NO="2" P_CHI2="1.0" P_Z="0.43111249685675057" STUDIES="1" TAU2="0.0" TOTAL_1="155" TOTAL_2="162" WEIGHT="48.95531052667915" Z="0.7872893716928385">
<NAME>Urokinase</NAME>
<DICH_DATA CI_END="1.3207488898179252" CI_START="0.5211364493831235" EFFECT_SIZE="0.829632681954138" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="58" LOG_CI_END="0.12082025430415837" LOG_CI_START="-0.28304855029828824" LOG_EFFECT_SIZE="-0.0811141479970649" ORDER="13656" O_E="-3.3186119873817006" SE="0.23723453500630234" STUDY_ID="STD-Chen-2002" TOTAL_1="155" TOTAL_2="162" VAR="17.76823044174745" WEIGHT="48.95531052667915"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.544671303033473" CI_END="1.5686019116258714" CI_START="0.4935052535940846" DF="2" EFFECT_SIZE="0.8798370782054434" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="44" I2="43.57727899090582" ID="CMP-001.01.03" LOG_CI_END="0.19551273994097318" LOG_CI_START="-0.3067082197019905" LOG_EFFECT_SIZE="-0.05559773988050865" MODIFIED="2011-11-24 14:31:10 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.16993566769145696" P_Z="0.6643242449617652" STUDIES="3" TAU2="0.0" TOTAL_1="96" TOTAL_2="86" WEIGHT="31.658531095901033" Z="0.4339506971795496">
<NAME>Desmoteplase</NAME>
<DICH_DATA CI_END="1.2363371783542012" CI_START="0.0695298394673031" EFFECT_SIZE="0.29319332451204627" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="10" LOG_CI_END="0.09213692927118744" LOG_CI_START="-1.1578287733260901" LOG_EFFECT_SIZE="-0.5328459220274514" MODIFIED="2011-03-14 05:05:51 +0000" MODIFIED_BY="[Empty name]" ORDER="80" O_E="-2.275862068965518" SE="0.7342360411356583" STUDY_ID="STD-DEDAS" TOTAL_1="15" TOTAL_2="14" VAR="1.8549346016646848" WEIGHT="5.110745255634233"/>
<DICH_DATA CI_END="2.4414151658081793" CI_START="0.14539630267087972" EFFECT_SIZE="0.5957958865191351" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" LOG_CI_END="0.3876416380358757" LOG_CI_START="-0.8374466371499579" LOG_EFFECT_SIZE="-0.22490249955704109" MODIFIED="2011-03-14 09:03:46 +0000" MODIFIED_BY="[Empty name]" ORDER="96" O_E="-1.0" SE="0.7196229171289245" STUDY_ID="STD-DIAS-2005" TOTAL_1="15" TOTAL_2="15" VAR="1.9310344827586206" WEIGHT="5.320416855865382"/>
<DICH_DATA CI_END="2.5609642123115175" CI_START="0.6238446360033687" EFFECT_SIZE="1.263979345894201" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="26" LOG_CI_END="0.40840350954838883" LOG_CI_START="-0.2049235547529092" LOG_EFFECT_SIZE="0.10173997739773981" MODIFIED="2011-02-25 11:25:16 +0000" MODIFIED_BY="[Empty name]" ORDER="70" O_E="1.8048780487804876" SE="0.36027135358851503" STUDY_ID="STD-DIAS_x002d_2" TOTAL_1="66" TOTAL_2="57" VAR="7.704430422952771" WEIGHT="21.227368984401416"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.560423071292637" CI_END="1.8978420071940432" CI_START="0.3736193513278155" DF="1" EFFECT_SIZE="0.8420632396978969" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="17" I2="78.07220987248112" ID="CMP-001.01.04" LOG_CI_END="0.27826005516198066" LOG_CI_START="-0.427570637909717" LOG_EFFECT_SIZE="-0.07465529137386814" MODIFIED="2012-12-26 18:21:38 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.03271904547532822" P_Z="0.6784285675141386" STUDIES="2" TAU2="0.0" TOTAL_1="56" TOTAL_2="56" WEIGHT="16.028000528149825" Z="0.4146084430285951">
<NAME>Tenecteplase</NAME>
<DICH_DATA CI_END="1.0571595272959289" CI_START="0.09172879339454684" EFFECT_SIZE="0.3114032239145977" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="10" LOG_CI_END="0.024140528080080225" LOG_CI_START="-1.0374943191876678" LOG_EFFECT_SIZE="-0.5066768955537938" MODIFIED="2012-12-26 18:21:38 +0000" MODIFIED_BY="[Empty name]" ORDER="96" O_E="-3.0" SE="0.6236095644623236" STUDY_ID="STD-Parsons-2012" TOTAL_1="25" TOTAL_2="25" VAR="2.571428571428571" WEIGHT="7.084840813167676"/>
<DICH_DATA CI_END="5.496107779738254" CI_START="0.6239301019561989" EFFECT_SIZE="1.8518064389601703" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="7" LOG_CI_END="0.7400552407339218" LOG_CI_START="-0.20486406101476298" LOG_EFFECT_SIZE="0.26759558985957943" MODIFIED="2011-02-25 12:01:56 +0000" MODIFIED_BY="[Empty name]" ORDER="79" O_E="2.0" SE="0.5550502752731576" STUDY_ID="STD-TNK_x002d_S2B" TOTAL_1="31" TOTAL_2="31" VAR="3.2459016393442623" WEIGHT="8.94315971498215"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.020911962461652" CI_END="1.7957274083203056" CI_START="0.6599389760758401" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.0886094373824915" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="31" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.25424041136954606" LOG_CI_START="-0.18049622139572616" LOG_EFFECT_SIZE="0.03687209498691" METHOD="PETO" MODIFIED="2012-12-26 19:45:19 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.6448894559631679" P_Q="0.6571463586917026" P_Z="0.7395360079942922" Q="0.8396970844833701" RANDOM="NO" SCALE="448.57070811727135" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="654" TOTAL_2="637" WEIGHT="100.0" Z="0.3324678564546142">
<NAME>Death from all causes within about the first two weeks</NAME>
<GROUP_LABEL_1>Higher dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Lower dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Higher dose better</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Lower dose better</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.468081272145697" CI_END="2.2038867695747473" CI_START="0.44994645193357885" DF="3" EFFECT_SIZE="0.9958067244367828" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="13" I2="13.496836879376117" ID="CMP-001.02.01" LOG_CI_END="0.3431892777423132" LOG_CI_START="-0.34683916847695206" LOG_EFFECT_SIZE="-0.0018249453673193747" MODIFIED="2011-02-24 13:46:27 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.32492564434669535" P_Z="0.9917283292039027" STUDIES="5" TAU2="0.0" TOTAL_1="251" TOTAL_2="245" WEIGHT="39.69341684215007" Z="0.010367187652326564">
<NAME>t-PA</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="13657" O_E="0.0" SE="0.0" STUDY_ID="STD-Abe-1990" TOTAL_1="71" TOTAL_2="76" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.877072579606752" CI_START="0.44508167937290877" EFFECT_SIZE="1.1316060690050755" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="9" LOG_CI_END="0.45895081792964487" LOG_CI_START="-0.3515602819497932" LOG_EFFECT_SIZE="0.053695267989925785" ORDER="13658" O_E="0.545454545454545" SE="0.4760982321638326" STUDY_ID="STD-Kikuchi-1994" TOTAL_1="72" TOTAL_2="60" VAR="4.411709040439089" WEIGHT="28.76964750320469"/>
<DICH_DATA CI_END="1.860473486356023" CI_START="0.006149286296911213" EFFECT_SIZE="0.10696066620686187" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.2696234852625127" LOG_CI_START="-2.2111752867123444" LOG_EFFECT_SIZE="-0.9707759007249158" ORDER="13659" O_E="-1.0526315789473684" SE="1.457233478810004" STUDY_ID="STD-Mori-1992" TOTAL_1="10" TOTAL_2="9" VAR="0.47091412742382266" WEIGHT="3.070926329473937"/>
<DICH_DATA CI_END="390.65751944319163" CI_START="0.1534959238853701" EFFECT_SIZE="7.743664305075447" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.5917961881010054" LOG_CI_START="-0.8139031528095675" LOG_EFFECT_SIZE="0.8889465176457187" ORDER="13660" O_E="0.5114503816793894" SE="2.000524651334498" STUDY_ID="STD-Ohtomo-1988a" TOTAL_1="64" TOTAL_2="67" VAR="0.24986888875939628" WEIGHT="1.6294455925656024"/>
<DICH_DATA CI_END="7.2068459335983155" CI_START="0.13034248991087802" EFFECT_SIZE="0.9692049542740124" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8577452379046915" LOG_CI_START="-0.8849139870060153" LOG_EFFECT_SIZE="-0.01358437455066199" MODIFIED="2011-02-24 13:46:27 +0000" MODIFIED_BY="[Empty name]" ORDER="58" O_E="-0.029850746268656803" SE="1.0236466550148358" STUDY_ID="STD-Wang-2003" TOTAL_1="34" TOTAL_2="33" VAR="0.9543328135442193" WEIGHT="6.223397416905837"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.303637243153572" CI_END="2.056451578747167" CI_START="0.4946032186589683" DF="2" EFFECT_SIZE="1.00852742643156" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="16" I2="0.0" ID="CMP-001.02.02" LOG_CI_END="0.3131184880584271" LOG_CI_START="-0.30574306176913973" LOG_EFFECT_SIZE="0.0036877131446437315" NO="2" P_CHI2="0.5210972684396089" P_Z="0.9813644468728685" STUDIES="3" TAU2="0.0" TOTAL_1="322" TOTAL_2="321" WEIGHT="49.347536083772376" Z="0.02335832610971082">
<NAME>Urokinase</NAME>
<DICH_DATA CI_END="17.237033890463362" CI_START="0.06541902078874015" EFFECT_SIZE="1.0618991846764179" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.236462535512454" LOG_CI_START="-1.1842959608106933" LOG_EFFECT_SIZE="0.02608328735088032" ORDER="13661" O_E="0.02970297029702973" SE="1.4219655236880322" STUDY_ID="STD-Abe-1981" TOTAL_1="49" TOTAL_2="52" VAR="0.4945632781099892" WEIGHT="3.2251472272608557"/>
<DICH_DATA CI_END="9.756950020602442" CI_START="0.4785850218125318" EFFECT_SIZE="2.160909562761432" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="0.9893140803479343" LOG_CI_START="-0.320040897544473" LOG_EFFECT_SIZE="0.33463659140173063" ORDER="13662" O_E="1.3025641025641024" SE="0.7691215954256715" STUDY_ID="STD-Atarashi-1985" TOTAL_1="103" TOTAL_2="92" VAR="1.6904798118438085" WEIGHT="11.023960975719664"/>
<DICH_DATA CI_END="1.8390224565663662" CI_START="0.3394525652023194" EFFECT_SIZE="0.7901018227710427" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="13" LOG_CI_END="0.2645870325025195" LOG_CI_START="-0.46922090506588154" LOG_EFFECT_SIZE="-0.10231693628168098" ORDER="13663" O_E="-1.2680115273775208" SE="0.43104241493555245" STUDY_ID="STD-Chen-2002" TOTAL_1="170" TOTAL_2="177" VAR="5.382201904616332" WEIGHT="35.09842788079186"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.40949636267901274" CI_END="9.617706657920262" CI_START="0.4675676037505921" DF="1" EFFECT_SIZE="2.1205961557118536" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" I2="0.0" ID="CMP-001.02.03" LOG_CI_END="0.9830715268665745" LOG_CI_START="-0.330155587330036" LOG_EFFECT_SIZE="0.3264579697682692" MODIFIED="2011-11-24 14:31:10 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.5222252574125101" P_Z="0.3298265279568413" STUDIES="2" TAU2="0.0" TOTAL_1="81" TOTAL_2="71" WEIGHT="10.95904707407755" Z="0.974463375443341">
<NAME>Desmoteplase</NAME>
<DICH_DATA CI_END="349.182217403384" CI_START="0.13684214658305954" EFFECT_SIZE="6.912513593340099" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.5430521185380273" LOG_CI_START="-0.8637801218454537" LOG_EFFECT_SIZE="0.8396359983462869" MODIFIED="2011-03-14 05:07:35 +0000" MODIFIED_BY="[Empty name]" ORDER="81" O_E="0.48275862068965514" SE="2.001190122092827" STUDY_ID="STD-DEDAS" TOTAL_1="15" TOTAL_2="14" VAR="0.2497027348394768" WEIGHT="1.6283620692272447"/>
<DICH_DATA CI_END="8.881892993191391" CI_START="0.33519222963756795" EFFECT_SIZE="1.7254395138022414" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="0.9485055365986965" LOG_CI_START="-0.47470605765703944" LOG_EFFECT_SIZE="0.2368997394708286" MODIFIED="2011-02-25 11:22:36 +0000" MODIFIED_BY="[Empty name]" ORDER="71" O_E="0.7804878048780486" SE="0.8360015354768314" STUDY_ID="STD-DIAS_x002d_2" TOTAL_1="66" TOTAL_2="57" VAR="1.4308227928340862" WEIGHT="9.330685004850304"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="14.653599188784636" CI_END="1.8047612296279947" CI_START="0.8182280431976612" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.2151980288650566" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="49" I2="31.757380073192817" I2_Q="51.5907290866924" ID="CMP-001.03" LOG_CI_END="0.256419752771179" LOG_CI_START="-0.08712563997173114" LOG_EFFECT_SIZE="0.08464705639972392" METHOD="PETO" MODIFIED="2013-01-24 12:35:02 +0000" MODIFIED_BY="jmw " NO="3" P_CHI2="0.14521066902128366" P_Q="0.10240227095699539" P_Z="0.3341235598529153" Q="6.1971600550904125" RANDOM="NO" SCALE="55.126415587869815" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="710" TOTAL_2="693" WEIGHT="100.0" Z="0.9658414023030928">
<NAME>Total deaths from all causes at end of follow-up</NAME>
<GROUP_LABEL_1>Higher dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Lower dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Higher dose better</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Lower dose better</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.594719671441224" CI_END="1.5167426200991954" CI_START="0.36588663063275256" DF="3" EFFECT_SIZE="0.7449535870141091" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="19" I2="0.0" ID="CMP-001.03.01" LOG_CI_END="0.18091189050713993" LOG_CI_START="-0.43665345918925974" LOG_EFFECT_SIZE="-0.12787078434105986" MODIFIED="2011-02-24 13:47:40 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.45841605320466006" P_Z="0.4169949646555714" STUDIES="5" TAU2="0.0" TOTAL_1="251" TOTAL_2="245" WEIGHT="30.945849989300505" Z="0.8116457055324547">
<NAME>t-PA</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="13664" O_E="0.0" SE="0.0" STUDY_ID="STD-Abe-1990" TOTAL_1="71" TOTAL_2="76" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.8806234189208997" CI_START="0.3379869540362726" EFFECT_SIZE="0.7972616766472322" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="13" LOG_CI_END="0.27430183996393387" LOG_CI_START="-0.4711000627383319" LOG_EFFECT_SIZE="-0.09839911138719903" ORDER="13665" O_E="-1.1818181818181817" SE="0.4378527674462376" STUDY_ID="STD-Kikuchi-1994" TOTAL_1="72" TOTAL_2="60" VAR="5.216074695602801" WEIGHT="21.24160180396406"/>
<DICH_DATA CI_END="1.860473486356023" CI_START="0.006149286296911213" EFFECT_SIZE="0.10696066620686187" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.2696234852625127" LOG_CI_START="-2.2111752867123444" LOG_EFFECT_SIZE="-0.9707759007249158" ORDER="13666" O_E="-1.0526315789473684" SE="1.457233478810004" STUDY_ID="STD-Mori-1992" TOTAL_1="10" TOTAL_2="9" VAR="0.47091412742382266" WEIGHT="1.917719925872731"/>
<DICH_DATA CI_END="20.193534278633482" CI_START="0.21068269877750773" EFFECT_SIZE="2.0626265536152237" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3052123359510344" LOG_CI_START="-0.6763711271065039" LOG_EFFECT_SIZE="0.31442060442226527" ORDER="13667" O_E="0.5343511450381679" SE="1.1639919351963375" STUDY_ID="STD-Ohtomo-1988a" TOTAL_1="64" TOTAL_2="67" VAR="0.7380742560277551" WEIGHT="3.005685378991062"/>
<DICH_DATA CI_END="3.8621638137403838" CI_START="0.10366428615213982" EFFECT_SIZE="0.6327467540446358" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5868306904414891" LOG_CI_START="-0.9843708385821508" LOG_EFFECT_SIZE="-0.19877007407033087" MODIFIED="2011-02-24 13:47:40 +0000" MODIFIED_BY="[Empty name]" ORDER="59" O_E="-0.5373134328358211" SE="0.9229315557214898" STUDY_ID="STD-Wang-2003" TOTAL_1="34" TOTAL_2="33" VAR="1.173980842058365" WEIGHT="4.780842880472653"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.5428338948124565" CI_END="1.9962383647180852" CI_START="0.5746361061083766" DF="2" EFFECT_SIZE="1.0710325115353658" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="21" I2="0.0" ID="CMP-001.03.02" LOG_CI_END="0.30021239782358017" LOG_CI_START="-0.24060708946313075" LOG_EFFECT_SIZE="0.029802654180224653" NO="2" P_CHI2="0.4623576012099009" P_Z="0.8289773005302309" STUDIES="3" TAU2="0.0" TOTAL_1="322" TOTAL_2="321" WEIGHT="40.35186324682613" Z="0.21601340266045474">
<NAME>Urokinase</NAME>
<DICH_DATA CI_END="20.670389901632852" CI_START="0.21318116697554804" EFFECT_SIZE="2.099175514593688" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3153486687187532" LOG_CI_START="-0.6712511647480348" LOG_EFFECT_SIZE="0.3220487519853592" ORDER="13668" O_E="0.5445544554455446" SE="1.166938576006165" STUDY_ID="STD-Abe-1981" TOTAL_1="49" TOTAL_2="52" VAR="0.7343515341633173" WEIGHT="2.9905252096901966"/>
<DICH_DATA CI_END="9.756950020602442" CI_START="0.4785850218125318" EFFECT_SIZE="2.160909562761432" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="0.9893140803479343" LOG_CI_START="-0.320040897544473" LOG_EFFECT_SIZE="0.33463659140173063" ORDER="13669" O_E="1.3025641025641024" SE="0.7691215954256715" STUDY_ID="STD-Atarashi-1985" TOTAL_1="103" TOTAL_2="92" VAR="1.6904798118438085" WEIGHT="6.884199540144135"/>
<DICH_DATA CI_END="1.7515329869686802" CI_START="0.4179480325891347" EFFECT_SIZE="0.8555990684418318" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="18" LOG_CI_END="0.24341832088498094" LOG_CI_START="-0.37887771478677684" LOG_EFFECT_SIZE="-0.06772969695089798" ORDER="13670" O_E="-1.1671469740633995" SE="0.3655397717686474" STUDY_ID="STD-Chen-2002" TOTAL_1="170" TOTAL_2="177" VAR="7.483947414873113" WEIGHT="30.477138496991792"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.8341561536386384" CI_END="8.393672980411582" CI_START="1.2266485312505298" DF="1" EFFECT_SIZE="3.208751569258537" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="4" I2="0.0" ID="CMP-001.03.03" LOG_CI_END="0.9239520449839642" LOG_CI_START="0.08872014316360201" LOG_EFFECT_SIZE="0.5063360940737831" MODIFIED="2011-12-21 15:33:15 +0000" MODIFIED_BY="jmw " NO="3" P_CHI2="0.3610735504515048" P_Z="0.017485000103657184" STUDIES="2" TAU2="0.0" TOTAL_1="81" TOTAL_2="71" WEIGHT="16.918198235629497" Z="2.376347230737699">
<NAME>Desmoteplase</NAME>
<DICH_DATA CI_END="15.685637272698129" CI_START="0.05524622057556743" EFFECT_SIZE="0.9308985855805254" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.195502167815022" LOG_CI_START="-1.2576974269517842" LOG_EFFECT_SIZE="-0.031097629568381073" MODIFIED="2011-03-14 05:09:10 +0000" MODIFIED_BY="[Empty name]" ORDER="82" O_E="-0.034482758620689724" SE="1.4410215854998645" STUDY_ID="STD-DEDAS" TOTAL_1="15" TOTAL_2="14" VAR="0.4815695600475624" WEIGHT="1.961112413528871"/>
<DICH_DATA CI_END="10.494293819550045" CI_START="1.357223053218986" EFFECT_SIZE="3.7740028483225663" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="3" LOG_CI_END="1.0209532194223458" LOG_CI_START="0.13265122777883195" LOG_EFFECT_SIZE="0.5768022236005889" MODIFIED="2011-02-25 11:47:13 +0000" MODIFIED_BY="[Empty name]" ORDER="75" O_E="4.878048780487806" SE="0.5217929870571753" STUDY_ID="STD-DIAS_x002d_2" TOTAL_1="66" TOTAL_2="57" VAR="3.6728528100954745" WEIGHT="14.957085822100625"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.484729413801906" CI_END="5.315104115615338" CI_START="0.5305636689509847" DF="1" EFFECT_SIZE="1.6792859019349127" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" I2="71.30336731341843" ID="CMP-001.03.04" LOG_CI_END="0.7255117761771613" LOG_CI_START="-0.27526249222462684" LOG_EFFECT_SIZE="0.2251246419762673" MODIFIED="2012-12-26 18:23:36 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.06193760761230083" P_Z="0.3778905852454997" STUDIES="2" TAU2="0.0" TOTAL_1="56" TOTAL_2="56" WEIGHT="11.784088528243863" Z="0.8817896387576017">
<NAME>Tenecteplase</NAME>
<DICH_DATA CI_END="2.6055637845792563" CI_START="0.0455892261772399" EFFECT_SIZE="0.3446529220743803" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.4159017092248037" LOG_CI_START="-1.341137779366514" LOG_EFFECT_SIZE="-0.4626180350708552" MODIFIED="2012-12-26 18:23:36 +0000" MODIFIED_BY="[Empty name]" ORDER="97" O_E="-1.0" SE="1.03209369308428" STUDY_ID="STD-Parsons-2012" TOTAL_1="25" TOTAL_2="25" VAR="0.9387755102040816" WEIGHT="3.8230080539066713"/>
<DICH_DATA CI_END="14.594120797000397" CI_START="0.8842930463668356" EFFECT_SIZE="3.592419733080347" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" LOG_CI_END="1.1641779366304754" LOG_CI_START="-0.05340379004354201" LOG_EFFECT_SIZE="0.5553870732934667" MODIFIED="2011-02-25 12:04:08 +0000" MODIFIED_BY="[Empty name]" ORDER="81" O_E="2.5" SE="0.7152135333750692" STUDY_ID="STD-TNK_x002d_S2B" TOTAL_1="31" TOTAL_2="31" VAR="1.9549180327868851" WEIGHT="7.961080474337192"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.740676169501583" CI_END="2.5245017742617364" CI_START="0.8126296038537798" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.432300553915441" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="21" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.40217568026098055" LOG_CI_START="-0.09010736050314365" LOG_EFFECT_SIZE="0.15603415987891844" METHOD="PETO" MODIFIED="2013-01-24 12:35:08 +0000" MODIFIED_BY="jmw " NO="4" P_CHI2="0.8365596426715126" P_Q="0.7743905391853855" P_Z="0.21406640407687105" Q="1.111119451466922" RANDOM="NO" SCALE="96.00778044726312" SORT_BY="STUDY" STUDIES="13" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="725" TOTAL_2="708" WEIGHT="99.99999999999999" Z="1.2424613825653936">
<NAME>'Significant' intracranial haemorrhage during follow-up</NAME>
<GROUP_LABEL_1>Higher dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Lower dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Higher dose better</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Lower dose better</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.4727720607122616" CI_END="2.7626431337356587" CI_START="0.5666384717010798" DF="3" EFFECT_SIZE="1.2511674081254898" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="12" I2="0.0" ID="CMP-001.04.01" LOG_CI_END="0.44132478826102883" LOG_CI_START="-0.24669394255775892" LOG_EFFECT_SIZE="0.097315422851635" MODIFIED="2011-02-24 13:49:00 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6885686551707904" P_Z="0.5792734413024528" STUDIES="5" TAU2="0.0" TOTAL_1="251" TOTAL_2="245" WEIGHT="51.19519782556557" Z="0.5544463119557917">
<NAME>t-PA</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="13671" O_E="0.0" SE="0.0" STUDY_ID="STD-Abe-1990" TOTAL_1="71" TOTAL_2="76" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.575365149473522" CI_START="0.6091142602524791" EFFECT_SIZE="1.4757391023328137" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="9" LOG_CI_END="0.5533204025855446" LOG_CI_START="-0.21530123291285172" LOG_EFFECT_SIZE="0.16900958483634645" ORDER="13672" O_E="1.9090909090909083" SE="0.45149215343021576" STUDY_ID="STD-Kikuchi-1994" TOTAL_1="72" TOTAL_2="60" VAR="4.905684183963157" WEIGHT="41.02083902277725"/>
<DICH_DATA CI_END="15.554662449299986" CI_START="0.05141168275389014" EFFECT_SIZE="0.8942546456056345" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1918605909511828" LOG_CI_START="-1.2889381810236744" LOG_EFFECT_SIZE="-0.04853879503624573" ORDER="13673" O_E="-0.05263157894736836" SE="1.457233478810004" STUDY_ID="STD-Mori-1992" TOTAL_1="10" TOTAL_2="9" VAR="0.47091412742382266" WEIGHT="3.9377366928252555"/>
<DICH_DATA CI_END="16.93599222272848" CI_START="0.0647592014333305" EFFECT_SIZE="1.04726373556282" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2288106455766081" LOG_CI_START="-1.1886985153114422" LOG_EFFECT_SIZE="0.020056065132583036" ORDER="13674" O_E="0.022900763358778664" SE="1.4200568479689863" STUDY_ID="STD-Ohtomo-1988a" TOTAL_1="64" TOTAL_2="67" VAR="0.495893640768648" WEIGHT="4.1466128775448325"/>
<DICH_DATA CI_END="6.619776622606302" CI_START="0.0026041012128297865" EFFECT_SIZE="0.13129572853520916" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8208433348768264" LOG_CI_START="-2.5843421401809397" LOG_EFFECT_SIZE="-0.8817494026520567" MODIFIED="2011-02-24 13:49:00 +0000" MODIFIED_BY="[Empty name]" ORDER="60" O_E="-0.5074626865671642" SE="2.0002228039888825" STUDY_ID="STD-Wang-2003" TOTAL_1="34" TOTAL_2="33" VAR="0.24994430830920028" WEIGHT="2.0900092324182347"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.081631748878868" CI_END="5.376435680640892" CI_START="0.6420457610092289" DF="2" EFFECT_SIZE="1.857933728122253" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="5" I2="0.0" ID="CMP-001.04.02" LOG_CI_END="0.7304944546200839" LOG_CI_START="-0.19243401703155305" LOG_EFFECT_SIZE="0.2690302187942655" NO="2" P_CHI2="0.5822731092647915" P_Z="0.2531862690279423" STUDIES="3" TAU2="0.0" TOTAL_1="322" TOTAL_2="321" WEIGHT="28.45074619038875" Z="1.1426444319050517">
<NAME>Urokinase</NAME>
<DICH_DATA CI_END="396.58199409708163" CI_START="0.1556051088111511" EFFECT_SIZE="7.855583004718345" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.5983329921642966" LOG_CI_START="-0.8079761483998705" LOG_EFFECT_SIZE="0.8951784218822131" ORDER="13675" O_E="0.5148514851485149" SE="2.0008828506695764" STUDY_ID="STD-Abe-1981" TOTAL_1="49" TOTAL_2="52" VAR="0.24977943338888342" WEIGHT="2.0886305648743027"/>
<DICH_DATA CI_END="336.76441199253554" CI_START="0.1309452679897139" EFFECT_SIZE="6.640610376897667" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.5273261906308067" LOG_CI_START="-0.8829101911913092" LOG_EFFECT_SIZE="0.8222079997197486" ORDER="13676" O_E="0.4717948717948718" SE="2.003189731624653" STUDY_ID="STD-Atarashi-1985" TOTAL_1="103" TOTAL_2="92" VAR="0.24920447074293228" WEIGHT="2.083822784907387"/>
<DICH_DATA CI_END="4.647615824380889" CI_START="0.46573350778173345" EFFECT_SIZE="1.471241115762744" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.6672302217387596" LOG_CI_START="-0.33186251508164416" LOG_EFFECT_SIZE="0.1676838533285577" ORDER="13677" O_E="1.1210374639769451" SE="0.5868720191971138" STUDY_ID="STD-Chen-2002" TOTAL_1="170" TOTAL_2="177" VAR="2.903442251282563" WEIGHT="24.278292840607058"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.0605653147148328" CI_END="4.483035277659878" CI_START="0.17339701873409807" DF="1" EFFECT_SIZE="0.8816716804037729" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" I2="5.710663348548013" ID="CMP-001.04.03" LOG_CI_END="0.6515721564059967" LOG_CI_START="-0.7609583737482786" LOG_EFFECT_SIZE="-0.05469310867114092" MODIFIED="2011-11-24 14:31:10 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.30308666898943504" P_Z="0.8793609247301792" STUDIES="3" TAU2="0.0" TOTAL_1="96" TOTAL_2="86" WEIGHT="12.14602196935161" Z="0.1517794071130819">
<NAME>Desmoteplase</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-03-14 05:13:01 +0000" MODIFIED_BY="[Empty name]" ORDER="83" O_E="0.0" SE="0.0" STUDY_ID="STD-DEDAS" TOTAL_1="15" TOTAL_2="14" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="6.820467167072353" CI_START="0.0026853936013588454" EFFECT_SIZE="0.1353352832366127" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8338141226232082" LOG_CI_START="-2.570992050236215" LOG_EFFECT_SIZE="-0.8685889638065036" MODIFIED="2011-03-14 09:04:39 +0000" MODIFIED_BY="[Empty name]" ORDER="97" O_E="-0.5" SE="2.0" STUDY_ID="STD-DIAS-2005" TOTAL_1="15" TOTAL_2="15" VAR="0.25" WEIGHT="2.0904749207498785"/>
<DICH_DATA CI_END="7.775438664489576" CI_START="0.21791890693538055" EFFECT_SIZE="1.3016970057231687" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.8907248998459065" LOG_CI_START="-0.661705088149849" LOG_EFFECT_SIZE="0.11450990584802871" MODIFIED="2011-02-25 11:31:47 +0000" MODIFIED_BY="[Empty name]" ORDER="72" O_E="0.31707317073170715" SE="0.9119050596010838" STUDY_ID="STD-DIAS_x002d_2" TOTAL_1="66" TOTAL_2="57" VAR="1.2025433728947446" WEIGHT="10.055547048601731"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.0145875937286977" CI_END="20.025268816208182" CI_START="0.3830830633663624" DF="1" EFFECT_SIZE="2.7697186360437263" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" I2="1.4377855415210619" ID="CMP-001.04.04" LOG_CI_END="1.3015783546994597" LOG_CI_START="-0.41670704835397937" LOG_EFFECT_SIZE="0.4424356531727402" MODIFIED="2012-12-26 18:24:18 +0000" MODIFIED_BY="jmw " NO="4" P_CHI2="0.31380657732535977" P_Z="0.3128167218193927" STUDIES="2" TAU2="0.0" TOTAL_1="56" TOTAL_2="56" WEIGHT="8.20803401469407" Z="1.0093293514035124">
<NAME>Tenecteplase</NAME>
<DICH_DATA CI_END="16.453394544425198" CI_START="0.06077773175012228" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2162555120018343" LOG_CI_START="-1.2162555120018343" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-12-26 18:24:18 +0000" MODIFIED_BY="[Empty name]" ORDER="98" O_E="0.0" SE="1.4288690166235205" STUDY_ID="STD-Parsons-2012" TOTAL_1="25" TOTAL_2="25" VAR="0.4897959183673469" WEIGHT="4.095624334530374"/>
<DICH_DATA CI_END="124.97877583346924" CI_START="0.4669760707982052" EFFECT_SIZE="7.639508994162071" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.096836266439783" LOG_CI_START="-0.3307053733665592" LOG_EFFECT_SIZE="0.883065446536612" MODIFIED="2011-02-25 11:55:03 +0000" MODIFIED_BY="[Empty name]" ORDER="78" O_E="1.0" SE="1.4259499757471625" STUDY_ID="STD-TNK_x002d_S2B" TOTAL_1="31" TOTAL_2="31" VAR="0.49180327868852464" WEIGHT="4.112409680163696"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.7997604026704415" CI_END="6.0351937643513365" CI_START="1.2159870093498357" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="2.7090066844436467" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="0.7806912180021666" LOG_CI_START="0.08492893530035209" LOG_EFFECT_SIZE="0.4328100766512593" METHOD="PETO" MODIFIED="2013-01-24 12:35:14 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.578590635966493" P_Q="0.3934722155149636" P_Z="0.01475023565980386" Q="2.9880453224550614" RANDOM="NO" SCALE="700.447734289358" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="645" TOTAL_2="629" WEIGHT="99.99999999999999" Z="2.4384540049752723">
<NAME>Fatal intracranial haemorrhage during follow-up</NAME>
<GROUP_LABEL_1>Higher dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Lower dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Higher dose better</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Lower dose better</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="16.86654245155502" CI_START="1.2784541892794037" DF="0" EFFECT_SIZE="4.643608710458863" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="1" I2="0.0" ID="CMP-001.05.01" LOG_CI_END="1.227026063732615" LOG_CI_START="0.10668517061060091" LOG_EFFECT_SIZE="0.6668556171716079" NO="1" P_CHI2="1.0" P_Z="0.019635468283122764" STUDIES="4" TAU2="0.0" TOTAL_1="217" TOTAL_2="212" WEIGHT="38.56749104125212" Z="2.3332416063156907">
<NAME>t-PA</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="13678" O_E="0.0" SE="0.0" STUDY_ID="STD-Abe-1990" TOTAL_1="71" TOTAL_2="76" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="16.866542451555027" CI_START="1.2784541892794035" EFFECT_SIZE="4.643608710458863" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="1" LOG_CI_END="1.2270260637326151" LOG_CI_START="0.10668517061060084" LOG_EFFECT_SIZE="0.6668556171716079" ORDER="13679" O_E="3.545454545454546" SE="0.6580937863967332" STUDY_ID="STD-Kikuchi-1994" TOTAL_1="72" TOTAL_2="60" VAR="2.309002586587597" WEIGHT="38.56749104125212"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="13680" O_E="0.0" SE="0.0" STUDY_ID="STD-Mori-1992" TOTAL_1="10" TOTAL_2="9" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="13681" O_E="0.0" SE="0.0" STUDY_ID="STD-Ohtomo-1988a" TOTAL_1="64" TOTAL_2="67" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.8117150802153809" CI_END="8.095961771145458" CI_START="0.6642834511901828" DF="2" EFFECT_SIZE="2.3190544249845217" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" I2="0.0" ID="CMP-001.05.02" LOG_CI_END="0.9082684487768781" LOG_CI_START="-0.17764656668581444" LOG_EFFECT_SIZE="0.36531094104553186" NO="2" P_CHI2="0.6664053492415232" P_Z="0.1872705218968678" STUDIES="3" TAU2="0.0" TOTAL_1="322" TOTAL_2="321" WEIGHT="41.0515998648498" Z="1.318696725641282">
<NAME>Urokinase</NAME>
<DICH_DATA CI_END="396.58199409708163" CI_START="0.1556051088111511" EFFECT_SIZE="7.855583004718345" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.5983329921642966" LOG_CI_START="-0.8079761483998705" LOG_EFFECT_SIZE="0.8951784218822131" ORDER="13682" O_E="0.5148514851485149" SE="2.0008828506695764" STUDY_ID="STD-Abe-1981" TOTAL_1="49" TOTAL_2="52" VAR="0.24977943338888342" WEIGHT="4.172089765283305"/>
<DICH_DATA CI_END="336.76441199253554" CI_START="0.1309452679897139" EFFECT_SIZE="6.640610376897667" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.5273261906308067" LOG_CI_START="-0.8829101911913092" LOG_EFFECT_SIZE="0.8222079997197486" ORDER="13683" O_E="0.4717948717948718" SE="2.003189731624653" STUDY_ID="STD-Atarashi-1985" TOTAL_1="103" TOTAL_2="92" VAR="0.24920447074293228" WEIGHT="4.162486109217442"/>
<DICH_DATA CI_END="7.0438321370750545" CI_START="0.42797242925415463" EFFECT_SIZE="1.7362505438336067" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.8478089976628311" LOG_CI_START="-0.3685842081094023" LOG_EFFECT_SIZE="0.23961239477671445" ORDER="13684" O_E="1.080691642651297" SE="0.7145153903140878" STUDY_ID="STD-Chen-2002" TOTAL_1="170" TOTAL_2="177" VAR="1.9587401456413707" WEIGHT="32.717023990349055"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="17.632429729936064" CI_START="0.3295723619982572" DF="0" EFFECT_SIZE="2.4106350851722285" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" I2="0.0" ID="CMP-001.05.03" LOG_CI_END="1.2463121617375768" LOG_CI_START="-0.48204921546679663" LOG_EFFECT_SIZE="0.38213147313539" MODIFIED="2011-11-24 14:31:10 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.38612003588775423" STUDIES="2" TAU2="0.0" TOTAL_1="81" TOTAL_2="71" WEIGHT="16.205135183413873" Z="0.866675146277626">
<NAME>Desmoteplase</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-03-14 05:13:59 +0000" MODIFIED_BY="[Empty name]" ORDER="84" O_E="0.0" SE="0.0" STUDY_ID="STD-DEDAS" TOTAL_1="15" TOTAL_2="14" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="17.632429729936064" CI_START="0.3295723619982572" EFFECT_SIZE="2.4106350851722285" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.2463121617375768" LOG_CI_START="-0.48204921546679663" LOG_EFFECT_SIZE="0.38213147313539" MODIFIED="2011-02-25 11:27:05 +0000" MODIFIED_BY="[Empty name]" ORDER="74" O_E="0.8536585365853657" SE="1.0152480284966479" STUDY_ID="STD-DIAS_x002d_2" TOTAL_1="66" TOTAL_2="57" VAR="0.9701875347422008" WEIGHT="16.205135183413873"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.820467167072357" CI_START="0.0026853936013588407" DF="0" EFFECT_SIZE="0.13533528323661262" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-001.05.04" LOG_CI_END="0.8338141226232084" LOG_CI_START="-2.570992050236216" LOG_EFFECT_SIZE="-0.8685889638065039" MODIFIED="2012-12-26 18:27:34 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.31731052126128756" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="25" WEIGHT="4.175773910484202" Z="1.0">
<NAME>Tenecteplase</NAME>
<DICH_DATA CI_END="6.8204671670723505" CI_START="0.0026853936013588433" EFFECT_SIZE="0.13533528323661262" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8338141226232081" LOG_CI_START="-2.5709920502362156" LOG_EFFECT_SIZE="-0.8685889638065039" MODIFIED="2012-12-26 18:27:34 +0000" MODIFIED_BY="[Empty name]" ORDER="99" O_E="-0.5" SE="2.0" STUDY_ID="STD-Parsons-2012" TOTAL_1="25" TOTAL_2="25" VAR="0.24999999999999997" WEIGHT="4.175773910484202"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.8996582896476353" CI_END="3.2101922792552897" CI_START="0.925126096926061" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.7233202411883932" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="16" I2="0.0" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="0.5065310458997799" LOG_CI_START="-0.03379906783737241" LOG_EFFECT_SIZE="0.23636598903120373" METHOD="PETO" MODIFIED="2013-01-24 12:36:55 +0000" MODIFIED_BY="jmw " NO="6" P_CHI2="0.5747553673149803" P_Q="0.6575296435193313" P_Z="0.08638883555835206" Q="0.8385309111556554" RANDOM="NO" SCALE="534.5865217503392" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="579" TOTAL_2="575" WEIGHT="100.0" Z="1.7147621940490605">
<NAME>Total major (including fatal) extracranial haemorrhage during follow-up</NAME>
<GROUP_LABEL_1>Higher dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Lower dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Higher dose better</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Lower dose better</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.06.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="3" TAU2="0.0" TOTAL_1="145" TOTAL_2="152" WEIGHT="0.0" Z="0.0">
<NAME>t-PA</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="13685" O_E="0.0" SE="0.0" STUDY_ID="STD-Abe-1990" TOTAL_1="71" TOTAL_2="76" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="13686" O_E="0.0" SE="0.0" STUDY_ID="STD-Mori-1992" TOTAL_1="10" TOTAL_2="9" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="13687" O_E="0.0" SE="0.0" STUDY_ID="STD-Ohtomo-1988a" TOTAL_1="64" TOTAL_2="67" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.936261978653464" CI_END="3.9069470951848566" CI_START="0.8794333365119045" DF="1" EFFECT_SIZE="1.8536179540277202" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="11" I2="48.354096138610814" ID="CMP-001.06.02" LOG_CI_END="0.5918375303891444" LOG_CI_START="-0.0557970756861127" LOG_EFFECT_SIZE="0.26802022735151587" NO="2" P_CHI2="0.16407524920749472" P_Z="0.10475156619614615" STUDIES="3" TAU2="0.0" TOTAL_1="322" TOTAL_2="321" WEIGHT="69.60785494766188" Z="1.6222418870438358">
<NAME>Urokinase</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="13688" O_E="0.0" SE="0.0" STUDY_ID="STD-Abe-1981" TOTAL_1="49" TOTAL_2="52" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="6.089795556478153" CI_START="0.0023679162130803644" EFFECT_SIZE="0.12008382752281582" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.7846027129639481" LOG_CI_START="-2.6256336688581676" LOG_EFFECT_SIZE="-0.9205154779471098" ORDER="13689" O_E="-0.5282051282051282" SE="2.003189731624653" STUDY_ID="STD-Atarashi-1985" TOTAL_1="103" TOTAL_2="92" VAR="0.24920447074293228" WEIGHT="2.51043729453358"/>
<DICH_DATA CI_END="4.388423437267139" CI_START="0.9608810085023426" EFFECT_SIZE="2.0534733351413568" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="10" LOG_CI_END="0.6423085258297966" LOG_CI_START="-0.01733039021953765" LOG_EFFECT_SIZE="0.31248906780512953" ORDER="13690" O_E="4.792507204610951" SE="0.38747516455267494" STUDY_ID="STD-Chen-2002" TOTAL_1="170" TOTAL_2="177" VAR="6.660583194360148" WEIGHT="67.0974176531283"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.12486539983851724" CI_END="4.091794311367664" CI_START="0.387681357323306" DF="1" EFFECT_SIZE="1.2594889330672177" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" I2="0.0" ID="CMP-001.06.03" LOG_CI_END="0.6119137942279995" LOG_CI_START="-0.4115250826819352" LOG_EFFECT_SIZE="0.10019435577303216" MODIFIED="2013-01-24 12:36:55 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.7238164000554153" P_Z="0.7011565164751119" STUDIES="2" TAU2="0.0" TOTAL_1="81" TOTAL_2="71" WEIGHT="27.873693751033784" Z="0.3837597597665182">
<NAME>Desmoteplase</NAME>
<DICH_DATA CI_END="7.3752652920224575" CI_START="0.11615862790996946" EFFECT_SIZE="0.9255812750879033" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8677776467233197" LOG_CI_START="-0.9349485265910228" LOG_EFFECT_SIZE="-0.03358543993385156" MODIFIED="2011-03-14 05:14:47 +0000" MODIFIED_BY="[Empty name]" ORDER="85" O_E="-0.06896551724137945" SE="1.0589302778433212" STUDY_ID="STD-DEDAS" TOTAL_1="15" TOTAL_2="14" VAR="0.89179548156956" WEIGHT="8.983773964224726"/>
<DICH_DATA CI_END="6.101302507129438" CI_START="0.3485087159931356" EFFECT_SIZE="1.4582033817836864" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.7854225581705727" LOG_CI_START="-0.45778635598666456" LOG_EFFECT_SIZE="0.1638181010919541" MODIFIED="2011-02-25 11:34:04 +0000" MODIFIED_BY="[Empty name]" ORDER="73" O_E="0.7073170731707314" SE="0.7302670701593365" STUDY_ID="STD-DIAS_x002d_2" TOTAL_1="66" TOTAL_2="57" VAR="1.8751523780731612" WEIGHT="18.88991978680906"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="372.3848896839504" CI_START="0.1466175227450357" DF="0" EFFECT_SIZE="7.38905609893065" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-001.06.04" LOG_CI_END="2.570992050236215" LOG_CI_START="-0.8338141226232083" LOG_EFFECT_SIZE="0.8685889638065036" MODIFIED="2011-11-24 14:31:10 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.31731052126128756" STUDIES="1" TAU2="0.0" TOTAL_1="31" TOTAL_2="31" WEIGHT="2.5184513013043315" Z="1.0">
<NAME>Tenecteplase</NAME>
<DICH_DATA CI_END="372.3848896839504" CI_START="0.1466175227450357" EFFECT_SIZE="7.38905609893065" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.570992050236215" LOG_CI_START="-0.8338141226232083" LOG_EFFECT_SIZE="0.8685889638065036" MODIFIED="2011-02-25 11:50:24 +0000" MODIFIED_BY="[Empty name]" ORDER="76" O_E="0.5" SE="2.0" STUDY_ID="STD-TNK_x002d_S2B" TOTAL_1="31" TOTAL_2="31" VAR="0.25" WEIGHT="2.5184513013043315"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2013-02-01 10:50:38 +0000" MODIFIED_BY="jmw " NO="2">
<NAME>Thrombolysis: one agent versus another</NAME>
<DICH_OUTCOME CHI2="2.6948814340437957" CI_END="1.0897204787962056" CI_START="0.3058678848254876" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.5773304927859024" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="32" I2="62.892616077010366" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.037315112542147824" LOG_CI_START="-0.5144661201884808" LOG_EFFECT_SIZE="-0.23857550382316656" METHOD="PETO" MODIFIED="2013-02-01 10:50:38 +0000" MODIFIED_BY="jmw " NO="1" P_CHI2="0.10067104321377351" P_Q="1.0" P_Z="0.0900996265568081" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="131" TOTAL_2="56" WEIGHT="100.0" Z="1.6948724144635032">
<NAME>Death or dependency at the end of follow-up</NAME>
<GROUP_LABEL_1>TNK</GROUP_LABEL_1>
<GROUP_LABEL_2>rt-PA</GROUP_LABEL_2>
<GRAPH_LABEL_1>TNK better</GRAPH_LABEL_1>
<GRAPH_LABEL_2>rt-PA better</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.6948814340437957" CI_END="1.0897204787962056" CI_START="0.3058678848254876" DF="1" EFFECT_SIZE="0.5773304927859024" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="32" I2="62.892616077010366" ID="CMP-002.01.01" LOG_CI_END="0.037315112542147824" LOG_CI_START="-0.5144661201884808" LOG_EFFECT_SIZE="-0.23857550382316656" MODIFIED="2013-02-01 10:50:38 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.10067104321377351" P_Z="0.0900996265568081" STUDIES="2" TAU2="0.0" TOTAL_1="131" TOTAL_2="56" WEIGHT="100.0" Z="1.6948724144635032">
<NAME>Tenecteplase vs t-PA</NAME>
<DICH_DATA CI_END="0.8228924787180508" CI_START="0.11454673248563878" EFFECT_SIZE="0.3070173360319589" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="14" LOG_CI_END="-0.08465690713282002" LOG_CI_START="-0.9410172948089027" LOG_EFFECT_SIZE="-0.5128371009708613" MODIFIED="2012-12-26 18:31:54 +0000" MODIFIED_BY="[Empty name]" ORDER="100" O_E="-4.666666666666668" SE="0.5030303307732165" STUDY_ID="STD-Parsons-2012" TOTAL_1="50" TOTAL_2="25" VAR="3.9519519519519517" WEIGHT="41.516497735604915"/>
<DICH_DATA CI_END="2.0743400027619296" CI_START="0.3938735742448134" EFFECT_SIZE="0.9038958519026611" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="18" LOG_CI_END="0.3168799426128944" LOG_CI_START="-0.40464315588707955" LOG_EFFECT_SIZE="-0.04388160663709253" MODIFIED="2011-04-18 11:21:50 +0100" MODIFIED_BY="[Empty name]" ORDER="97" O_E="-0.5625" SE="0.4238262396558242" STUDY_ID="STD-TNK_x002d_S2B" TOTAL_1="81" TOTAL_2="31" VAR="5.567039695945946" WEIGHT="58.483502264395085"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.0303814469175467" CI_END="2.770566679393119" CI_START="0.38156252986880296" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.0281752921362424" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="8" I2="1.4963418309239762" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.4425686068128375" LOG_CI_START="-0.41843428037834984" LOG_EFFECT_SIZE="0.012067163217243859" METHOD="PETO" MODIFIED="2013-02-01 10:50:38 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.36233344557298586" P_Q="0.7034835324522765" P_Z="0.9561872713303355" Q="0.14487347132588843" RANDOM="NO" SCALE="66.51" SORT_BY="YEAR" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="336" TOTAL_2="352" WEIGHT="100.00000000000001" Z="0.054938736334603326">
<NAME>Death from all causes within about the first two weeks</NAME>
<GROUP_LABEL_1>Newer drug</GROUP_LABEL_1>
<GROUP_LABEL_2>UK or rt-PA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Newer drug better</GRAPH_LABEL_1>
<GRAPH_LABEL_2>UK or rt-PA drug better</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.085947213163974" CI_START="0.23173945392551923" DF="0" EFFECT_SIZE="1.368880196236761" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" I2="0.0" ID="CMP-002.02.01" LOG_CI_END="0.907730901837325" LOG_CI_START="-0.6350000207483738" LOG_EFFECT_SIZE="0.13636544054447552" MODIFIED="2013-02-01 10:50:38 +0000" MODIFIED_BY="jmw " NO="1" P_CHI2="1.0" P_Z="0.7289735894618352" STUDIES="1" TAU2="0.0" TOTAL_1="89" TOTAL_2="81" WEIGHT="31.147905346568887" Z="0.3464912102172027">
<NAME>Tissue-cultured urokinase (newer drug) vs urokinase (control)</NAME>
<DICH_DATA CI_END="8.085947213163974" CI_START="0.2317394539255192" EFFECT_SIZE="1.368880196236761" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.907730901837325" LOG_CI_START="-0.6350000207483738" LOG_EFFECT_SIZE="0.13636544054447552" ORDER="13691" O_E="0.38235294117647056" SE="0.9062077805680685" STUDY_ID="STD-Ohtomo-1985" TOTAL_1="89" TOTAL_2="81" VAR="1.2177115538174894" WEIGHT="31.147905346568887"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.8855079755916584" CI_END="2.9830135592464067" CI_START="0.2735374803308427" DF="1" EFFECT_SIZE="0.9033083708175194" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" I2="46.963894454691584" ID="CMP-002.02.02" LOG_CI_END="0.47465522744604177" LOG_CI_START="-0.5629831578657034" LOG_EFFECT_SIZE="-0.044163965209830784" MODIFIED="2012-12-28 18:34:28 +0000" MODIFIED_BY="jmw " NO="2" P_CHI2="0.16970966421495126" P_Z="0.8674959639074615" STUDIES="2" TAU2="0.0" TOTAL_1="247" TOTAL_2="271" WEIGHT="68.85209465343112" Z="0.16683997518025995">
<NAME>t-PA (newer drug) vs urokinase (control)</NAME>
<DICH_DATA CI_END="5.037815156703307" CI_START="0.3580683379707161" EFFECT_SIZE="1.3430867805783944" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.7022422286848274" LOG_CI_START="-0.4460340795815994" LOG_EFFECT_SIZE="0.12810407455161404" ORDER="13693" O_E="0.6483516483516487" SE="0.6745031875350964" STUDY_ID="STD-Ohtomo-1988b" TOTAL_1="176" TOTAL_2="188" VAR="2.1980217584613193" WEIGHT="56.22330959053496"/>
<DICH_DATA CI_END="2.513719075270628" CI_START="0.009494712858238908" EFFECT_SIZE="0.15448961397444308" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.4003167407815528" LOG_CI_START="-2.0225181647835213" LOG_EFFECT_SIZE="-0.8111007120009843" ORDER="13692" O_E="-0.922077922077922" SE="1.4231852167551315" STUDY_ID="STD-Abe-1990" TOTAL_1="71" TOTAL_2="83" VAR="0.4937159436777466" WEIGHT="12.628785062896164"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.047964545497234" CI_END="1.3144970690089532" CI_START="0.3767902728551702" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.703768221291076" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="22" I2="1.1849052766676995" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="0.11875962207824517" LOG_CI_START="-0.42390031739681555" LOG_EFFECT_SIZE="-0.15257034765928523" METHOD="PETO" MODIFIED="2013-02-01 10:50:38 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.399553708340742" P_Q="0.41815611479792325" P_Z="0.27041881461665995" Q="1.7438026284987314" RANDOM="NO" SCALE="66.51" SORT_BY="YEAR" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="467" TOTAL_2="408" WEIGHT="99.99999999999997" Z="1.1020986248228364">
<NAME>Total deaths from all causes at end of follow-up</NAME>
<GROUP_LABEL_1>Newer drug</GROUP_LABEL_1>
<GROUP_LABEL_2>UK or rt-PA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Newer drug better</GRAPH_LABEL_1>
<GRAPH_LABEL_2>UK or rt-PA better</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="9.185550444282299" CI_START="0.3552252758476927" DF="0" EFFECT_SIZE="1.8063608970477287" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" I2="0.0" ID="CMP-002.03.01" LOG_CI_END="0.9631051865265925" LOG_CI_START="-0.44949613982296266" LOG_EFFECT_SIZE="0.25680452335181486" MODIFIED="2013-02-01 10:50:38 +0000" MODIFIED_BY="jmw " NO="1" P_CHI2="1.0" P_Z="0.4760777491801037" STUDIES="1" TAU2="0.0" TOTAL_1="89" TOTAL_2="81" WEIGHT="14.757619367526779" Z="0.7126251511277168">
<NAME>Tissue-cultured urokinase (newer drug) vs urokinase (control)</NAME>
<DICH_DATA CI_END="9.185550444282299" CI_START="0.3552252758476927" EFFECT_SIZE="1.8063608970477287" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="0.9631051865265925" LOG_CI_START="-0.44949613982296266" LOG_EFFECT_SIZE="0.25680452335181486" ORDER="13694" O_E="0.8588235294117648" SE="0.8297690115870675" STUDY_ID="STD-Ohtomo-1985" TOTAL_1="89" TOTAL_2="81" VAR="1.452397780553224" WEIGHT="14.757619367526779"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.227911271200886" CI_END="2.0169372132103818" CI_START="0.2585773887039673" DF="1" EFFECT_SIZE="0.7221733571461892" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="9" I2="55.114909066330036" ID="CMP-002.03.02" LOG_CI_END="0.3046923789362727" LOG_CI_START="-0.5874094546699958" LOG_EFFECT_SIZE="-0.14135853786686156" MODIFIED="2012-12-28 18:35:37 +0000" MODIFIED_BY="jmw " NO="2" P_CHI2="0.13553705997754784" P_Z="0.5345110906489456" STUDIES="2" TAU2="0.0" TOTAL_1="247" TOTAL_2="271" WEIGHT="37.002124500730794" Z="0.6211345671296316">
<NAME>t-PA (newer drug) vs urokinase (control)</NAME>
<DICH_DATA CI_END="3.379825871602161" CI_START="0.3390230354245832" EFFECT_SIZE="1.070438613932206" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.528894326031993" LOG_CI_START="-0.4697707920095922" LOG_EFFECT_SIZE="0.029561767011200415" ORDER="13696" O_E="0.197802197802198" SE="0.5866208338096888" STUDY_ID="STD-Ohtomo-1988b" TOTAL_1="176" TOTAL_2="188" VAR="2.905929235599565" WEIGHT="29.526757849775507"/>
<DICH_DATA CI_END="1.4993940722325276" CI_START="0.01552886557986381" EFFECT_SIZE="0.15259059276031245" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.1759157895554504" LOG_CI_START="-1.8088602693455116" LOG_EFFECT_SIZE="-0.8164722398950307" ORDER="13695" O_E="-1.3831168831168832" SE="1.165867281798369" STUDY_ID="STD-Abe-1990" TOTAL_1="71" TOTAL_2="83" VAR="0.7357017187040106" WEIGHT="7.475366650955286"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.07625064579761709" CI_END="1.2713020901435836" CI_START="0.21034855000164765" DF="1" EFFECT_SIZE="0.5171233424201298" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="11" I2="0.0" ID="CMP-002.03.03" LOG_CI_END="0.10424876101316002" LOG_CI_START="-0.6770604773643779" LOG_EFFECT_SIZE="-0.28640585817560893" MODIFIED="2012-12-28 18:35:52 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.7824442372674045" P_Z="0.15073655702101488" STUDIES="2" TAU2="0.0" TOTAL_1="131" TOTAL_2="56" WEIGHT="48.240256131742406" Z="1.4369346717342448">
<NAME>Tenecteplase (newer drug) vs rt-PA (control)</NAME>
<DICH_DATA CI_END="1.395573874821598" CI_START="0.1622510632957888" EFFECT_SIZE="0.4758501288195983" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="8" LOG_CI_END="0.14475283084843138" LOG_CI_START="-0.7898124484136912" LOG_EFFECT_SIZE="-0.32252980878263" MODIFIED="2011-04-17 22:49:04 +0100" MODIFIED_BY="[Empty name]" ORDER="97" O_E="-2.4642857142857135" SE="0.5489682712113131" STUDY_ID="STD-TNK_x002d_S2B" TOTAL_1="81" TOTAL_2="31" VAR="3.3182225592939876" WEIGHT="33.71601510444936"/>
<DICH_DATA CI_END="3.231494574903519" CI_START="0.12175823798999566" EFFECT_SIZE="0.6272647650828815" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.5094034311572083" LOG_CI_START="-0.9145016453694854" LOG_EFFECT_SIZE="-0.20254910710613855" MODIFIED="2012-12-26 18:37:52 +0000" MODIFIED_BY="[Empty name]" ORDER="101" O_E="-0.666666666666667" SE="0.8364088903955846" STUDY_ID="STD-Parsons-2012" TOTAL_1="50" TOTAL_2="25" VAR="1.4294294294294292" WEIGHT="14.524241027293046"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.670018536552494" CI_END="1.1352136012758896" CI_START="0.16593948968038216" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.43402392292816067" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="11" I2="14.347235055026475" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="0.0550775858705585" LOG_CI_START="-0.7800502498439046" LOG_EFFECT_SIZE="-0.362486331986673" METHOD="PETO" MODIFIED="2013-02-01 10:50:38 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.3228610521135631" P_Q="0.4885751072464366" P_Z="0.08886030422739082" Q="1.4325244315321726" RANDOM="NO" SCALE="1000.0" SORT_BY="YEAR" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="467" TOTAL_2="408" WEIGHT="300.0" Z="1.7014404865911346">
<NAME>'Significant' intracranial haemorrhage during follow-up</NAME>
<GROUP_LABEL_1>Newer drug</GROUP_LABEL_1>
<GROUP_LABEL_2>UK or rt-PA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Newer drug better</GRAPH_LABEL_1>
<GRAPH_LABEL_2>UK or rt-PA better</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.205960268899448" CI_START="0.0024222921246076874" DF="0" EFFECT_SIZE="0.12260770238848512" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-002.04.01" LOG_CI_END="0.7928089908657808" LOG_CI_START="-2.615773482805356" LOG_EFFECT_SIZE="-0.9114822459697876" MODIFIED="2013-02-01 10:50:38 +0000" MODIFIED_BY="jmw " NO="1" P_CHI2="1.0" P_Z="0.29453721527799714" STUDIES="1" TAU2="0.0" TOTAL_1="89" TOTAL_2="81" WEIGHT="100.0" Z="1.048220125784067">
<NAME>Tissue-cultured urokinase (newer drug) vs urokinase (control)</NAME>
<DICH_DATA CI_END="6.205960268899448" CI_START="0.0024222921246076874" EFFECT_SIZE="0.12260770238848512" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.7928089908657808" LOG_CI_START="-2.615773482805356" LOG_EFFECT_SIZE="-0.9114822459697876" ORDER="13697" O_E="-0.5235294117647059" SE="2.0022182177897907" STUDY_ID="STD-Ohtomo-1985" TOTAL_1="89" TOTAL_2="81" VAR="0.24944636678200696" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.3712841867628005" CI_END="1.184544496660042" CI_START="0.05901098344311788" DF="1" EFFECT_SIZE="0.2643882290875336" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" I2="27.07565582297667" ID="CMP-002.04.02" LOG_CI_END="0.07355137936098369" LOG_CI_START="-1.2290671475985808" LOG_EFFECT_SIZE="-0.5777578841187985" MODIFIED="2012-12-28 18:36:31 +0000" MODIFIED_BY="jmw " NO="2" P_CHI2="0.24159154913159375" P_Z="0.0821001849832767" STUDIES="2" TAU2="0.0" TOTAL_1="247" TOTAL_2="271" WEIGHT="100.0" Z="1.7386281881004793">
<NAME>t-PA (newer drug) vs urokinase (control)</NAME>
<DICH_DATA CI_END="17.172875891487337" CI_START="0.06647330252885526" EFFECT_SIZE="1.0684277113709295" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2348430312829797" LOG_CI_START="-1.1773527440567777" LOG_EFFECT_SIZE="0.0287451436131009" ORDER="13699" O_E="0.03296703296703296" SE="1.4169357389962363" STUDY_ID="STD-Ohtomo-1988b" TOTAL_1="176" TOTAL_2="188" VAR="0.4980806739048498" WEIGHT="29.16146892655939"/>
<DICH_DATA CI_END="0.883915459777078" CI_START="0.025045290448479043" EFFECT_SIZE="0.14878816963057853" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" LOG_CI_END="-0.053589270177016285" LOG_CI_START="-1.6012739274625762" LOG_EFFECT_SIZE="-0.8274315988197962" ORDER="13698" O_E="-2.3051948051948052" SE="0.9091176288521491" STUDY_ID="STD-Abe-1990" TOTAL_1="71" TOTAL_2="83" VAR="1.2099288751313197" WEIGHT="70.8385310734406"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.8662099182575207" CI_END="2.7621077543871264" CI_START="0.19631754733193452" DF="1" EFFECT_SIZE="0.7363764117676489" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" I2="46.41546000710898" ID="CMP-002.04.03" LOG_CI_END="0.44124061711839135" LOG_CI_START="-0.7070408803855133" LOG_EFFECT_SIZE="-0.13290013163356101" MODIFIED="2012-12-28 18:36:45 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.17190999140678287" P_Z="0.650055032063316" STUDIES="2" TAU2="0.0" TOTAL_1="131" TOTAL_2="56" WEIGHT="99.99999999999999" Z="0.4536857418823405">
<NAME>Tenecteplase (newer drug) vs rt-PA (control)</NAME>
<DICH_DATA CI_END="11.091346534532676" CI_START="0.28534905273810657" EFFECT_SIZE="1.779018051403352" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.0449842744645526" LOG_CI_START="-0.5446235648227367" LOG_EFFECT_SIZE="0.25018035482090795" MODIFIED="2011-04-17 22:52:35 +0100" MODIFIED_BY="[Empty name]" ORDER="98" O_E="0.6607142857142856" SE="0.9337435134830626" STUDY_ID="STD-TNK_x002d_S2B" TOTAL_1="81" TOTAL_2="31" VAR="1.1469508411472698" WEIGHT="52.18152200952622"/>
<DICH_DATA CI_END="1.902561171030011" CI_START="0.0415713595842772" EFFECT_SIZE="0.28123309650887834" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.27933862907662016" LOG_CI_START="-1.3812057717340134" LOG_EFFECT_SIZE="-0.5509335713286967" MODIFIED="2012-12-26 18:38:50 +0000" MODIFIED_BY="[Empty name]" ORDER="102" O_E="-1.3333333333333335" SE="0.9754120008635179" STUDY_ID="STD-Parsons-2012" TOTAL_1="50" TOTAL_2="25" VAR="1.0510510510510511" WEIGHT="47.81847799047377"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.2728624896700185" CI_END="13.857163262318611" CI_START="0.12288356789964978" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.304920557981083" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="21.436918118370848" I2_Q="21.436918118370862" ID="CMP-002.05" LOG_CI_END="1.1416743337668431" LOG_CI_START="-0.910506187476669" LOG_EFFECT_SIZE="0.11558407314508701" METHOD="PETO" MODIFIED="2013-02-01 10:50:38 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.25923046695771" P_Q="0.2592304669577101" P_Z="0.8252634239074286" Q="1.2728624896700187" RANDOM="NO" SCALE="840.43" SORT_BY="YEAR" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="386" TOTAL_2="377" WEIGHT="100.0" Z="0.2207804023142587">
<NAME>Fatal intracranial haemorrhage during follow-up</NAME>
<GROUP_LABEL_1>Newer drug</GROUP_LABEL_1>
<GROUP_LABEL_2>UK or rt-PA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Newer drug better</GRAPH_LABEL_1>
<GRAPH_LABEL_2>UK or rt-PA better</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-002.05.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-02-01 10:50:38 +0000" MODIFIED_BY="jmw " NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="89" TOTAL_2="81" WEIGHT="0.0" Z="0.0">
<NAME>Tissue-cultured urokinase (newer drug) vs urokinase (control)</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="13700" O_E="0.0" SE="0.0" STUDY_ID="STD-Ohtomo-1985" TOTAL_1="89" TOTAL_2="81" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="399.5111455335439" CI_START="0.15662857713737657" DF="0" EFFECT_SIZE="7.910427439490382" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-002.05.02" LOG_CI_END="2.601528899735608" LOG_CI_START="-0.8051289973176118" LOG_EFFECT_SIZE="0.898199951208998" MODIFIED="2012-12-28 18:37:18 +0000" MODIFIED_BY="jmw " NO="2" P_CHI2="1.0" P_Z="0.30135650605182684" STUDIES="2" TAU2="0.0" TOTAL_1="247" TOTAL_2="271" WEIGHT="36.288922731560284" Z="1.0335288182638247">
<NAME>t-PA (newer drug) vs urokinase (control)</NAME>
<DICH_DATA CI_END="399.5111455335439" CI_START="0.15662857713737657" EFFECT_SIZE="7.910427439490382" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.601528899735608" LOG_CI_START="-0.8051289973176118" LOG_EFFECT_SIZE="0.898199951208998" ORDER="13702" O_E="0.5164835164835164" SE="2.0010877119576183" STUDY_ID="STD-Ohtomo-1988b" TOTAL_1="176" TOTAL_2="188" VAR="0.24972829368433766" WEIGHT="36.288922731560284"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="13701" O_E="0.0" SE="0.0" STUDY_ID="STD-Abe-1990" TOTAL_1="71" TOTAL_2="83" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="9.022668454061337" CI_START="0.024226987699126654" DF="0" EFFECT_SIZE="0.46753831677183644" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-002.05.03" LOG_CI_END="0.9553349991257093" LOG_CI_START="-1.615700581197777" LOG_EFFECT_SIZE="-0.3301827910360339" MODIFIED="2012-12-28 18:37:33 +0000" MODIFIED_BY="jmw " NO="3" P_CHI2="1.0" P_Z="0.6146739291966534" STUDIES="1" TAU2="0.0" TOTAL_1="50" TOTAL_2="25" WEIGHT="63.711077268439716" Z="0.5034130089044644">
<NAME>Tenecteplase (newer drug) vs rt-PA (control)</NAME>
<DICH_DATA CI_END="9.022668454061334" CI_START="0.024226987699126665" EFFECT_SIZE="0.46753831677183644" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="0.9553349991257091" LOG_CI_START="-1.6157005811977767" LOG_EFFECT_SIZE="-0.3301827910360339" MODIFIED="2012-12-26 18:39:55 +0000" MODIFIED_BY="[Empty name]" ORDER="103" O_E="-0.33333333333333326" SE="1.5102390267133938" STUDY_ID="STD-Parsons-2012" TOTAL_1="50" TOTAL_2="25" VAR="0.43843843843843844" WEIGHT="63.711077268439716"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.24748893566377617" CI_END="16.266987097263137" CI_START="0.1492817970003656" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.5583212331419993" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-002.06" LOG_CI_END="1.2113071221930434" LOG_CI_START="-0.8259931456859629" LOG_EFFECT_SIZE="0.19265698825354022" METHOD="PETO" MODIFIED="2013-02-01 10:50:38 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.6188488032212787" P_Q="0.6188488032212787" P_Z="0.7108703851858242" Q="0.24748893566377617" RANDOM="NO" SCALE="840.43" SORT_BY="YEAR" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="417" TOTAL_2="383" WEIGHT="100.0" Z="0.37068738889433117">
<NAME>Total major (including fatal) extracranial haemorrhage during follow-up</NAME>
<GROUP_LABEL_1>Newer drug</GROUP_LABEL_1>
<GROUP_LABEL_2>UK or rt-PA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Newer drug better</GRAPH_LABEL_1>
<GRAPH_LABEL_2>UK or rt-PA better</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-002.06.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-02-01 10:50:38 +0000" MODIFIED_BY="jmw " NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="89" TOTAL_2="81" WEIGHT="0.0" Z="0.0">
<NAME>Tissue-cultured urokinase (newer drug) vs urokinase (control)</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="13703" O_E="0.0" SE="0.0" STUDY_ID="STD-Ohtomo-1985" TOTAL_1="89" TOTAL_2="81" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="17.17287589148733" CI_START="0.06647330252885529" DF="0" EFFECT_SIZE="1.0684277113709295" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-002.06.02" LOG_CI_END="1.2348430312829795" LOG_CI_START="-1.1773527440567775" LOG_EFFECT_SIZE="0.0287451436131009" MODIFIED="2012-12-28 18:38:06 +0000" MODIFIED_BY="jmw " NO="2" P_CHI2="1.0" P_Z="0.9627426328915036" STUDIES="2" TAU2="0.0" TOTAL_1="247" TOTAL_2="271" WEIGHT="71.33209504263579" Z="0.04671216721965613">
<NAME>t-PA (newer drug) vs urokinase (control)</NAME>
<DICH_DATA CI_END="17.172875891487337" CI_START="0.06647330252885526" EFFECT_SIZE="1.0684277113709295" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2348430312829797" LOG_CI_START="-1.1773527440567777" LOG_EFFECT_SIZE="0.0287451436131009" ORDER="13705" O_E="0.03296703296703296" SE="1.4169357389962363" STUDY_ID="STD-Ohtomo-1988b" TOTAL_1="176" TOTAL_2="188" VAR="0.4980806739048498" WEIGHT="71.33209504263579"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="13704" O_E="0.0" SE="0.0" STUDY_ID="STD-Abe-1990" TOTAL_1="71" TOTAL_2="83" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="318.4318338103987" CI_START="0.04988792294003154" DF="0" EFFECT_SIZE="3.9857123311631644" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-002.06.03" LOG_CI_END="2.5030164779007826" LOG_CI_START="-1.302004577328827" LOG_EFFECT_SIZE="0.6005059502859779" MODIFIED="2012-12-28 18:38:24 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.5361532286714202" STUDIES="1" TAU2="0.0" TOTAL_1="81" TOTAL_2="31" WEIGHT="28.66790495736421" Z="0.6186404847588913">
<NAME>Tenecteplase (newer drug) vs rt-PA (control)</NAME>
<DICH_DATA CI_END="318.4318338103987" CI_START="0.04988792294003154" EFFECT_SIZE="3.9857123311631644" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.5030164779007826" LOG_CI_START="-1.302004577328827" LOG_EFFECT_SIZE="0.6005059502859779" MODIFIED="2011-04-17 22:53:56 +0100" MODIFIED_BY="[Empty name]" ORDER="99" O_E="0.2767857142857143" SE="2.2350882029998655" STUDY_ID="STD-TNK_x002d_S2B" TOTAL_1="81" TOTAL_2="31" VAR="0.20017538265306123" WEIGHT="28.66790495736421"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2013-03-20 01:04:43 +0000" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Thrombolysis: different routes of administration of the same agent</NAME>
<DICH_OUTCOME CHI2="6.096210971312262" CI_END="1.5474727898348326" CI_START="0.7525266790190317" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.0791267578031427" ESTIMABLE="YES" EVENTS_1="136" EVENTS_2="129" I2="50.78910467309132" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="0.1896230212924929" LOG_CI_START="-0.12347809859742931" LOG_EFFECT_SIZE="0.0330724613475318" METHOD="PETO" MODIFIED="2013-03-20 01:04:43 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.10702209562241094" P_Q="0.392962360259941" P_Z="0.6788324674216493" Q="0.7297558656410312" RANDOM="NO" SCALE="55.13" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="241" TOTAL_2="237" WEIGHT="100.00000000000001" Z="0.414056858972875">
<NAME>Death or dependency at end of follow-up</NAME>
<GROUP_LABEL_1>Favours intravenous</GROUP_LABEL_1>
<GROUP_LABEL_2>Favours intra-arterial</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours intravenous</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours intra-arterial</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="5.36645510567123" CI_END="1.5053495876751701" CI_START="0.7169962715011562" DF="2" EFFECT_SIZE="1.0389081006849932" ESTIMABLE="YES" EVENTS_1="126" EVENTS_2="122" I2="62.731450079841075" ID="CMP-003.01.01" LOG_CI_END="0.177637367948362" LOG_CI_START="-0.1444831027292485" LOG_EFFECT_SIZE="0.016577132609556757" MODIFIED="2013-03-20 01:04:43 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.06834238825383365" P_Z="0.8401282858557092" STUDIES="3" TAU2="0.0" TOTAL_1="227" TOTAL_2="224" WEIGHT="94.47841351316147" Z="0.20172938909053956">
<NAME>rt-PA</NAME>
<DICH_DATA CI_END="8.149537149763201" CI_START="0.5813480903980839" EFFECT_SIZE="2.1766299317162483" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="6" LOG_CI_END="0.9111329438305382" LOG_CI_START="-0.23556374975881306" LOG_EFFECT_SIZE="0.33778459703586255" ORDER="13706" O_E="1.7142857142857144" SE="0.6735753140545634" STUDY_ID="STD-EMS-Bridging-Trial" TOTAL_1="17" TOTAL_2="18" VAR="2.204081632653061" WEIGHT="7.4554201214503895"/>
<DICH_DATA CI_END="7.955029457507525" CI_START="0.9328041304785855" EFFECT_SIZE="2.7240565956018314" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="11" LOG_CI_END="0.9006417921798702" LOG_CI_START="-0.030209539514643374" LOG_EFFECT_SIZE="0.4352161263326134" MODIFIED="2011-09-17 07:34:07 +0100" MODIFIED_BY="[Empty name]" ORDER="91" O_E="3.351851851851851" SE="0.5467866800257626" STUDY_ID="STD-SYNTHESIS" TOTAL_1="29" TOTAL_2="25" VAR="3.3447537334679205" WEIGHT="11.313802500035736"/>
<DICH_DATA CI_END="1.2656288060151812" CI_START="0.5526696570715398" EFFECT_SIZE="0.836346003876549" ESTIMABLE="YES" EVENTS_1="97" EVENTS_2="105" LOG_CI_END="0.10230635091266353" LOG_CI_START="-0.2575343786028356" LOG_EFFECT_SIZE="-0.07761401384508608" MODIFIED="2013-03-20 01:04:43 +0000" MODIFIED_BY="[Empty name]" ORDER="103" O_E="-4.0" SE="0.21137222575774278" STUDY_ID="STD-SYNTHESIS-EXPANSION" TOTAL_1="181" TOTAL_2="181" VAR="22.382271468144044" WEIGHT="75.70919089167535"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="9.584012939929341" CI_START="0.44575065571801875" DF="0" EFFECT_SIZE="2.066901074648586" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="7" I2="0.0" ID="CMP-003.01.02" LOG_CI_END="0.9815473914116922" LOG_CI_START="-0.3509080092866341" LOG_EFFECT_SIZE="0.31531969106252905" MODIFIED="2011-11-24 14:31:10 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.3535976437055406" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="13" WEIGHT="5.521586486838544" Z="0.9276336570439175">
<NAME>Urokinase</NAME>
<DICH_DATA CI_END="9.584012939929341" CI_START="0.44575065571801875" EFFECT_SIZE="2.066901074648586" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="7" LOG_CI_END="0.9815473914116922" LOG_CI_START="-0.3509080092866341" LOG_EFFECT_SIZE="0.31531969106252905" MODIFIED="2011-02-24 15:33:03 +0000" MODIFIED_BY="[Empty name]" ORDER="66" O_E="1.1851851851851851" SE="0.7826908981308054" STUDY_ID="STD-Ducrocq-2005" TOTAL_1="14" TOTAL_2="13" VAR="1.6323731138545952" WEIGHT="5.521586486838544"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.210157510635768" CI_END="1.7925896593145725" CI_START="0.5119453320012859" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.9579707241246316" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="22" I2="28.743758578595894" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="0.2534808868345469" LOG_CI_START="-0.2907764126135764" LOG_EFFECT_SIZE="-0.01864776288951469" METHOD="PETO" MODIFIED="2013-03-19 00:56:06 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.23964703390382136" P_Q="0.6909679766989052" P_Z="0.8931593501271183" Q="0.15803968582089592" RANDOM="NO" SCALE="260.07" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="245" TOTAL_2="240" WEIGHT="99.99999999999999" Z="0.13430759198912726">
<NAME>Death from all causes within about the first two weeks</NAME>
<GROUP_LABEL_1>Favours intravenous</GROUP_LABEL_1>
<GROUP_LABEL_2>Favours intra-arterial</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours intravenous</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours intra-arterial</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.052117824814872" CI_END="1.7878219534816953" CI_START="0.4637908270196544" DF="2" EFFECT_SIZE="0.9105906996939785" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="19" I2="50.64309364964299" ID="CMP-003.02.01" LOG_CI_END="0.2523242658745433" LOG_CI_START="-0.33367784520674754" LOG_EFFECT_SIZE="-0.040676789666102164" MODIFIED="2013-03-19 00:56:06 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.1318543867912395" P_Z="0.7855465586129748" STUDIES="4" TAU2="0.0" TOTAL_1="231" TOTAL_2="227" WEIGHT="86.26014099211692" Z="0.2720981417802835">
<NAME>rt-PA</NAME>
<DICH_DATA CI_END="91.95290183046694" CI_START="0.8639187885415963" EFFECT_SIZE="8.912902981198737" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.963565439164892" LOG_CI_START="-0.06352708083816523" LOG_EFFECT_SIZE="0.9500191791633634" ORDER="13707" O_E="1.542857142857143" SE="1.1907241805196005" STUDY_ID="STD-EMS-Bridging-Trial" TOTAL_1="17" TOTAL_2="18" VAR="0.7053061224489796" WEIGHT="7.208773540415826"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-02-24 14:43:31 +0000" MODIFIED_BY="[Empty name]" ORDER="62" O_E="0.0" SE="0.0" STUDY_ID="STD-Sen-2008" TOTAL_1="4" TOTAL_2="3" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.6733325940975763" CI_START="0.15558435228768847" EFFECT_SIZE="0.6449253601016457" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.42705299347246073" LOG_CI_START="-0.8080340838041407" LOG_EFFECT_SIZE="-0.19049054516583996" MODIFIED="2011-03-14 08:16:04 +0000" MODIFIED_BY="[Empty name]" ORDER="92" O_E="-0.833333333333333" SE="0.7254962629719099" STUDY_ID="STD-SYNTHESIS" TOTAL_1="29" TOTAL_2="25" VAR="1.8998951781970657" WEIGHT="19.418396713465864"/>
<DICH_DATA CI_END="1.740774147415939" CI_START="0.3435186403506078" EFFECT_SIZE="0.7732970763411768" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="14" LOG_CI_END="0.24074242827200815" LOG_CI_START="-0.4640496918452885" LOG_EFFECT_SIZE="-0.11165363178664017" MODIFIED="2013-03-19 00:56:06 +0000" MODIFIED_BY="[Empty name]" ORDER="107" O_E="-1.5" SE="0.4139983801341609" STUDY_ID="STD-SYNTHESIS-EXPANSION" TOTAL_1="181" TOTAL_2="181" VAR="5.834487534626039" WEIGHT="59.63297073823523"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.14166921281937" CI_START="0.24294356044220233" DF="0" EFFECT_SIZE="1.3172025455725471" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" I2="0.0" ID="CMP-003.02.02" LOG_CI_END="0.8537997307105613" LOG_CI_START="-0.6144946080291777" LOG_EFFECT_SIZE="0.1196525613406918" MODIFIED="2011-11-24 14:31:10 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.7493941854601791" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="13" WEIGHT="13.739859007883068" Z="0.3194382824999698">
<NAME>Urokinase</NAME>
<DICH_DATA CI_END="7.14166921281937" CI_START="0.24294356044220233" EFFECT_SIZE="1.3172025455725471" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.8537997307105613" LOG_CI_START="-0.6144946080291777" LOG_EFFECT_SIZE="0.1196525613406918" MODIFIED="2011-02-24 15:36:03 +0000" MODIFIED_BY="[Empty name]" ORDER="67" O_E="0.37037037037037024" SE="0.862483362749919" STUDY_ID="STD-Ducrocq-2005" TOTAL_1="14" TOTAL_2="13" VAR="1.344307270233196" WEIGHT="13.739859007883068"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.821475386770153" CI_END="1.385072902161082" CI_START="0.4706204990513511" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.8073683796369235" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="33" I2="58.51892129351353" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="0.14147263273117977" LOG_CI_START="-0.3273291599670626" LOG_EFFECT_SIZE="-0.09292826361794142" METHOD="PETO" MODIFIED="2013-03-19 00:51:40 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.08974910640035494" P_Q="1.0" P_Z="0.43714228233065056" Q="0.0" RANDOM="NO" SCALE="238.02" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="231" TOTAL_2="227" WEIGHT="100.00000000000001" Z="0.7770279579721915">
<NAME>Total deaths from all causes at end of follow-up</NAME>
<GROUP_LABEL_1>Favours intravenous</GROUP_LABEL_1>
<GROUP_LABEL_2>Favours intraarterial</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours intravenous</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours intra-arterial</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.821475386770153" CI_END="1.385072902161082" CI_START="0.4706204990513511" DF="2" EFFECT_SIZE="0.8073683796369235" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="33" I2="58.51892129351353" ID="CMP-003.03.01" LOG_CI_END="0.14147263273117977" LOG_CI_START="-0.3273291599670626" LOG_EFFECT_SIZE="-0.09292826361794142" MODIFIED="2013-03-19 00:51:40 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.08974910640035494" P_Z="0.43714228233065056" STUDIES="4" TAU2="0.0" TOTAL_1="231" TOTAL_2="227" WEIGHT="100.00000000000001" Z="0.7770279579721915">
<NAME>rt-PA</NAME>
<DICH_DATA CI_END="28.9343945687111" CI_START="0.9030834333618147" EFFECT_SIZE="5.111768029689636" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.4614143994965663" LOG_CI_START="-0.04427212457599352" LOG_EFFECT_SIZE="0.7085711374602864" ORDER="13708" O_E="2.085714285714286" SE="0.8844477175087206" STUDY_ID="STD-EMS-Bridging-Trial" TOTAL_1="17" TOTAL_2="18" VAR="1.2783673469387755" WEIGHT="9.694142526227107"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-02-24 14:44:14 +0000" MODIFIED_BY="[Empty name]" ORDER="63" O_E="0.0" SE="0.0" STUDY_ID="STD-Sen-2008" TOTAL_1="4" TOTAL_2="3" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.476445187742287" CI_START="0.1782234346230367" EFFECT_SIZE="0.6643497324565739" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.39382871999281244" LOG_CI_START="-0.749035191105436" LOG_EFFECT_SIZE="-0.17760323555631177" MODIFIED="2011-03-14 08:17:31 +0000" MODIFIED_BY="[Empty name]" ORDER="93" O_E="-0.9074074074074074" SE="0.6713239186467103" STUDY_ID="STD-SYNTHESIS" TOTAL_1="29" TOTAL_2="25" VAR="2.2188899241659557" WEIGHT="16.826333390306957"/>
<DICH_DATA CI_END="1.2421353144543432" CI_START="0.3525909896584244" EFFECT_SIZE="0.6617897852136545" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="26" LOG_CI_END="0.09416890914153915" LOG_CI_START="-0.45272879014113643" LOG_EFFECT_SIZE="-0.1792799404997987" MODIFIED="2013-03-19 00:51:40 +0000" MODIFIED_BY="[Empty name]" ORDER="105" O_E="-4.0" SE="0.3212504157459161" STUDY_ID="STD-SYNTHESIS-EXPANSION" TOTAL_1="181" TOTAL_2="181" VAR="9.689750692520775" WEIGHT="73.47952408346595"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-003.03.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-11-24 14:31:10 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Urokinase</NAME>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.7881216488581773" CI_END="2.24686827775981" CI_START="0.5378986596561992" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.0993577375136059" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="15" I2="0.0" I2_Q="61.64581007794833" ID="CMP-003.04" LOG_CI_END="0.3515776127311545" LOG_CI_START="-0.2692995378981915" LOG_EFFECT_SIZE="0.0411390374164815" METHOD="PETO" MODIFIED="2013-03-19 00:53:30 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.43543927914381764" P_Q="0.10637431657913987" P_Z="0.7950700112265681" Q="2.607277072028712" RANDOM="NO" SCALE="217.81" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="245" TOTAL_2="240" WEIGHT="100.0" Z="0.259732643126643">
<NAME>'Significant' intracranial haemorrhage during follow-up</NAME>
<GROUP_LABEL_1>Favours intravenous</GROUP_LABEL_1>
<GROUP_LABEL_2>Favours intraarterial</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours intravenous</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours intra-arterial</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.180844576829465" CI_END="2.684043221343021" CI_START="0.6124699917380045" DF="3" EFFECT_SIZE="1.2821450501407425" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="13" I2="0.0" ID="CMP-003.04.01" LOG_CI_END="0.4287895050288621" LOG_CI_START="-0.212915184909317" LOG_EFFECT_SIZE="0.10793716005977254" MODIFIED="2013-03-19 00:53:30 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.7576022001158791" P_Z="0.5096731415622948" STUDIES="4" TAU2="0.0" TOTAL_1="231" TOTAL_2="227" WEIGHT="93.6140270479467" Z="0.6593467357424804">
<NAME>rt-PA</NAME>
<DICH_DATA CI_END="22.27472071576135" CI_START="0.20927615499663266" EFFECT_SIZE="2.1590664429374042" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3478122674849342" LOG_CI_START="-0.6792802525181229" LOG_EFFECT_SIZE="0.3342660074834056" ORDER="13709" O_E="0.5428571428571429" SE="1.1907241805196005" STUDY_ID="STD-EMS-Bridging-Trial" TOTAL_1="17" TOTAL_2="18" VAR="0.7053061224489796" WEIGHT="9.3813256669119"/>
<DICH_DATA CI_END="302.0371639578039" CI_START="0.10964032215359668" EFFECT_SIZE="5.754602676005732" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.4800603837147177" LOG_CI_START="-0.9600296970533363" LOG_EFFECT_SIZE="0.7600153433306908" MODIFIED="2011-02-24 14:45:34 +0000" MODIFIED_BY="[Empty name]" ORDER="64" O_E="0.4285714285714286" SE="2.0207259421636903" STUDY_ID="STD-Sen-2008" TOTAL_1="4" TOTAL_2="3" VAR="0.24489795918367346" WEIGHT="3.2574047454555206"/>
<DICH_DATA CI_END="9.601418319907424" CI_START="0.3293838408115102" EFFECT_SIZE="1.7783565568943431" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="0.9823353916866252" LOG_CI_START="-0.48229771062629495" LOG_EFFECT_SIZE="0.25001884053016504" MODIFIED="2011-03-14 08:18:24 +0000" MODIFIED_BY="[Empty name]" ORDER="94" O_E="0.7777777777777777" SE="0.860332734349393" STUDY_ID="STD-SYNTHESIS" TOTAL_1="29" TOTAL_2="25" VAR="1.3510365711623578" WEIGHT="17.97023116426856"/>
<DICH_DATA CI_END="2.4609348641782605" CI_START="0.4063496415757081" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="10" LOG_CI_END="0.39110011898426683" LOG_CI_START="-0.39110011898426683" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-03-19 00:53:30 +0000" MODIFIED_BY="[Empty name]" ORDER="104" O_E="0.0" SE="0.45946829173634074" STUDY_ID="STD-SYNTHESIS-EXPANSION" TOTAL_1="181" TOTAL_2="181" VAR="4.7368421052631575" WEIGHT="63.00506547131072"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.9515833286144049" CI_START="0.006814919633427332" DF="0" EFFECT_SIZE="0.11532512103806251" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" ID="CMP-003.04.02" LOG_CI_END="0.2903870994987987" LOG_CI_START="-2.1665392613208465" LOG_EFFECT_SIZE="-0.938076080911024" MODIFIED="2011-11-24 14:31:10 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.13448098014019946" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="13" WEIGHT="6.385972952053289" Z="1.4966629547095764">
<NAME>Urokinase</NAME>
<DICH_DATA CI_END="1.9515833286144049" CI_START="0.006814919633427332" EFFECT_SIZE="0.11532512103806251" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.2903870994987987" LOG_CI_START="-2.1665392613208465" LOG_EFFECT_SIZE="-0.938076080911024" MODIFIED="2011-02-24 15:37:19 +0000" MODIFIED_BY="[Empty name]" ORDER="68" O_E="-1.037037037037037" SE="1.4432107063270918" STUDY_ID="STD-Ducrocq-2005" TOTAL_1="14" TOTAL_2="13" VAR="0.4801097393689986" WEIGHT="6.385972952053289"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.4203614396419155" CI_END="2.110487533230453" CI_START="0.2115598813719814" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.6682024335239137" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" I2="44.65313737088742" I2_Q="43.67235659029991" ID="CMP-003.05" LOG_CI_END="0.32438279109587" LOG_CI_START="-0.6745666851750248" LOG_EFFECT_SIZE="-0.1750919470395774" METHOD="PETO" MODIFIED="2013-03-19 00:54:06 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.1434803196629163" P_Q="0.18272429006819957" P_Z="0.4920388726959677" Q="1.7753272451440631" RANDOM="NO" SCALE="312.88" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="245" TOTAL_2="240" WEIGHT="99.99999999999999" Z="0.6870696032829281">
<NAME>Fatal intracranial haemorrhage during follow-up</NAME>
<GROUP_LABEL_1>Favours intravenous</GROUP_LABEL_1>
<GROUP_LABEL_2>Favours intraarterial</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours intravenous</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours intraarterial</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.6450341944978524" CI_END="3.3321230867890357" CI_START="0.2687295799841659" DF="2" EFFECT_SIZE="0.9462769349235772" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" I2="45.13083023970028" ID="CMP-003.05.01" LOG_CI_END="0.5227210356296915" LOG_CI_START="-0.5706845266563471" LOG_EFFECT_SIZE="-0.023981745513327747" MODIFIED="2013-03-19 00:54:06 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.16161850213821127" P_Z="0.9314854388251895" STUDIES="4" TAU2="0.0" TOTAL_1="231" TOTAL_2="227" WEIGHT="83.4688613992443" Z="0.08597607166778098">
<NAME>rt-PA</NAME>
<DICH_DATA CI_END="395.5797654127923" CI_START="0.15525204429265727" EFFECT_SIZE="7.836744685208636" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.597234068581565" LOG_CI_START="-0.8089626725093522" LOG_EFFECT_SIZE="0.8941356980361066" ORDER="13710" O_E="0.5142857142857142" SE="2.000816826662603" STUDY_ID="STD-EMS-Bridging-Trial" TOTAL_1="17" TOTAL_2="18" VAR="0.24979591836734694" WEIGHT="8.600973089737545"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-02-24 14:46:37 +0000" MODIFIED_BY="[Empty name]" ORDER="65" O_E="0.0" SE="0.0" STUDY_ID="STD-Sen-2008" TOTAL_1="4" TOTAL_2="3" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="18.75405951485541" CI_START="0.3277446167733114" EFFECT_SIZE="2.4792220652132317" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.2730952898810406" LOG_CI_START="-0.48446443289446306" LOG_EFFECT_SIZE="0.3943154284932888" MODIFIED="2011-03-14 08:19:28 +0000" MODIFIED_BY="[Empty name]" ORDER="95" O_E="0.8518518518518516" SE="1.0323992812192715" STUDY_ID="STD-SYNTHESIS" TOTAL_1="29" TOTAL_2="25" VAR="0.9382198410849706" WEIGHT="32.30478567533119"/>
<DICH_DATA CI_END="1.7322018192076591" CI_START="0.050981926906462166" EFFECT_SIZE="0.2971716449025473" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.2385984903730311" LOG_CI_START="-1.2925837540172256" LOG_EFFECT_SIZE="-0.5269926318220972" MODIFIED="2013-03-19 00:54:06 +0000" MODIFIED_BY="[Empty name]" ORDER="106" O_E="-1.5" SE="0.8994240298291867" STUDY_ID="STD-SYNTHESIS-EXPANSION" TOTAL_1="181" TOTAL_2="181" VAR="1.2361495844875345" WEIGHT="42.56310263417558"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.9515833286144049" CI_START="0.006814919633427332" DF="0" EFFECT_SIZE="0.11532512103806251" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" ID="CMP-003.05.02" LOG_CI_END="0.2903870994987987" LOG_CI_START="-2.1665392613208465" LOG_EFFECT_SIZE="-0.938076080911024" MODIFIED="2011-11-24 14:31:10 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.13448098014019946" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="13" WEIGHT="16.53113860075568" Z="1.4966629547095764">
<NAME>Urokinase</NAME>
<DICH_DATA CI_END="1.9515833286144049" CI_START="0.006814919633427332" EFFECT_SIZE="0.11532512103806251" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.2903870994987987" LOG_CI_START="-2.1665392613208465" LOG_EFFECT_SIZE="-0.938076080911024" MODIFIED="2011-02-24 15:38:07 +0000" MODIFIED_BY="[Empty name]" ORDER="69" O_E="-1.037037037037037" SE="1.4432107063270918" STUDY_ID="STD-Ducrocq-2005" TOTAL_1="14" TOTAL_2="13" VAR="0.4801097393689986" WEIGHT="16.53113860075568"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2013-03-19 01:01:34 +0000" MODIFIED_BY="jmw ">
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2013-03-19 01:01:34 +0000" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAl4AAAEACAMAAABVk4iuAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK MODIFIED="2013-01-24 12:50:49 +0000" MODIFIED_BY="Hazel Fraser">
<FEEDBACK_ITEM ID="FBK-01" MODIFIED="2013-01-24 12:50:49 +0000" MODIFIED_BY="Hazel Fraser" NO="1">
<TITLE>Comment</TITLE>
<DATE_SUBMITTED>
<DATE DAY="" MONTH="" YEAR=""/>
</DATE_SUBMITTED>
<FEEDBACK_SUMMARY MODIFIED="2013-01-24 12:50:49 +0000" MODIFIED_BY="Hazel Fraser">
<P>The reviewers found a five-fold increase in intracerebral haemorrhage comparing high with low dose thrombolysis. This is discussed in the review and while the finding is not methodologically robust enough to make definitive statements, this potential adverse effect is so important that it should be mentioned in the conclusions of the review. There also should be more discussion of the Wardlaw et al Cochrane review (and Lancet 1997) which indicated a significant (nearly five-fold) increase in intracranial haemorrhage with thrombolysis.</P>
</FEEDBACK_SUMMARY>
<FEEDBACK_REPLY>
<P>It is important to note that there are very few data in the review at present comparing doses of thrombolytic drugs. Hence, it is difficult to draw any firm conclusions. While the notion that a higher dose of a drug might cause more symptomatic intracranial haemorrhage seems logical, and fits with other data, the fact is that the data in the review are scant. We believe that over-emphasis of these data would be potentially misleading. There are no data on the relative benefits of a higher dose of drug versus a lower dose and it is entirely possible that a higher dose has greater long-term benefit in terms of functional outcome, albeit at an increased risk of early hazard from symptomatic haemorrhage. However, further trials would be required to provide more robust data to sort out these relationships. Hence, we will leave the conclusions section unamended.</P>
</FEEDBACK_REPLY>
<FEEDBACK_CONTRIBUTORS>
<P>Philippa Middleton<BR/>Victoria Hadhazy</P>
</FEEDBACK_CONTRIBUTORS>
</FEEDBACK_ITEM>
</FEEDBACK>
<APPENDICES MODIFIED="2013-02-01 10:40:02 +0000" MODIFIED_BY="Hazel Fraser">
<APPENDIX ID="APP-01" MODIFIED="2013-02-01 10:40:02 +0000" MODIFIED_BY="Hazel Fraser" NO="1">
<TITLE MODIFIED="2008-10-14 11:43:08 +0100" MODIFIED_BY="Hazel Fraser">MEDLINE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2013-02-01 10:40:02 +0000" MODIFIED_BY="Hazel Fraser">
<SUBSECTION>
<HEADING LEVEL="3">MEDLINE (Ovid) 1966 to May 2012</HEADING>
<P>1. cerebrovascular disorders/ or basal ganglia cerebrovascular disease/ or exp brain ischemia/ or carotid artery diseases/ or carotid artery thrombosis/ or intracranial arterial diseases/ or cerebral arterial diseases/ or exp "intracranial embolism and thrombosis"/ or exp stroke/<BR/>2. (isch?emi$ adj6 (stroke$ or apoplex$ or cerebral vasc$ or cerebrovasc$ or cva)).tw.<BR/>3. ((brain or cerebr$ or cerebell$ or vertebrobasil$ or hemispher$ or intracran$ or intracerebral or infratentorial or supratentorial or middle cerebr$ or mca$ or anterior circulation) adj5 (isch?emi$ or infarct$ or thrombo$ or emboli$ or occlus$ or hypoxi$)).tw.<BR/>4. 1 or 2 or 3<BR/>5. thrombolytic therapy/<BR/>6. fibrinolytic agents/ or plasmin/ or plasminogen/ or tissue plasminogen activator/ or exp plasminogen activators/ or urokinase-type plasminogen activator/<BR/>7. fibrinolysis/<BR/>8. (thromboly$ or fibrinoly$ or recanalis$ or recanaliz$).tw.<BR/>9. ((clot$ or thrombus) adj5 (lyse or lysis or dissolve$ or dissolution)).tw.<BR/>10. (tPA or t-PA or rtPA or rt-PA or plasminogen or plasmin or alteplase or actilyse).tw.<BR/>11. (anistreplase or streptodornase or streptokinase or urokinase or pro?urokinase or rpro?uk or lumbrokinase or duteplase or lanoteplase or pamiteplase or reteplase or saruplase or staphylokinase or streptase or tenecteplase or desmoteplase or retevase).tw.<BR/>12. 5 or 6 or 7 or 8 or 9 or 10 or 11<BR/>13. Randomized Controlled Trials as Topic/<BR/>14. random allocation/<BR/>15. Controlled Clinical Trials as Topic/<BR/>16. control groups/<BR/>17. clinical trials as topic/ or clinical trials, phase i as topic/ or clinical trials, phase ii as topic/ or clinical trials, phase iii as topic/ or clinical trials, phase iv as topic/<BR/>18. double-blind method/<BR/>19. single-blind method/<BR/>20. Placebos/<BR/>21. placebo effect/<BR/>22. Drug Evaluation/<BR/>23. Research Design/<BR/>24. randomized controlled trial.pt.<BR/>25. controlled clinical trial.pt.<BR/>26. (clinical trial or clinical trial phase i or clinical trial phase ii or clinical trial phase iii or clinical trial phase iv).pt.<BR/>27. (random$ or RCT or RCTs or quasi-random$ or quasi random$ or pseudo-random$ or pseudo random$).tw<BR/>28. (controlled adj5 (trial$ or stud$)).tw.<BR/>29. (clinical$ adj5 trial$).tw.<BR/>30. ((control or treatment or experiment$ or intervention) adj5 (group$ or subject$ or patient$)).tw.<BR/>31. ((control or experiment$ or conservative) adj5 (treatment or therapy or procedure or manage$)).tw.<BR/>32. ((singl$ or doubl$ or tripl$ or trebl$) adj5 (blind$ or mask$)).tw.<BR/>33. placebo$.tw.<BR/>34. (assign$ or allocat$).tw.<BR/>35. controls.tw.<BR/>36. trial.ti.<BR/>37. or/13-36<BR/>38. 4 and 12 and 37<BR/>39. exp animals/ not humans.sh.<BR/>40. 38 not 39<BR/>
</P>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2013-01-31 16:04:57 +0000" MODIFIED_BY="Hazel Fraser" NO="2">
<TITLE MODIFIED="2008-10-14 11:43:19 +0100" MODIFIED_BY="Hazel Fraser">EMBASE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2013-01-31 16:04:57 +0000" MODIFIED_BY="Hazel Fraser">
<SUBSECTION>
<HEADING LEVEL="3">EMBASE (Ovid) 1980 to May 2012</HEADING>
<P>1. cerebrovascular disease/ or cerebral artery disease/ or cerebrovascular accident/ or stroke/ or vertebrobasilar insufficiency/ or carotid artery disease/ or exp carotid artery obstruction/ or exp brain infarction/ or exp brain ischemia/ or exp occlusive cerebrovascular disease/ or stroke patient/ or stroke unit/<BR/>2. (isch?emi$ adj6 (stroke$ or apoplex$ or cerebral vasc$ or cerebrovasc$ or cva or attack$)).tw.<BR/>3. ((brain or cerebr$ or cerebell$ or vertebrobasil$ or hemispher$ or intracran$ or intracerebral or infratentorial or supratentorial or middle cerebr$ or mca$ or anterior circulation) adj5 (isch?emi$ or infarct$ or thrombo$ or emboli$ or occlus$ or hypoxi$)).tw.<BR/>4. 1 or 2 or 3<BR/>5. fibrinolytic therapy/<BR/>6. fibrinolytic agent/ or plasmin/ or plasminogen/ or exp plasminogen activator/<BR/>7. blood clot lysis/<BR/>8. fibrinolysis/<BR/>9. (thromboly$ or fibrinoly$ or recanalis$ or recanaliz$).tw.<BR/>10. ((clot$ or thrombus) adj5 (lyse or lysis or dissolve$ or dissolution)).tw.<BR/>11. (tPA or t-PA or rtPA or rt-PA or plasminogen or plasmin or alteplase or actilyse).tw.<BR/>12. (anistreplase or streptodornase or streptokinase or urokinase or pro?urokinase or rpro?uk or lumbrokinase or duteplase or lanoteplase or pamiteplase or reteplase or saruplase or staphylokinase or streptase or tenecteplase or desmoteplase or retevase).tw.<BR/>13. 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12<BR/>14. Randomized Controlled Trial/<BR/>15. Randomization/<BR/>16. Controlled Study/<BR/>17. control group/<BR/>18. clinical trial/ or phase 1 clinical trial/ or phase 2 clinical trial/ or phase 3 clinical trial/ or phase 4 clinical trial/ or controlled clinical trial/<BR/>19. Double Blind Procedure/<BR/>20. Single Blind Procedure/ or triple blind procedure/<BR/>21. placebo/<BR/>22. drug comparison/ or drug dose comparison/<BR/>23. "types of study"/<BR/>24. (random$ or RCT or RCTs or quasi-random$ or quasi random$ or pseudo-random$ or pseudo random$).tw<BR/>25. (controlled adj5 (trial$ or stud$)).tw.<BR/>26. (clinical$ adj5 trial$).tw.<BR/>27. ((control or treatment or experiment$ or intervention) adj5 (group$ or subject$ or patient$)).tw.<BR/>28. ((control or experiment$ or conservative) adj5 (treatment or therapy or procedure or manage$)).tw.<BR/>29. ((singl$ or doubl$ or tripl$ or trebl$) adj5 (blind$ or mask$)).tw.<BR/>30. placebo$.tw.<BR/>31. (assign$ or allocat$).tw.<BR/>32. trial.ti.<BR/>33. or/14-32<BR/>34. 4 and 13 and 33<BR/>35. (ANIMAL/ or NONHUMAN/ or ANIMAL EXPERIMENT/) and HUMAN/<BR/>36. ANIMAL/ or NONHUMAN/ or ANIMAL EXPERIMENT/<BR/>37. 36 not 35<BR/>38. 34 not 37</P>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>